Compositions and methods for reprogramming cells using circular rna

Circular RNA-based reprogramming of blood cells addresses the limitations of existing iPSC production methods by enhancing efficiency and safety, producing stable iPSCs for diverse cell differentiation applications.

JP2024547057APending Publication Date: 2024-12-26ELEVATEBIO MANAGEMENT INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024536988
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-20
Filing Date
2022-12-19
Publication Date
2024-12-26

AI Technical Summary

Technical Problem

Current methods for producing induced pluripotent stem cells (iPSCs) using reprogramming factors face challenges such as genomic integration risks with self-replicating RNA systems, laborious processes with mRNA, and immunogenicity issues with exogenous mRNA, necessitating immune evasion factors.

Method used

The use of circular RNA (circRNA) encoding reprogramming factors, such as Oct3/4, Klf4, Sox2, Nanog, Lin28, and c-Myc, to reprogram blood cells like CD34+ cells in suspension, avoiding genomic integration and reducing the need for multiple transfections and immune responses.

Benefits of technology

This approach enhances reprogramming efficiency with fewer factors, reduces cell death, and produces stable, viable iPSCs suitable for differentiation into various cell types, offering a safer and more efficient method for iPSC production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024547057000001_ABST
    Figure 2024547057000001_ABST
Patent Text Reader

Abstract

The present disclosure provides methods of generating iPSCs, the methods comprising contacting cells in suspension (e.g., CD34+ cells or other blood cells) with one or more circular RNAs encoding one or more reprogramming factors, and maintaining the cells under conditions such that reprogrammed iPSCs are obtained. In some embodiments, the circular RNAs encode a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc, or a fragment or variant thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 291,645, filed December 20, 2021, the contents of which are incorporated by reference in their entirety into this specification.

[0002] Statement regarding electronically submitted text files

[0002] The contents of the text file submitted electronically herewith are incorporated by reference in their entirety: Computer-readable copy of the sequence listing (filename: ELVT_015_01WO_SeqList_ST26.xml, size 50.8 KB, created November 16, 2022). [Background technology]

[0003] background

[0003] Drug discovery and healthcare are being transformed by induced pluripotent stem cells (iPSCs), which arise by reprogramming somatic cells back to an embryonic-like pluripotent state that allows for the generation of a range of human cell types required for research and / or therapeutic purposes.

[0004]

[0004] iPSCs are typically derived by introducing one or more reprogramming factors (e.g., Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, and / or L-Myc) into somatic cells. Reprogramming factors can be introduced into cells using standard techniques, but such techniques suffer from various drawbacks. For example, self-replicating RNA systems use RNA replicons capable of self-replication. Such replicating vectors, by their nature, are at risk for genomic integration. mRNA-based reprogramming is laborious and involves multiple transfections of mRNA due to the rapid turnover of mRNA molecules. Exogenous mRNA is also immunogenic, necessitating the use of immune evasion factors (e.g., inhibitors of the interferon pathway) and / or modified nucleotides to minimize toxicity. Summary of the Invention [Problem to be solved by the invention]

[0005]

[0005] Thus, there is a need in the art for improved compositions and methods for generating iPSCs. [Means for solving the problem]

[0006] overview

[0006] In some embodiments, the present disclosure provides a method for generating induced pluripotent stem cells (iPSCs), comprising contacting blood cells in suspension with a circular RNA encoding at least one reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc, or a fragment or variant thereof, and maintaining the cells under conditions to obtain iPSCs. In some embodiments, the blood cells are selected from T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, peripheral blood mononuclear cells (PBMCs), and cord blood mononuclear cells (CBMCs). In some embodiments, the blood cells are selected from T cells and NK cells.

[0007]

[0007] In some embodiments, the present disclosure provides a method for producing induced pluripotent stem cells (iPSCs), comprising contacting CD34+ cells in suspension with circular RNA encoding at least one reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc, or a fragment or variant thereof, and maintaining the cells under conditions such that iPSCs are obtained.

[0008] In some embodiments, the at least one reprogramming factor is a human or humanized reprogramming factor. In some embodiments, the at least one reprogramming factor is Oct3 / 4, wherein Oct3 / 4 has an amino acid sequence of SEQ ID NO:7, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the circular RNA comprises a nucleic acid sequence of SEQ ID NO:8, or a sequence at least 90% or at least 95% identical thereto.

[0009] In some embodiments, the at least one reprogramming factor is Klf4, wherein Klf4 has the amino acid sequence of SEQ ID NO: 9 or 10, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 11, or a sequence at least 90% or at least 95% identical thereto.

[0010] In some embodiments, the at least one reprogramming factor is Sox2, wherein Sox2 has an amino acid sequence of SEQ ID NO: 12, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the circular RNA comprises a nucleic acid sequence of SEQ ID NO: 13, or a sequence at least 90% or at least 95% identical thereto.

[0011] In some embodiments, the at least one reprogramming factor is Nanog, wherein Nanog has the amino acid sequence of SEQ ID NO: 14 or 15, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 16, or a sequence at least 90% or at least 95% identical thereto.

[0012] In some embodiments, the at least one reprogramming factor is Lin28A, wherein Lin28A has an amino acid sequence of SEQ ID NO: 17, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the circular RNA comprises a nucleic acid sequence of SEQ ID NO: 18, or a sequence at least 90% or at least 95% identical thereto.

[0013] In some embodiments, the at least one reprogramming factor is c-Myc, wherein c-Myc has an amino acid sequence of SEQ ID NO: 19 or 20, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the circular RNA comprises a nucleic acid sequence of SEQ ID NO: 21, or a sequence at least 90% or at least 95% identical thereto.

[0014] In some embodiments, the at least one reprogramming factor is L-Myc, wherein L-Myc has the amino acid sequence of any one of SEQ ID NOs: 22-24, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 25, or a sequence at least 90% or at least 95% identical thereto.

[0015]

[0015] In some embodiments, the circular RNA is substantially non-immunogenic. In some embodiments, the circular RNA comprises one or more M-6-methyladenosine (m6A) residues. In some embodiments, the circular RNA comprises about 200 nucleotides to about 5,000 nucleotides.

[0016] In some embodiments, the circular RNA comprises an internal ribosome entry site (IRES) operably linked to a protein coding sequence. In some embodiments, the circular RNA encodes two or more reprogramming factors selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc.

[0017]

[0017] In some embodiments, the method includes contacting a cell with a first circular RNA encoding Oct4 or a fragment or variant thereof, a second circular RNA encoding Sox2 or a fragment or variant thereof, a third circular RNA encoding Klf4 or a fragment or variant thereof, a fourth circular RNA encoding C-Myc or a fragment or variant thereof, a fifth circular RNA encoding Lin28 or a fragment or variant thereof, and a sixth circular RNA encoding Nanog or a fragment or variant thereof.

[0018]

[0018] In some embodiments, the method includes contacting a cell with one or more circular RNAs encoding one or more of the group of reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc, or fragments or variants thereof.

[0019]

[0019] In some embodiments, the present disclosure provides a method for producing induced pluripotent stem cells (iPSCs), comprising contacting blood cells or CD34+ cells in suspension with six circular RNAs, the six circular RNAs being a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, a third circular RNA encoding Klf4, a fourth circular RNA encoding C-Myc, a fifth circular RNA encoding Lin28, and a sixth circular RNA encoding Nanog, and maintaining the cells under conditions to obtain iPSCs.

[0020] In some embodiments, the present disclosure provides a method for generating induced pluripotent stem cells (iPSCs), comprising contacting blood cells or CD34+ cells in suspension with three circular RNAs, a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, and a third circular RNA encoding Klf4, and maintaining the cells under conditions to obtain iPSCs. In some embodiments, the method does not include contacting CD34+ cells with circular RNAs encoding any of Nanog, Lin28, and c-Myc.

[0021]

[0021] In some embodiments, the present disclosure provides a method for generating induced pluripotent stem cells (iPSCs), comprising contacting blood cells or CD34+ cells in suspension with three circular RNAs, a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, and a third circular RNA encoding Klf4, and a fourth circular RNA encoding C-Myc, and maintaining the cells under conditions to obtain iPSCs. In some embodiments, the method does not include contacting CD34+ cells with a circular RNA encoding either Nanog or Lin28.

[0022]

[0022] In some embodiments, the present disclosure provides a method of generating induced pluripotent stem cells (iPSCs), comprising contacting blood cells or CD34+ cells in suspension with three circular RNAs, a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, and a third circular RNA encoding Klf4, a fourth circular RNA encoding Nanog, and a fifth circular RNA encoding Lin 28, and maintaining the cells under conditions to obtain iPSCs. In some embodiments, the method does not include contacting the CD34+ cells with a circular RNA encoding c-Myc.

[0023]

[0023] In some embodiments, the cells are not contacted with any factor selected from E3, K3, B18R. In some embodiments, the cells are not contacted with any microRNA (miR). In some embodiments, the cells are not contacted with one or more factors selected from E3, K3, B18R, one or more microRNA (miR), or combinations thereof. In some embodiments, the miR comprises miR302a, miR302b, miR302c, miR302d, and miR367.

[0024] In some embodiments, the cell is directly contacted with at least one circular RNA. In some embodiments, the cell is contacted once with each of the at least one circular RNA. In some embodiments, the method includes contacting the cell two, three, four, or more times with each of the at least one circular RNA. In some embodiments, the method includes contacting the cell less than four times with each of the at least one circular RNA. In some embodiments, the method includes contacting the cell two to four times with each of the at least one circular RNA.

[0025] In some embodiments, the concentration of each of the at least one circular RNA is at least 3 pg RNA / cell. In some embodiments, the concentration of each of the at least one circular RNA is about 5 pg RNA / cell to about 15 pg RNA / cell.

[0026]

[0026] In some embodiments, the contacting of the cells is performed by electroporation.

[0027]

[0027] In some embodiments, the method further comprises contacting the cell with an RNA polynucleotide encoding one or more viral proteins selected from E3, K3, or B18R. In some embodiments, (a) B18R has a sequence of SEQ ID NO:26, or a sequence at least 90% or at least 95% identical thereto; (b) E3 has a sequence of SEQ ID NO:27, or a sequence at least 90% or at least 95% identical thereto; and / or (c) K3 has a sequence of SEQ ID NO:28, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the method further comprises contacting the cell with one or more microRNAs (miR). In some embodiments, the miR is selected from miR302a, miR302b, miR302c, miR302d, and miR367.

[0028]

[0028] In some embodiments, the method results in one or more of: (i) an increase in the number of reprogrammed iPSCs present at the end of the culture compared to a method of generating iPSCs with one or more linear RNAs; and / or (ii) a decrease in cell death at one or more time points during reprogramming compared to a method of generating iPSCs with one or more linear RNAs. In some embodiments, the method results in each of: (i) an increase in the number of reprogrammed iPSCs present at the end of the culture compared to a method of generating iPSCs with one or more linear RNAs; and (ii) a decrease in cell death at one or more time points during reprogramming compared to a method of generating iPSCs with one or more linear RNAs.

[0029] In some embodiments, the present disclosure provides iPSCs produced by the methods described herein. In some embodiments, the present disclosure provides differentiated cells derived from iPSCs described herein. In some embodiments, the differentiated cells are muscle cells, nervous system cells, central nervous system cells, eye cells, chondrocytes, bone cells, tendon cells, kidney cells, cardiomyocytes, hepatocytes, pancreatic islet cells, keratinocytes, T cells, or NK cells.

[0030]

[0030] In some embodiments, the disclosure provides a method for reprogramming and editing the genome of a cell, the method comprising: (i) contacting the cell with a recombinant circular RNA comprising a protein coding sequence, where the protein coding sequence encodes at least one reprogramming factor, and (ii) contacting the cell with an enzyme capable of editing the DNA or RNA of the cell, or a nucleic acid encoding the same.

[0031]

[0031] In some embodiments, the present disclosure provides a method for reprogramming and editing the genome of a cell, the method comprising simultaneously contacting the cell with (i) a recombinant circular RNA comprising a protein coding sequence, where the protein coding sequence encodes at least one reprogramming factor, and (ii) an enzyme capable of editing the cell's DNA or RNA, or a nucleic acid encoding the same.

[0032] In some embodiments, at least one reprogramming factor is a human or humanized reprogramming factor.

[0033] In some embodiments, the at least one reprogramming factor is Oct3 / 4, wherein Oct3 / 4 has an amino acid sequence of SEQ ID NO: 7, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 8, or a sequence at least 90% or at least 95% identical thereto.

[0034] In some embodiments, the at least one reprogramming factor is Klf4, wherein Klf4 has the amino acid sequence of SEQ ID NO: 9 or 10, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the recombinant circular RNA comprises the nucleic acid sequence of SEQ ID NO: 11, or a sequence at least 90% or at least 95% identical thereto.

[0035] In some embodiments, the at least one reprogramming factor is Sox2, wherein Sox2 has an amino acid sequence of SEQ ID NO: 12, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 13, or a sequence at least 90% or at least 95% identical thereto.

[0036] In some embodiments, the at least one reprogramming factor is Nanog, wherein Nanog has the amino acid sequence of SEQ ID NO: 14 or 15, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the recombinant circular RNA comprises the nucleic acid sequence of SEQ ID NO: 16, or a sequence at least 90% or at least 95% identical thereto.

[0037] In some embodiments, at least one reprogramming factor is Lin28A, wherein Lin28A has an amino acid sequence of SEQ ID NO: 17, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 18, or a sequence at least 90% or at least 95% identical thereto.

[0038] In some embodiments, the at least one reprogramming factor is c-Myc, wherein c-Myc has the amino acid sequence of SEQ ID NO: 19 or 20, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the recombinant circular RNA comprises the nucleic acid sequence of SEQ ID NO: 21, or a sequence at least 90% or at least 95% identical thereto.

[0039] In some embodiments, the at least one reprogramming factor is L-Myc, wherein L-Myc has the amino acid sequence of any one of SEQ ID NOs: 22-24, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the recombinant circular RNA comprises the nucleic acid sequence of SEQ ID NO: 25, or a sequence at least 90% or at least 95% identical thereto.

[0040]

[0040] In some embodiments, the circular RNA is substantially non-immunogenic. In some embodiments, the circular RNA comprises one or more M-6-methyladenosine (m6A) residues. In some embodiments, the circular RNA comprises about 200 nucleotides to about 5,000 nucleotides.

[0041] In some embodiments, the circular RNA comprises an internal ribosome entry site (IRES) operably linked to a protein coding sequence. In some embodiments, the circular RNA encodes two or more reprogramming factors selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc.

[0042] In some embodiments, the method includes contacting the cell with a first circular RNA encoding Oct4 or a fragment or variant thereof, a second circular RNA encoding Sox2 or a fragment or variant thereof, a third circular RNA encoding Klf4 or a fragment or variant thereof, a fourth circular RNA encoding C-Myc or a fragment or variant thereof, a fifth circular RNA encoding Lin28 or a fragment or variant thereof, and a sixth circular RNA encoding Nanog or a fragment or variant thereof. In some embodiments, the method includes contacting the cell with one or more circular RNAs encoding Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, and L-Myc, or a fragment or variant thereof.

[0043] In some embodiments, the cell is not contacted with any auxiliary factor selected from E3, K3, B18R, or any microRNA (miR). In some embodiments, the cell is directly contacted with at least one circular RNA. In some embodiments, the cell is contacted once with each of the at least one circular RNA. In some embodiments, the method includes contacting the cell with each of at least one of the circular RNAs two, three, four, or more times. In some embodiments, the method includes contacting the cell with each of the at least one circular RNA less than four times. In some embodiments, the method includes contacting the cell with each of the at least one circular RNA two to four times.

[0044] In some embodiments, the concentration of the at least one circular RNA is at least 3 pg RNA / cell. In some embodiments, the concentration of the at least one circular RNA is about 5 pg RNA / cell to about 15 pg RNA / cell.

[0045]

[0045] In some embodiments, the contacting of the cells is performed by electroporation.

[0046] In some embodiments, the method includes contacting the cell with an RNA polynucleotide encoding one or more viral proteins selected from E3, K3, or B18R. In some embodiments, (a) B18R has a sequence of SEQ ID NO:26, or a sequence at least 90% or at least 95% identical thereto; (b) E3 has a sequence of SEQ ID NO:27, or a sequence at least 90% or at least 95% identical thereto; and / or (c) K3 has a sequence of SEQ ID NO:28, or a sequence at least 90% or at least 95% identical thereto. In some embodiments, the method includes contacting the cell with a microRNA (miR) selected from miR302a, miR302b, miR302c, miR302d, and miR367.

[0047]

[0047] In some embodiments, the cells are not contacted with any viral protein selected from E3, K3, B18R, or with any microRNA (miR) selected from miR302a, miR302b, miR302c, miR302d, and miR367.

[0048] In some embodiments, the enzyme is a transcription activator-like effector nuclease (TALEN), an argonaute endonuclease (NgAgo), a structure-guided endonuclease (SGN), an RNA-guided nuclease (RGN), an adenosine deaminase acting on RNA (ADAR), or modified or truncated variants thereof. In some embodiments, the RGN is a Cas nuclease selected from Cas9 nuclease, Cas12(a) nuclease (Cpf1), Cas12b nuclease, Cas12c nuclease, TrpB-like nuclease, Cas13a nuclease (C2c2), Cas13b nuclease, Cas14 nuclease, or modified or truncated variants thereof. In some embodiments, the RGN is a Cas9 nuclease, and the Cas9 nuclease is isolated or derived from S. pyogenes or S. aureus. In some embodiments, the RGN is selected from the group consisting of APG05083.1, APG07433.1, APG07513.1, APG08290.1, APG05459.1, APG04583.1, and APG1688.1, APG05733.1, APG06207.1, APG01647.1, APG08032.1, APG05712.1, APG01658.1, APG06498.1, APG09106.1, APG09882.1, APG02675.1, APG01405.1, APG0625 0.1, APG06877.1, APG09053.1, APG04293.1, APG01308.1, APG06646.1, APG09748, APG07433.1, APG00969, APG03128, APG09748, APG00771, APG02789, APG09106, APG02312, APG07386, APG09980, APG05840, APG05241, APG07280, APG09866, and APG00868.

[0049]

[0049] In some embodiments, the method further comprises contacting the cell with a guide RNA, or a nucleic acid encoding same.

[0050]

[0050] In some embodiments, the cells are contacted with the circular RNA before contacting the enzyme or the nucleic acid encoding it. In some embodiments, the cells are contacted with the recombinant circular RNA after contacting the enzyme or the nucleic acid encoding it. In some embodiments, the cells are contacted with an enzyme capable of editing the DNA or RNA of the cell, or a nucleic acid encoding it, and a guide RNA or a nucleic acid encoding it. In some embodiments, the enzyme is capable of editing the DNA of the cell, where the enzyme and the guide RNA are complexed as a ribonucleoprotein before contacting the cell. In some embodiments, the contacting of the cells is performed by electroporation.

[0051]

[0051] In some embodiments, the present disclosure provides cells produced by the methods described herein.

[0052] In some embodiments, the disclosure provides a method of reprogramming a cell, the method comprising contacting a cell with one or more circular RNAs encoding six reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc. In some embodiments, the method comprises contacting a cell with six circular RNAs, each encoding a reprogramming factor from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0053] In some embodiments, either the circular RNA or the linear RNA is conjugated to a lipid nanoparticle. In some embodiments, the cell is not contacted with one or more factors selected from E3, K3, B18R, or one or more microRNAs (miRs).

[0054]

[0054] In some embodiments, the present disclosure provides a composition comprising an isolated somatic cell comprising one or more circular RNAs encoding a reprogramming factor, wherein the reprogramming factor is selected from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0055] In some embodiments, the somatic cell comprises one or more circular RNAs, where each of the one or more circular RNAs encodes a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc. In some embodiments, the somatic cell comprises six circular RNAs, where each of the circular RNAs encodes one of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc. In some embodiments, the somatic cell comprises five circular RNAs, where each of the circular RNAs encodes one of Oct3 / 4, Klf4, Sox2, Nanog, and Lin28. In some embodiments, the somatic cell comprises four circular RNAs, where each of the circular RNAs encodes one of Oct3 / 4, Klf4, Sox2, and c-Myc. In some embodiments, the somatic cell comprises three circular RNAs, where each of the circular RNAs encodes one of Oct3 / 4, Klf4, and Sox2.

[0056] In some embodiments, the present disclosure provides a suspension culture comprising one or more CD34+ cells, wherein the CD34+ cells comprise one or more circRNAs encoding reprogramming factors. In some embodiments, the CD34+ cells comprise six circRNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc. In some embodiments, the CD34+ cells do not comprise exogenous nucleic acids encoding auxiliary factors selected from E3, K3, B18R, or microRNAs (miR).

[0057] In some embodiments, the circular RNA is exogenous to the cell.

[0058]

[0058] In some embodiments, the present disclosure provides a composition comprising one or more circular RNAs encoding reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc. In some embodiments, the present disclosure provides a composition comprising two or more circular RNAs encoding reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc. In some embodiments, the present disclosure provides a composition comprising six circular RNAs, each encoding one of the reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc. In some embodiments, the present disclosure provides a composition comprising five circular RNAs, each encoding one of the reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, and Lin28. In some embodiments, the disclosure provides a composition comprising four circular RNAs, each encoding one of the reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, and c-Myc. In some embodiments, the disclosure provides a composition comprising three circular RNAs, each encoding one of the reprogramming factors consisting of Oct3 / 4, Klf4, and Sox2.

[0059] In some embodiments, the present disclosure provides a kit comprising a composition described herein. In some embodiments, the present disclosure provides a cell comprising a composition described herein. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is a CD34+ cell, a T cell, or a NK cell.

[0060]

[0060] In some embodiments, the present disclosure provides CD34+ cells comprising one or more circular RNAs encoding one or more reprogramming factors selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc, or L-Myc. In some embodiments, the reprogramming factors consist of all six of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc. In some embodiments, the reprogramming factors consist of all six of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and L-Myc. In some embodiments, the reprogramming factors consist of Oct3 / 4, Klf4, Sox2, Nanog, and Lin28. In some embodiments, the reprogramming factors consist of Oct3 / 4, Klf4, Sox2, Nanog, and Lin28. In some embodiments, the reprogramming factors consist of Oct3 / 4, Klf4, Sox2, and c-Myc. In some embodiments, the reprogramming factors consist of Oct3 / 4, Klf4, and Sox2. In some embodiments, the cells exhibit at least one stemness marker selected from SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, TRA-2-49 / 6E, alkaline phosphatase, Sox2, E-cadherin, UTF-1, Oct4, Rex1, Nanog, or a combination thereof. In some embodiments, the one or more circular RNAs are exogenous to the cells.

[0061] In some embodiments, the CD34+ further comprises one or more genetic modifications. In some embodiments, the one or more genetic modifications comprise a gene knockout. In some embodiments, the one or more genetic modifications comprise a gene knockin.

[0062] In some embodiments, the present disclosure provides induced pluripotent stem cells (iPSCs) derived from the CD34+ cells described herein. In some embodiments, the cells are hypoimmunogenic.

[0063] In some embodiments, the present disclosure provides differentiated cells generated from the iPSCs described herein.

[0064]

[0064] In some embodiments, the present disclosure provides a method for treating a disease or condition, comprising administering to a subject in need thereof an iPSC or differentiated cell described herein.

[0065] In some embodiments, the present disclosure provides a method of transdifferentiating a somatic cell, the method comprising contacting the cell with one or more exogenous circular RNAs. In some embodiments, the present disclosure provides a transdifferentiated cell produced by the method described herein.

[0066] In some embodiments, the present disclosure provides a method for differentiating a cell from an induced pluripotent stem cell (iPSC), comprising contacting the iPSC with one or more circular RNAs. In some embodiments, the present disclosure provides a differentiated cell produced by the method described herein.

[0067]

[0067] Other objects, advantages and features of the present invention will become apparent from the following specification.

[0068] BRIEF DESCRIPTION OF THE DRAWINGS

[0068] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief description of the drawings]

[0069] [Figure 1]

[0069] Schematic diagram showing an exemplary protocol for generating circular RNA by circularizing linear RNA generated using chemical synthesis or in vitro transcription (IVT). First, linear RNA is prepared. Then, the 5' end of the linear RNA is phosphorylated by amplifying it using primers specific for the flanking sequences. The 5' and 3' ends are then ligated using T4 RNA ligase. The circular RNA is purified or the linear by-product is enzymatically denatured. The circular RNA may then be contacted with (e.g., transfected into) a cell and / or conjugated to a lipid nanoparticle. [Figure 2A]

[0070] 2A-2G are schematic diagrams depicting exemplary methods for circularizing linear RNA, including enzymatic ligation of the 5' phosphate and 3'-OH termini (FIG. 2A); [Figure 2B]

[0070] Chemical ligation of the OH terminus with a phosphate (either the 5' or 3' terminus may be phosphorylated) (Figure 2B); [Figure 2C]

[0070] Chemical ligation of the tosylated 5' end with a 3' thiophosphate (Figure 2C); [Figure 2D]

[0070] Chemical ligation of the iodized 5' end with a 3'-thiophosphate (Figure 2D); [Figure 2E]

[0070] Chemical ligation of 3'-aldehydes and 50-oxoamines (oxime cyclization) (Figure 2E); [Figure 2F]

[0070] Chemical ligation of 5'- or 3'-azide with 3'- or 5'-alkyne (click cyclization) (Figure 2F); [Figure 2G]

[0070] Cyclization by metal chelation (M = Zn2+ or Fe2+, (= terpyridine)) (Figure 2G) is included. [Diagram 3]

[0071] Schematic diagram of an exemplary method for circularizing linear RNA. In the illustrated intron-exon construct, the group I catalytic intron of the T4 phage Td gene is split into two in a manner that preserves structural elements critical for ribozyme folding. Exon fragment 2 (E2) is then ligated upstream of exon fragment 1 (E1), inserting an approximately 1.1 kb long coding region between the exon-exon junctions. During splicing, the 3' hydroxyl group of the guanosine nucleotide associates with the 5' splice site in a transesterification reaction, resulting in circularization of the intervening region and excision of the 3' intron. [Figure 4]

[0072] 1 provides a timeline and process scheme for reprogramming CD34+ cells in suspension. [Diagram 5]

[0073] 1 provides representative images of iPSC colony formation during CD34+ cell reprogramming. [Figure 6A]

[0074] Figures 6A-C provide immunofluorescence images of Tra-1-81+ and Oct4+ cells after reprogramming with various amounts of C14 reprogramming cocktail. Figure 6A provides images of iPSCs generated by treating CD34+ cells in suspension with 5.2 pg of C14 cocktail transfected on days 0 and 2. [Figure 6B] FIG. 6B provides images of iPSCs generated by treating CD34+ cells in suspension with 13 pg of C14 cocktail transfected on days 0 and 2. [Figure 6C] FIG. 6C provides images of iPSCs generated by treating CD34+ cells in suspension with 5.2 pg of C14 cocktail transfected on days 0, 1, 2, and 3. [Figure 7]

[0075] Representative phase contrast images of passage 1 of circRNA-reprogrammed iPSC clones are provided. [Figure 8]

[0076] Tra-1-81+ and Oct4+ staining results of the one-step simultaneous editing and reprogramming protocol are shown. [Figure 9]

[0077] Representative phase contrast images of iPSC clones derived from the one-step simultaneous reprogramming and editing protocol are provided. [Figure 10]

[0078] Tra-1-81+ and Oct4+ staining results of the two-step editing and reprogramming protocol are shown. [Figure 11]

[0079] 1 provides a timeline and experimental design scheme for reprogramming CD34+ cells in suspension. [Figure 12A]

[0080] C14 (Figure 12A) provides phase contrast images showing the morphological progression of CD34+ cell reprogramming using the circRNA cocktail. [Figure 12B]

[0080] C6 (Figure 12B) Provides phase contrast images showing the morphological progression of CD34+ cell reprogramming using circRNA cocktail. [Figure 12C]

[0080] C11 (Figure 12C) Provides phase contrast images showing the morphological progression of CD34+ cell reprogramming using circRNA cocktail. [Figure 13A]

[0081] Figures 13A-B show the results of CD34+ cell reprogramming. Figure 13A provides representative images of plates of iPSC-like colonies at various plating densities. [Figure 13B]

[0081] Figure 13B provides a comparison of reprogramming efficiency observed early (days 8-10) during reprogramming with different circRNA cocktails. [Figure 14]

[0082] A scheme of the experimental design for optimizing the electroporation protocol for CD34+ cells is provided. [Figure 15]

[0083] Shown is the kinetics of nGFP protein expression after electroporation as determined by IncuCyte imaging. [Figure 16]

[0084] Illustrates flow cytometry analysis of nGFP protein levels one day after initial transfection by electroporation. [Figure 17]

[0085] 1 provides the results of nGFP protein expression in fibroblasts (HDFs) after RNA transfection with RNAiMAX (50 ng / 24 wells) as analyzed by IncuCyte. [Figure 18]

[0086] 1 provides the results of nGFP protein expression in CD34+ cells following RNA transfection of suspension cultured cells with Neon® (250 ng / 6 wells) as analyzed by IncuCyte. [Figure 19]

[0087] 1 provides a scheme of the experimental design to evaluate the reduction in the number of reprogramming factors for reprogramming CD34+ cells in suspension. [Figure 20A]

[0088] Figures 20A-B show phase contrast images of iPSC clones generated with reprogramming cocktails C6, C5, C4, and C3. Figure 20A shows phase contrast images of iPSC clones illustrating morphological progression over time with reprogramming cocktails C6, C5, C4, and C3. [Figure 20B] FIG. 20B shows a comparison of iPSC morphology at day 14 with C6, C5, C4, and C3 reprogramming cocktails. [Figure 21]

[0089] Phase contrast images of iPSC clones reprogrammed with two different concentrations of C6 cocktail are shown. [Figure 22]

[0090] Phase contrast images are shown demonstrating the absence of iPSC clone formation following reprogramming by two transfections of S6 or L6 reprogramming cocktails. [Diagram 23]

[0091] Phase contrast images of iPSC clones reprogrammed with C6 reprogramming cocktail compared to no iPSC clone formation with S6 or L6 reprogramming cocktails on day 14 are shown. [Figure 24A]

[0092] Figures 24A-B show the reprogramming efficiency achieved with different reprogramming cocktails and their concentrations. Figure 24A provides the reprogramming efficiency for CD34+ cells observed with various reprogramming cocktails. [Figure 24B] FIG. 24B provides the reprogramming efficiency for CD34+ cells observed with various concentrations of the C6 reprogramming cocktail. [Diagram 25]

[0093] Shown is staining for pluripotency markers Tra-1-81 (green) and OCT4 (red) after transfection with various concentrations of C6 cocktail. [Figure 26]

[0094] Shown is staining for pluripotency markers Tra-1-81 (green) and OCT4 (red) after transfection with C3, C4, or C5 cocktails. [Figure 27]

[0095] A schematic diagram of the experimental design to characterize circ-RNA-reprogrammed iPSCs in long-term in vitro culture conditions with cell passaging up to 20 passages is provided. [Figure 28A]

[0096] Figures 28A-B show phase contrast images of iPSC clones generated with reprogramming cocktails C14, C6, C4, and C3. Figure 28A shows phase contrast images illustrating the morphology of iPSC clones derived from mixed donor CD34+ cells at cell passages 10, 15, and 20 with reprogramming cocktails C14, C6, and C4. [Figure 28B] FIG. 28B shows phase contrast images illustrating the morphology of iPSC clones derived from a single donor CD34+ cell at cell passages 10, 15, and 20 with reprogramming cocktails C6, C4, and C3. [Figure 29A]

[0097] Figures 29A-B provide the results of viability of iPSCs derived from cord blood CD34+ cells with reprogramming cocktails C14, C6, C4 and C3 as analyzed by Incucyte. Figure 29A provides the results of viability of iPSCs derived from mixed donor cord blood CD34+ cells with reprogramming cocktails C14, C6 and C4 at each cell passage from 4 to 20 as analyzed by Incucyte. [Figure 29B]

[0097] Figure 29B provides the results of viability of iPSCs induced from single donor cord blood CD34+ cells with reprogramming cocktails C6, C4, and C3 at each cell passage from 4 to 18, as analyzed by Incucyte. [Figure 30A]

[0098] Figures 30A-B provide population doubling time results for iPSCs derived from cord blood CD34+ cells with reprogramming cocktails C14, C6, C4, and C3 as analyzed by Incucyte. Figure 30A provides population doubling time results for iPSCs derived from mixed donor cord blood CD34+ cells with reprogramming cocktails C14, C6, and C4 over 5-20 cell passages as analyzed by Incucyte. [Figure 30B]

[0098] Figure 30B provides the results of population doubling times for each cell passage from 4 to 20 of iPSCs induced from single donor cord blood CD34+ cells with reprogramming cocktails C6, C4, and C3 as analyzed by Incucyte. [Figure 31A]

[0099] Figures 31A-B provide the cumulative population doubling results of iPSCs derived from cord blood CD34+ cells with reprogramming cocktails C14, C6, C4 and C3 as analyzed by Incucyte. Figure 31A provides the cumulative population doubling results of iPSCs derived from mixed donor cord blood CD34+ cells with reprogramming cocktails C14, C6 and C4 from initial cell passages 5-8 to cell passage 20 as analyzed by Incucyte. [Figure 31B]

[0099] Figure 31B provides the cumulative population doublings of iPSCs induced from single-donor cord blood CD34+ cells with reprogramming cocktails C6, C4, and C3 over 4 to 20 cell passages as analyzed by Incucyte. [Diagram 32]

[0100] Exemplary fluorescent images of staining of three primary germ layer cell layers with DAPI counterstain for markers SOX17 and FOXA2 for endoderm, T (Brachyury) and FOXA2 for mesoderm, and PAX6 for ectoderm after reprogramming with C14, C6, C4, or C3 cocktails are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0070] Detailed Description overview

[0101] The present disclosure provides compositions and methods for reprogramming cells, comprising contacting cells with a circular RNA polynucleotide (circRNA) encoding one or more reprogramming factors. In various embodiments, the methods disclosed herein unexpectedly provide efficient reprogramming, allowing reprogramming to occur with fewer transfection rounds and minimal use of reprogramming factors. Importantly, these features of the disclosed methods allow for the reprogramming of hard-to-transfect cells, including blood cells (e.g., CD34+ cells, T cells, B cells, NK cells, NKT cells, peripheral blood mononuclear cells, umbilical cord blood mononuclear cells), directly in suspension culture. This is a major advance in reprogramming technology, as blood cells are known to be transfection-resistant. See Warren et al., Molecular Therapy. 2019;27(4):729-734. As shown herein, harsh methods utilized in the prior art to transfect more robust cell types such as fibroblasts are not suitable for use in reprogramming CD34+ cells. Moreover, the methods disclosed herein do not work with linear RNA species - rather, the inventors unexpectedly demonstrate that circRNAs are uniquely capable of reprogramming such susceptible cells. The present disclosure further provides methods and compositions for simultaneously reprogramming and editing cells, comprising contacting the cells with (i) a circRNA encoding one or more reprogramming factors; (ii) an enzyme capable of editing the DNA or RNA of the cell; and (iii) optionally a guide RNA polynucleotide. With such simultaneous reprogramming and editing, blood-derived cells (e.g., CD34+ cells) can be directly reprogrammed and edited in suspension culture using circular RNA.

[0071]

[0102] The reprogramming methods utilizing circRNA polynucleotides described herein provide advantages over the reprogramming methods currently known in the art. As demonstrated herein, the use of circRNAs encoding reprogramming factors unexpectedly reduces the total number of exogenous factors required for cell reprogramming. For example, the methods described herein achieve cellular reprogramming by contacting cells with circRNAs encoding the reprogramming factors Oct3 / 4, Sox2, Klf4, cMyc, Nanog, and Lin28, and regulating viral proteins including E3, K3, and B18R (Kogut et al., Nat Commun 9, 745 (2018). https: / / doi.org / 10.1038 / s41467-018-03190-3; Poleganov et al., Hum Gene Ther. 2015 Nov;26(11):751-66. doi: 10.1089 / hum.2015.045) and / or miR302 (Ying et al. Methods Mol Biol. 2018;1733:283-304. doi: No additional auxiliary factors are required, such as exogenous miRNAs, including miR367 (see Anokye-Danso et al. Cell Stem Cell. 2011;8:376-388; Kogut et al., Nat Commun 9, 745 (2018)), and miR401 (see Anokye-Danso et al. Cell Stem Cell. 2011;8:376-388).The reprogramming methods disclosed herein do not require auxiliary factors, which not only reduces the cost of producing iPSCs by reducing the number of reagents required, but also improves the safety of the generated iPSCs by avoiding potential undesirable effects of the introduction of such auxiliary factors (see, e.g., Ventura and Jacks, MicroRNAs and cancer: short RNAs go a long way. Cell 2009; 586-91; describing the expression of certain microRNAs and their involvement in tumor development, and Yu et al. Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun 2006; 349:59-68, describing the overexpression of the miR302 / 367 cluster in leukemia cell lines).

[0072]

[0103] Furthermore, the present disclosure describes successful reprogramming of CD34+ cells in suspension using a reduced number of reprogramming factors compared to those previously described. For example, the present disclosure demonstrates successful reprogramming with Oct3 / 4, Sox2, and Klf4 (without Nanog, Lin28A or LIN28B, and / or c-Myc), with Oct3 / 4, Sox2, Klf4, and cMyc (without Nanog or Lin28A or Lin28B), and with Oct3 / 4, Sox2, Klf4, Nanog, and Lin28A or LIN28B (without c-Myc). In addition to reducing the number of auxiliary factors required, the present disclosure describes a reduction in the number of transfections required to successfully reprogram blood cells, including CD34+ cells, in suspension. Each of these improvements increases the feasibility and success rate of the manufacturing process for reprogramming, and importantly, reduces the stress on the starting cell population.

[0073]

[0104] Furthermore, the compositions and methods described herein allow for "footprint-free" reprogramming of cells in suspension without the need for the use of viruses or integrated plasmids. Thus, the compositions and methods described herein allow for easier production of safe iPSC technology than available in the art. Previously described reprogramming methods utilize viral vectors or DNA plasmids to deliver the required transgenes to blood cells. These viruses either persist in the cells or are integrated into the genome, and thus their clinical use is limited due to safety concerns. DNA plasmids can also be integrated into the genome, which can lead to numerous manufacturing failures. Delivery of RNA opens the possibility of "footprint-free" reprogramming of cells, but previously described methods using RNA have been unsuccessful with suspension cells. In particular, blood cells tend to be resistant to transfection with cationic reagents, which constitutes a significant obstacle to their reprogramming with RNA polynucleotides, where cultures typically need to be transfected multiple times to sustain the expression of RNA-encoded transgenes (Chong, Yeap and Ho, Transfection types, methods and strategies: a technical review (2021) PeerJ 9:e11165). Electroporation can achieve efficient mRNA delivery to blood cells, but the harshness of this procedure poses similar difficulties when repeated administration of RNA polynucleotides is required.

[0074]

[0105] Recently, mRNA reprogramming of endothelial progenitor cells that can be differentiated from peripheral blood CD34+ cells has been reported, but this requires a differentiation process and reprogramming in adherent cell culture for 2-4 weeks. Thus, there remains a need, as yet unmet, for RNA-based reprogramming protocols that work with true blood lineages.

[0075]

[0106] The present disclosure illustrates the reprogramming of blood cells in suspension (e.g., CD34+ cells). Reprogramming in suspension culture offers many advantages over adherent culture methods known in the art. For example, cells that can be grown in suspension are easy to source. There are many blood banks, including umbilical cord blood banks, that have specific haplotypes, blood types, ages, etc. available. Furthermore, the methods described herein allow for the reprogramming of cells obtained directly from a patient's blood draw, rather than relying on cells obtained from a biopsy sample that must be grown in adherent culture. This allows for the potential for sourcing cells from a wider range of donors, allowing for a broader selection of healthy donors, and minimizing the possibility of using starting cell types with pre-existing genomic abnormalities (e.g., skin fibroblasts). Furthermore, it has been shown that fibroblasts from older individuals are difficult to reprogram (Narayan et al. OCT4 and SOX2 Work as Transcriptional Activators in Reprogramming Human Fibroblasts. Cell Rep. 2017;20(7):1585-1596. doi:10.1016 / j.celrep.2017.07.071); however, no such correlation between age and blood cell reprogramming has been found (Hokayem et al. Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road Ahead. J Alzheimers Dis Parkinsonism. 2016 Oct;6(5):275. doi: 10.4172 / 2161-0460.1000275. Epub 2016 Oct 25). Obtaining feedstock directly from a blood draw also reduces time, reagent costs, and invasiveness to the patient, as well as the extent of manipulation the starting material must undergo to successfully obtain reprogrammed iPSCs. For example, many adherent cell types (e.g., fibroblasts, keratinocytes, endothelial progenitor cells) must be characterized and expanded in vitro for several passages before being reprogrammed.

[0076]

[0107] Moreover, the disclosed method allows for long-term propagation of circRNA-reprogrammed iPSCs (see Examples 7 and 8). The iPSCs generated by the disclosed method are morphologically stable, remain viable, undergo cell division at a consistent rate, and maintain a cellular identity closely resembling ESCs even after multiple cell passages and under long-term cell culture conditions (see Example 7). These iPSCs also remain genetically and epigenetically stable (see Example 8).

[0077]

[0108] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terms used in the detailed description herein are for the purpose of describing specific embodiments only and are not intended to be limiting.

[0078]

[0109] Unless the context indicates otherwise, it is specifically intended that the various features described herein can be used in any combination. Moreover, in some embodiments, any feature or combination of features described herein can be excluded or omitted. To further illustrate, for example, if a particular amino acid is indicated herein as being A, G, I, L, and / or V, the language also indicates that the amino acid can be any partial set of one or more of these amino acids, such as A, G, I, or L; A, G, I, or V; A or G; L only, etc., with each such partial combination being expressly indicated herein. Moreover, the language also indicates that one or more of the specified amino acids can be disclaimed. For example, in some embodiments, the amino acid is not A, G, or I; is not A; is not G or V, etc., with each such possible disclaimer being expressly indicated herein.

[0079]

[0110] All publications, patent applications, patents, GenBank or other accession numbers, and other references mentioned herein are incorporated by reference in their entirety for all purposes.

[0080] General method

[0111] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell culture, molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of those in the art. Such techniques are described in Molecular Cloning: A Laboratory Manual, third edition (Sambrook et al., 2001) Cold Spring Harbor Press;Oligonucleotide Synthesis (P. Herdewijn, ed., 2004);Animal Cell Culture (RI Freshney), ed., 1987);Methods in Enzymology (Academic Press, Inc.);Handbook of Experimental Immunology (DM Weir & CC Blackwell, eds.);Gene Transfer Vectors for Mammalian Cells (JM Miller & MP Calos, eds., 1987);Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987);PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994);Current Protocols in Immunology (JE Coligan et al., eds., 1991);Short Protocols in Molecular Biology (Wiley and Sons, 1999);Manual of Clinical Laboratory Immunology (B. Detrick, NR Rose, and JD Folds eds., 2006);Immunochemical Protocols (J. Pound, ed., 2003);Lab Manual in Biochemistry: Immunology and Biotechnology (A. Nigam and A.Ayyagari, eds. 2007); Immunology Methods Manual: The Comprehensive Sourcebook of Techniques (Ivan Lefkovits, ed., 1996); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane, eds.,1988).

[0081] definition

[0112] The following terminology is used in the specification and appended claims.

[0082]

[0113] The singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly dictates otherwise.

[0083]

[0114] The term "about" as used herein when referring to a measurable value, such as the amount of a polynucleotide or polypeptide length, dosage, time, temperature, etc., is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% from the specified amount.

[0084]

[0115] As used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, as well as the lack of a combination ("or") when otherwise interpreted.

[0085]

[0116] As used herein, "circular RNA" or "circRNA" refers to a type of single-stranded RNA that forms a covalently closed continuous loop, unlike the more familiar linear RNA. As used herein, the "circ" in front of any protein name refers to the circular RNA that encodes that gene. RNA may be circularized in cells by the cellular splicing machinery. For example, circular RNA may be generated by the pre-mRNA splicing machinery joining a splice donor to an upstream splice acceptor by "back-splicing," thereby creating a circular RNA with covalently linked ends. Alternatively, circular RNA may be generated in vitro, for example, by circularization of linear RNA produced by in vitro transcription (IVT). There are three general strategies for in vitro RNA circularization: chemical methods using cyanogen bromide or similar condensing agents, enzymatic methods using RNA or DNA ligases (e.g., T4 RNA ligase I or II), and ribozyme methods using self-splicing introns. The ribozyme method using group I catalytic intron swapping is applicable to the circularization of long RNAs and requires GTP and Mg as cofactors. 2+ It is sufficient to add the exon 3′ to the intron-exon 3′ splicing site. This permuted intron-exon (PIE) splicing strategy consists of a partial exon fusion flanked by half intron sequences. In vitro, these constructs undergo the double transesterification reaction characteristic of group I catalytic introns, but because the exons are already fused, they are excised as covalently 5′ to 3′ linked circles (see FIG. 3). An illustrative protocol for circularizing linear RNA is provided in FIG. 1, and a list of illustrative linear RNA circularization strategies is provided in FIG. 2A-G.

[0086]

[0117] The terms "linear RNA" and "linear mRNA" are used interchangeably herein, as would be clear to one of skill in the art based on the context.

[0087]

[0118] As used herein, "pluripotency" refers to cells with the capacity to differentiate into two or more differentiated cell types under a variety of different conditions, and to differentiate into cell types characteristic of all three germ layers. In some embodiments, pluripotency may be evidenced by the expression of one or more pluripotent stem cell markers.

[0088]

[0119] As used herein, the terms "induced pluripotent stem cells" and "iPSCs" refer to pluripotent cells generated from various differentiated (i.e., multipotent or non-pluripotent) somatic cells. iPSCs are substantially identical genetically to their respective original differentiated somatic cells and exhibit similar characteristics to higher potency cells, such as embryonic stem (ES) cells, including the ability to self-renew indefinitely in culture and to differentiate into other cell types. In some embodiments, iPSCs exhibit morphological characteristics (i.e., round, large nucleoli and scant cytoplasm) and growth characteristics (i.e., doubling time) similar to ES cells. In some embodiments, iPSCs express pluripotent cell-specific markers (e.g., Oct-4, SSEA-3, SSEA-4, Tra-1-60, Tra-1-81, but excluding SSEA-1).

[0089]

[0120] As used herein, a "differentiated cell" or "somatic cell" is any cell that, in its native form, is not pluripotent as that term is defined herein. The term "somatic cell" also encompasses progenitor cells that are multipotent (e.g., capable of producing more than one cell type), but not pluripotent (e.g., capable of producing cells from all three germ layers).

[0090]

[0121] The term "reprogramming" as used herein refers to the process of changing the differentiation state of a cell, such as a somatic cell, a multipotent cell, or a progenitor cell. In some embodiments, reprogramming a cell may include converting a cell from a first cell type to a second cell type. In some embodiments, reprogramming may include changing the phenotype of a differentiated cell to a pluripotent phenotype. In some embodiments, reprogramming may refer to the process of "directed differentiation" or "transcription factor-directed differentiation" in which iPSCs are converted into differentiated cells.

[0091]

[0122] As used herein, the term "reprogramming factor" refers to any factor or combination of factors that promotes the reprogramming of cells. Reprogramming factors can be, for example, transcription factors. Illustrative reprogramming factors for generating iPSCs from differentiated cells include Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, and L-Myc. Illustrative reprogramming factors and their combinations for generating reprogrammed cells are provided in Tables 1 and 3.

[0092]

[0123] As used herein, "transdifferentiation" refers to a type of cell reprogramming in which one somatic cell type is directly converted into a second somatic cell type. In some embodiments, transdifferentiation can refer to "direct reprogramming" or "direct cell fate conversion" in which a somatic cell of a first cell type is converted into a somatic cell of a second cell type without passing through an intermediate pluripotent state or progenitor cell type.

[0093]

[0124] As used herein, an "internal ribosome entry site" or "IRES" is an RNA element that allows for cap-independent initiation of translation. The IRES can be, for example, a viral IRES or a mammalian IRES (e.g., a human IRES).

[0094]

[0125] A "nucleotide triphosphate" or "NTP" is a molecule that contains a nitrogenous base attached to a five-carbon sugar (either ribose or deoxyribose) with three phosphate groups attached to the sugar.

[0095]

[0126] As used herein, a "modified NTP" is an NTP that has been chemically modified to impart advantageous properties to the nucleic acid that contains the NTP, such as reduced immunogenicity, increased stability, chemical functionality, or altered binding affinity.

[0096]

[0127] The term "modified RNA" (eg, "modified linear RNA" or "modified circular RNA") is used to describe an RNA molecule that includes one or more modified NTPs.

[0097]

[0128] The term "vector" refers to a carrier for a nucleic acid (i.e., a DNA or RNA molecule) and can be used to introduce the nucleic acid into a cell. An "expression vector" is a vector that contains a sequence encoding a protein or RNA (e.g., a circular RNA) and the necessary regulatory regions required for the sequence to be expressed in a cell. In some embodiments, the sequence encoding the protein or RNA is operably linked to another sequence in the vector. The term "operably linked" means that the regulatory sequences required for the expression of the sequence encoding the protein or RNA are appropriately positioned relative to the effector sequences for the expression of the protein or RNA within the nucleic acid molecule.

[0098]

[0129] As used herein, the terms "lipid nanoparticle" and "LNP" describe lipid-based particles in the submicron range. LNPs may have a structure characteristic of liposomes and / or another non-bilayer type structure. LNPs may be conjugated to nucleic acids (e.g., DNA or RNA molecules) and may be used to deliver nucleic acids to cells.

[0099]

[0130] The term "variant" as used herein refers to a mutant of a reference polynucleotide or polypeptide sequence, e.g., a naturally occurring polynucleotide or polypeptide sequence, i.e., one that has less than 100% sequence identity with the reference polynucleotide or polypeptide sequence. In other words, a variant comprises at least one amino acid difference (e.g., amino acid substitution, amino acid insertion, amino acid deletion) compared to a reference polypeptide sequence or at least one nucleic acid difference (e.g., nucleic acid substitution, nucleic acid insertion, nucleic acid deletion) compared to a reference polynucleotide, e.g., a naturally occurring polynucleotide or polypeptide sequence. For example, a variant can be a polynucleotide that has 50% or more, 60% or more, or 70% or more sequence identity with a full-length naturally occurring polynucleotide sequence, e.g., 75% or 80% or more identity, 85%, 90%, or 95% or more identity, e.g., 98% or 99% identity, with a full-length naturally occurring polynucleotide sequence. As another example, a variant can be a polypeptide having 70% or more sequence identity with a full-length naturally occurring polypeptide sequence, e.g., 75% or 80% or more identity, such as 85%, 90%, or 95% or more identity, e.g., 98% or 99% identity, to a full-length naturally occurring polypeptide sequence. Variants can also include variant fragments of a reference sequence, e.g., a naturally occurring sequence, that share 70% or more sequence identity with a reference sequence, e.g., a fragment of a naturally occurring sequence, e.g., 75% or 80% or more identity, such as 85%, 90%, or 95% or more identity, e.g., 98% or 99% identity, to a naturally occurring sequence.

[0100]

[0131] Methods for determining sequence similarity or identity between two or more nucleic acid or amino acid sequences are known in the art. For example, sequence similarity or identity may be determined using the local sequence identity algorithm of Smith & Waterman, Adv. Appl. Math. 2, 482 (1981), by the sequence identity alignment algorithm of Needleman & Wunsch J Mol. Biol. 48, 443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85, 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, WI), by the Best Fit sequence program described by Devereux et al. Nucl. Acid Res. 12, 387-395 (1984), or by visual inspection.

[0101]

[0132] Another suitable algorithm is the BLAST algorithm described in Altschul et al. J. Mol. Biol. 215, 403-410, (1990) and Karlin et al. Proc. Natl. Acad. Sci. USA 90, 5873-5787 (1993). A particularly useful BLAST program is the WU-BLAST-2 program, obtained from Altschul et al. Methods in Enzymology, 266, 460-480 (1996); blast.wustl / edu / blast / README.html. WU-BLAST-2 uses several search parameters, which are optionally set to default values. The parameters are dynamic values, established by the program itself depending on the composition of the particular sequence and the composition of the particular database in which the sequence of interest is searched; however, these values ​​may be adjusted to increase sensitivity. Yet an additional useful algorithm is Gapped BLAST as reported by Altschul et al, (1997) Nucleic Acids Res. 25, 3389-3402. Unless otherwise indicated, percent identity is determined herein using the algorithm available at the internet address: blast.ncbi.nlm.nih.gov / Blast.cgi.

[0102] Circular RNA

[0133] Provided herein is a circular RNA. In particular embodiments, the circular RNA encodes a reprogramming factor that (alone or in combination with other reprogramming factors) has the ability to reprogram a differentiated cell into an iPSC, has the ability to differentiate an iPSC into a differentiated cell, and / or has the ability to differentiate one differentiated cell type into another differentiated cell type.

[0103]

[0134] In some embodiments, the circular RNA comprises from about 200 nucleotides to about 5,000 nucleotides. In some embodiments, the circular RNA comprises from about 200 to about 1,000 nucleotides. In some embodiments, the circular RNA comprises from about 1,000 nucleotides to about 2,500 nucleotides. In some embodiments, the circular RNA comprises from about 2,500 nucleotides to about 5,000 nucleotides. In some embodiments, the circular RNA comprises more than about 5,000 nucleotides.

[0104]

[0135] In some embodiments, the circular RNA comprises one or more open reading frames. In some embodiments, the circular RNA comprises one or more protein coding sequences. In some embodiments, the circular RNA does not comprise an open reading frame and / or a protein coding sequence.

[0105]

[0136] In embodiments in which the circular RNA comprises two or more protein-encoding nucleic acid sequences, each sequence may be separated by a sequence encoding a self-cleaving peptide, such as a 2A peptide. Exemplary 2A peptides include, but are not limited to, EGRGSLLTCGDVEENPGP (SEQ ID NO: 1), ATNFSLLKQAGDVEENPGP (SEQ ID NO: 2), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 3), and VKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 4). In some embodiments, each protein-encoding nucleic acid sequence may be separated by an IRES.

[0106]

[0137] Circular RNAs lack the 5' 7-methylguanosine cap structure required for efficient translation of linear mRNA. Therefore, alternative mechanisms may be used to recruit ribosomes so that circular RNAs can be translated. For example, an internal ribosome entry site (IRES) may be used that is directly bound to an initiation factor or to the ribosome itself. Thus, in some embodiments, circular RNAs contain an internal ribosome entry site (IRES). In some embodiments, the IRES associates with eukaryotic ribosomes. In some embodiments, the IRES is operably linked to a protein-coding nucleic acid sequence.

[0107]

[0138] Examples of IRES sequences include sequences from a wide variety of viruses, such as picornavirus UTR (such as encephalomyocarditis virus (EMCV)) leader sequences, polio leader sequences, hepatitis A virus leader, hepatitis C virus IRES, human rhinovirus type 2 IRES, foot and mouth disease virus IRES element, giardia virus IRES, etc. Various non-viral IRES sequences can also be used, including, but not limited to, yeast IRES sequences, as well as human angiotensin II type 1 receptor IRES, fibroblast growth factor IRES, vascular endothelial growth factor IRES, and insulin-like growth factor 2 IRES. Additional IRES sequences suitable for use in the circular RNAs described herein include those described in the database available at http: / / iresite.org / .

[0108]

[0139] In some embodiments, the circular RNA comprises an intron element adjacent to the protein coding sequence. When the intron element is back-spliced ​​by the cellular splicing machinery, a covalently closed circular RNA can be generated. Thus, in some embodiments, the circular RNA comprises a first intron element located 5' to the protein coding sequence and a second intron element located 3' to the protein coding sequence.

[0109]

[0140] In some embodiments, circular RNA is generated by circularizing linear RNA. In some embodiments, linear RNA can self-circularize, for example, if it contains a self-splicing intron. Because circular RNA does not have a 5' or 3' end, it can be resistant to exonuclease-mediated degradation and can be more stable in cells than many linear RNAs.

[0110]

[0141] In some embodiments, the intron element is selected from any known intron element or elements, in any combination, and in any multiple and / or ratio. Examples of intron elements include those described in the circBase circular RNA database (Glazar et al. RNA 20:1666-1670 (2014); and www.circbase.org) and Rybak-Wolf et al. Mol. Cell 58(5):870-885 (2015), each of which is incorporated herein by reference in its entirety. In some embodiments, the intron element is a mammalian intron or a fragment thereof. In some embodiments, the intron element is a non-mammalian intron (e.g., a self-splicing group I intron, a self-splicing group II intron, a spliceosomal intron, or a tRNA intron), or a fragment thereof.

[0111]

[0142] In some embodiments, the circular RNA comprises one or more additional elements that improve the stability and / or translation of the protein coding sequence from the circular RNA. For example, in some embodiments, the circular RNA may comprise a Kozak sequence. One example of a Kozak consensus sequence is RCC(AUG)G (SEQ ID NO:5) (where the start codon is bracketed and "R" at position -3 represents a purine (A or G)). Another example of a Kozak consensus sequence is RXY(AUG) (SEQ ID NO:6) (where R is a purine (A or G), Y is either C or G, and X is any base).

[0112]

[0143] In some embodiments, the circular RNA comprises a first intron element, a protein coding sequence, and a second intron element. In some embodiments, the circular RNA comprises an IRES and a protein coding sequence. In some embodiments, the circular RNA comprises a first intron sequence, an IRES, a protein coding sequence, and a second intron sequence.

[0113]

[0144] In some embodiments, the circular RNA comprises a sequence encoding a reprogramming factor (e.g., a transcription factor). In some embodiments, the circular RNA comprises a first intron element, a sequence encoding the reprogramming factor, and a second intron element.

[0114]

[0145] In some embodiments, the circular RNA comprises an IRES and a sequence encoding a reprogramming factor. In some embodiments, the circular RNA comprises a first intron sequence, an IRES, a sequence encoding a reprogramming factor, and a second intron sequence. In some embodiments, the circular RNA comprises an IRES and a sequence encoding a reprogramming factor. In some embodiments, the circular RNA comprises a first intron element, an IRES, a sequence encoding a reprogramming factor, and a second intron element. See also US Patent Application Publication No. 2020 / 0080106, which is incorporated herein by reference. The circular RNA may also comprise modified bases and / or NTPs. In some embodiments, the circular RNA comprises modified NTPs. In some embodiments, the circular RNA is a modified circular RNA.

[0115]

[0146] Modified bases include 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyluracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified bases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as substituted phenoxazine cytidines (e.g., 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one), and the like. Modified bases also include those in which the purine or pyrimidine base is replaced by other heterocycles, such as 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine, and 2-pyridone.

[0116]

[0147] In some embodiments, the circular RNA comprises modified backbones.Examples of modified RNA backbones include phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphate triesters, aminoalkyl phosphate triesters, methyl and other alkyl phosphonates, including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates, including 3'-amino phosphoramidates and aminoalkyl-phosphoramidates, thionophosphoramidates, thionoalkyl phosphonates, thionoalkyl-phosphate triesters, selenophosphates and boranophosphates with normal 3'-5' linkages, their 2'-5' linked analogs, and those with reverse polarity, where one or more internucleotide linkages are 3' to 3', 5' to 5' or 2' to 2' linkages.

[0117]

[0148] In some embodiments, the circular RNA may be modified by chemically linking one or more moieties or conjugates that enhance activity, cellular distribution, or cellular uptake to the RNA. For example, the circular RNA may be conjugated to an intercalator, a reporter molecule, a polyamine, a polyamide, a polyethylene glycol, a polyether, a group that enhances the pharmacodynamic properties of the oligomer, or a group that enhances the pharmacokinetic properties of the oligomer. In some embodiments, the circular RNA may be conjugated to cholesterol, a lipid, a phospholipid, biotin, a phenazine, a folate, a phenanthridine, anthraquinone, an acridine, a fluorescein, a rhodamine, a coumarin, or a dye. Groups that enhance pharmacodynamic properties include groups that improve RNA uptake, groups that enhance resistance to degradation of the oligomer, and / or groups that enhance sequence-specific hybridization with the RNA. Groups that enhance pharmacokinetic properties include groups that improve oligomer uptake, distribution, metabolism, or excretion. The circular RNA may also be conjugated to an active drug substance, such as aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, benzothiadiazid, chlorothiazide, diazepines, indomethicin, barbiturates, cephalosporins, sulfa drugs, antidiabetics, antibacterials, or antibiotics. In some embodiments, the circular RNA is conjugated to a lipid nanoparticle (LNP).

[0118]

[0149] In some embodiments, the circular RNA is part of a complex. In some embodiments, the complex comprises a circular RNA and a lipid nanoparticle (LNP). In some embodiments, the circular RNA and the LNP are conjugated. In some embodiments, the circular RNA and the LNP are covalently conjugated. In some embodiments, the circular RNA and the LNP are non-covalently conjugated. In some embodiments, the methods described herein include contacting a cell with one or more circular RNAs complexed with a LNP.

[0119]

[0150] The LNPs may include, for example, one or more cationic lipids, non-cationic lipids, and / or PEG-modified lipids. In some embodiments, the LNPs may include at least one of the following cationic lipids: C12-200, DLin-KC2-DMA, DODAP, HGT4003, ICE, HGT5000, or HGT5001. In some embodiments, the LNPs include cholesterol and / or PEG-modified lipids. In some embodiments, the LNPs include DMG-PEG2K. In some embodiments, the LNPs include one of the following: C12-200, DOPE, cholesterol, DMG-PEG2K; DODAP, DOPE, cholesterol, DMG-PEG2K; HGT5000, DOPE, cholesterol, DMG-PEG2K, HGT5001, DOPE, or DMG-PEG2K. In some embodiments, the LNPs include polyethyleneimine (PEI).

[0120]

[0151] In some embodiments, the circular RNA is substantially non-immunogenic. In some embodiments, the circular RNA is considered non-immunogenic if it does not induce the expression or activity of one or more interferon-regulated genes (e.g., one or more genes listed at www.interferome.org). In some embodiments, the interferon-regulated genes are selected from IFN-α, IFN-β, and / or TNF-α. Various modifications can be made to the circular RNA to reduce its immunogenicity. For example, in some embodiments, the circular RNA is modified with one or more M-6-methyladenosine (m-6-methyladenosine) amines. 6 A), 5-methyl-cytosine (5mC), or pseudouridine residues.

[0121]

[0152] In some embodiments, the circular RNA described herein is less immunogenic than linear RNA.For example, in some embodiments, the circular RNA does not substantially induce the expression and / or activity of one or more interferon-regulating genes.In some embodiments, the expression and / or activity of one or more interferon-regulating genes induced by the circular RNA is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% lower than that of linear RNA.

[0122]

[0153] In some embodiments, the circular RNA described herein has a longer cellular half-life than linear RNA.For example, the circular RNA can have about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, 2 times, 3 times, 4 times, 5 times, 10 times or more longer half-life than linear RNA.In some embodiments, the circular RNA can have about 4 hours, about 12 hours, about 18 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 10 days, or about 10 days longer half-life than linear RNA.

[0123]

[0154] In some embodiments, circular RNA does not replicate in cells.In some embodiments, circular RNA does not have the risk of genome integration.Therefore, the circular RNA described herein provides "footprint-free" cell modification, in which the genomic DNA of cells remains unmodified by circular RNA composition.

[0124]

[0155] Circular RNA may be generated using any suitable method known in the art. In some embodiments, circular RNA is generated using in vitro transcription (IVT) following standard protocols and / or using commercially available kits (e.g., MAXIscript® or MEGAscript® kits from ThermoFisher®). For example, an illustrative IVT protocol uses a purified linear DNA template (i.e., a DNA molecule encoding a circular RNA as described herein), a buffer system containing ribonucleotide triphosphates, DTT and magnesium ions, and a suitable phage RNA polymerase for the generation of circular RNA. The DNA template includes a double-stranded promoter region where the phage polymerase binds and initiates RNA synthesis. The reaction conditions (e.g., type of nucleotide salt, type and concentration of salt in the transcription buffer, enzyme concentration and pH) are optimized for the specific polymerase and overall set of components used to achieve optimal yields. Large scale IVT reactions can produce up to 120-180 μg of RNA per microgram of template in a 20 μl reaction. In some embodiments, circular RNA may be generated using RNA synthesis following standard protocols.

[0125]

[0156] Various methods of circularizing RNA are known in the art. For example, an exemplary protocol for circularizing linear RNA is provided in Figure 1, and a list of exemplary linear RNA circularization strategies is provided in Figures 2A-2G. In some embodiments, the RNA self-circularizes, for example, if it contains a self-splicing intron.

[0126]

[0157] Also provided herein are nucleic acids (ie, DNA molecules) encoding the circular RNAs described herein, and vectors containing same.

[0127] Circular RNAs encoding reprogramming factors

[0158] In some embodiments, the circular RNA encodes a reprogramming factor. In some embodiments, the reprogramming factor is a human or humanized reprogramming factor. In some embodiments, the reprogramming factor is a transcription factor.

[0128]

[0159] In some embodiments, the reprogramming factor can be, for example, any one of the reprogramming factors listed in Table 1. In some embodiments, the reprogramming factor is a fragment or variant of any one of the reprogramming factors listed in Table 1. In some embodiments, the reprogramming factor has at least 90%, at least 95%, or at least 99% sequence identity to any one of the reprogramming factors listed in Table 1.

[0129] [Table 1]

[0130] [Table 2]

[0131] [Table 3]

[0132]

[0160] In some embodiments, the reprogramming factors are the following reprogramming factors: Oct4, Sox2, Klf4, c-Myc, Lin28 (e.g., Lin28A or Lin28B), Nanog, Sall4, Utf1, p53, p21, p16 Ink4a, GLIS1, L-Myc, TGF-β, MDM2, REM2, cyclin D1, SV40 large T antigen, DOT1L, CX43, MBD3, SIRT6, TCL1a, RARy, SNAIL, Lrh-1, or RCOR2, or any combination thereof. In some embodiments, the reprogramming factor is any one of the following reprogramming factors: Oct4, Sox2, Klf4, c-Myc, Lin28 (e.g., Lin28A or Lin28B), Nanog, Sall4, Utf1, p53, p21, p16 Ink4a , GLIS1, L-Myc, TGF-β, MDM2, REM2, cyclin D1, SV40 large T antigen, DOT1L, CX43, MBD3, SIRT6, TCL1a, RARy, SNAIL, Lrh-1, or RCOR2, or a fragment or variant of any one of these combinations.

[0133]

[0161] In some embodiments, the reprogramming factor is any one of Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, and / or L-Myc, or a fragment or variant thereof. In some embodiments, the reprogramming factor is Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), and / or c-Myc, or a fragment or variant thereof. In some embodiments, the reprogramming factor is Oct3 / 4, Klf4, and / or Sox2, or a fragment or variant thereof. In some embodiments, the reprogramming factor is Oct3 / 4, Klf4, Sox2, and / or c-Myc, or a fragment or variant thereof. In some embodiments, the reprogramming factors are Oct3 / 4, Klf4, Sox2, Nanog, and / or Lin28 (e.g., Lin28A or Lin28B), or fragments or variants thereof. In some embodiments, the reprogramming factors are human or humanized reprogramming factors.

[0134]

[0162] In some embodiments, the circular RNA encodes the reprogramming factor Oct3 / 4. In some embodiments, the encoded Oct3 / 4 has the amino acid sequence of SEQ ID NO:7, or a sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto. In some embodiments, the circular RNA encodes the reprogramming factor Oct3 / 4 and comprises or consists of the nucleic acid sequence of SEQ ID NO:8. In some embodiments, the circular RNA encodes the reprogramming factor Oct3 / 4 and comprises a nucleic acid sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto.

[0135]

[0163] In some embodiments, the circular RNA encodes the reprogramming factor Klf4. In some embodiments, the encoded Klf4 has the amino acid sequence of SEQ ID NO: 9 or 10, or a sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto. In some embodiments, the circular RNA encodes the reprogramming factor Klf4 and comprises or consists of the nucleic acid sequence of SEQ ID NO: 11. In some embodiments, the circular RNA encodes the reprogramming factor Klf4 and comprises a nucleic acid sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto.

[0136]

[0164] In some embodiments, the circular RNA encodes the reprogramming factor Sox2. In some embodiments, Sox2 has the amino acid sequence of SEQ ID NO: 12, or a sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto. In some embodiments, the circular RNA encodes the reprogramming factor Sox2 and comprises or consists of the nucleic acid sequence of SEQ ID NO: 13. In some embodiments, the circular RNA encodes the reprogramming factor Sox2 and comprises a nucleic acid sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto.

[0137]

[0165] In some embodiments, the circular RNA encodes the reprogramming factor Nanog. In some embodiments, Nanog has the amino acid sequence of SEQ ID NO: 14 or 15, or a sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto. In some embodiments, the circular RNA encodes the reprogramming factor Nanog and comprises or consists of the nucleic acid sequence of SEQ ID NO: 16. In some embodiments, the circular RNA encodes the reprogramming factor Nanog and comprises a nucleic acid sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto.

[0138]

[0166] In some embodiments, the circular RNA encodes the reprogramming factor Lin28A. In some embodiments, Lin28A has the amino acid sequence of SEQ ID NO: 17, or a sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto. In some embodiments, the circular RNA encodes the reprogramming factor Lin28A and comprises or consists of the nucleic acid sequence of SEQ ID NO: 18. In some embodiments, the circular RNA encodes the reprogramming factor Lin28A and comprises a nucleic acid sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto.

[0139]

[0167] In some embodiments, the circular RNA encodes the reprogramming factor c-Myc. In some embodiments, the c-Myc has an amino acid sequence of SEQ ID NO: 19 or 20, or a sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto. In some embodiments, the circular RNA encodes the reprogramming factor c-Myc and comprises or consists of the nucleic acid sequence of SEQ ID NO: 21. In some embodiments, the circular RNA encodes the reprogramming factor c-Myc and comprises a nucleic acid sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto.

[0140]

[0168] In some embodiments, the circular RNA encodes the reprogramming factor L-Myc. In some embodiments, the L-Myc has the amino acid sequence of any one of SEQ ID NOs: 22-24, or a sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto. In some embodiments, the circular RNA encodes the reprogramming factor L-Myc and comprises or consists of the nucleic acid sequence of SEQ ID NO: 25. In some embodiments, the circular RNA encodes the reprogramming factor L-Myc and comprises a nucleic acid sequence at least 90% or at least 95%, 96%, 97%, 98%, or 99% identical thereto.

[0141]

[0169] In some embodiments, the circular RNA comprises two or more protein-coding nucleic acid sequences. For example, the circular RNA may comprise three, four, five, or six protein-coding sequences. In some embodiments, at least one of the protein-coding sequences encodes a reprogramming factor (e.g., a transcription factor). In some embodiments, the circular RNA comprises two, three, four, five, or six protein-coding sequences that encode a combination of reprogramming factors according to any one of combinations 1-106 in Table 3.

[0142]

[0170] In some embodiments, the circular RNA comprises two or more protein coding sequences, where at least one of the protein coding sequences encodes a reprogramming factor. In some embodiments, the circular RNA comprises two or more protein coding sequences, where at least one of the protein coding sequences encodes one or more of Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, or L-Myc, or a fragment or variant thereof. In some embodiments, the circular RNA comprises two or more protein coding sequences, where each of the protein coding sequences encodes a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, and L-Myc, or a fragment or variant thereof.

[0143]

[0171] In some embodiments, the circular RNA comprises a sequence encoding Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, or L-Myc. In some embodiments, the circular RNA comprises a first intron element, a sequence encoding Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, or L-Myc, and a second intron element.

[0144]

[0172] In some embodiments, the circular RNA comprises an IRES and a sequence encoding Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, or L-Myc. In some embodiments, the circular RNA comprises a first intron element, an IRES, a sequence encoding Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, or L-Myc, and a second intron element.

[0145] RNA polynucleotides encoding accessory factors

[0173] In some embodiments, the present disclosure provides an RNA polynucleotide (e.g., a linear RNA polynucleotide or a circular RNA) that encodes an exogenous factor that aids in the reprogramming of cells. In some embodiments, the exogenous factor is an RNA, such as a microRNA (miRNA) or a long non-coding RNA (e.g., LINcRNA-ROR). miRNAs, such as the miRNA302(a-d) cluster and miR367, have been shown to improve reprogramming efficiency when used in conjunction with reprogramming factors (see U.S. Pat. No. 8,791,248; U.S. Pat. No. 8,852,940; Poleganov et al., Human Gene Therapy. Nov 2015. 751-766). For example, the miRNA can be any one of the miRNA302 family (e.g., miR302d, miR302a, miR302c, and miR302b), miR367, miR766, miR200c, miR369, miR372, Let7, miR19a / b), or a fragment or variant thereof.

[0146]

[0174] In some embodiments, the auxiliary factor is a circular RNA that is enriched in human stem cells (e.g., human ESCs), such as circBIRC6, circCORO1C, or circMAN1A2. circBIRC6, circCORO1C, and circMAN1A2. These circular RNAs are thought to act as "miR sponges." As such, these factors may have a regulatory role in promoting pluripotency by acting against certain miRNAs (e.g., miR34a and / or miR145) known to suppress the expression of pluripotency-associated transcription factors NANOG, SOX2, and OCT4 (Yu et al. Nat Commun 8, 1149 (2017)).

[0147]

[0175] In some embodiments, the auxiliary factor is one or more viral proteins that inhibit the innate immune response. The viral protein can be, for example, an inhibitor of the RIG-1 (retinoic acid inducible gene I) or PKR (protein kinase R) pathway. Exemplary viral proteins are provided in Table 2 below. Exemplary viral proteins suitable for use in the methods described herein include, but are not limited to, B18R, E3, or K3 from vaccinia virus. An exemplary B18R sequence is provided as SEQ ID NO:26. In some embodiments, the B18R protein has a sequence at least 90%, or at least 95% identical to SEQ ID NO:26. An exemplary E3 sequence is provided as SEQ ID NO:27. In some embodiments, the E3 protein has a sequence at least 90%, or at least 95% identical to SEQ ID NO:27. An exemplary K3 sequence is provided as SEQ ID NO:28. In some embodiments, the K3 protein has a sequence at least 90%, or at least 95% identical to SEQ ID NO:28.

[0148] [Table 4]

[0149] Circular RNA composition

[0176] In some embodiments, the present disclosure provides a composition of a circular RNA encoding a reprogramming factor. In some embodiments, the composition further comprises a buffer. The buffer may comprise, for example, 1 to 10 mM sodium citrate. In some embodiments, the pH of the buffer is about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10, about 10.5, about 11, about 11.5, or about 12. In some embodiments, the pH of the buffer is about 6.5.

[0150]

[0177] In some embodiments, the composition comprises two or more circular RNAs, each encoding a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, and L-Myc. In some embodiments, the composition comprises two or more circular RNAs, each encoding a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), and c-Myc. In some embodiments, the composition comprises two or more circular RNAs, each encoding a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, and Lin28 (e.g., Lin28A or Lin28B). In some embodiments, the composition comprises two or more circular RNAs, each encoding a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, and Lin28 (e.g., Lin28A or Lin28B). In some embodiments, the composition comprises two or more circular RNAs, each encoding a reprogramming factor selected from Oct3 / 4, Klf4, and Sox2. In some embodiments, the composition comprises two or more circular RNAs, each encoding a reprogramming factor selected from the combinations provided in Table 3. In Table 3, each row represents a different combination of circular RNAs, where "X" indicates that the circular RNA is contacted with a cell. For example, in combination #1, the composition comprises a circular RNA encoding Oct3 / 4 and a circular RNA encoding Klf4. In combination #104, the composition comprises a circular RNA encoding Oct3 / 4, Klf4, Sox2, and Nanog, Lin28 (e.g., Lin28A or Lin28B), and L-Myc.

[0151] [Table 5]

[0152] [Table 6]

[0153] [Table 7]

[0154] [Table 8]

[0155]

[0178] In some embodiments, the composition comprises two circular RNAs, one of which encodes Oct3 / 4 and the other of which encodes a reprogramming factor selected from the group consisting of Klf4, Sox2, Lin28 (e.g., Lin28A or Lin28B), Nanog, and c-Myc or L-Myc. In some embodiments, the composition comprises two circular RNAs, each of which encodes a reprogramming factor selected from Oct3 / 4 and Lin28 (e.g., Lin28A or Lin28B), or a fragment or variant thereof. In some embodiments, the composition comprises two circular RNAs, each of which encodes a reprogramming factor selected from Oct3 / 4 and Sox2, or a fragment or variant thereof.

[0156]

[0179] In some embodiments, the composition comprises three circular RNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Klf4, Sox2, or a fragment or variant thereof. In some embodiments, the composition does not comprise a circular RNA encoding a reprogramming factor selected from the group consisting of Nanog, Lin28 (e.g., Lin28A or Lin28B), and / or c-Myc, or a fragment or variant thereof. In some embodiments, the composition comprises three circular RNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Klf4, Sox2, or a fragment or variant thereof. In some embodiments, the composition comprises three circular RNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Klf4, Lin28 (e.g., Lin28A or Lin28B), or a fragment or variant thereof. In some embodiments, the composition does not comprise a circular RNA encoding a reprogramming factor selected from the group consisting of Nanog, Sox2, and / or c-Myc, or a fragment or variant thereof. In some embodiments, the composition comprises three circular RNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Klf4, Lin28 (e.g., Lin28A or Lin28B), or a fragment or variant thereof. In some embodiments, the composition comprises three circular RNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Sox2, Lin28 (e.g., Lin28A or Lin28B), or a fragment or variant thereof. In some embodiments, the composition does not comprise a circular RNA encoding a reprogramming factor selected from Nanog, Klf4, and / or c-Myc, or a fragment or variant thereof. In some embodiments, the composition comprises three circular RNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Sox2, Lin28 (e.g., Lin28A or Lin28B), or a fragment or variant thereof.

[0157]

[0180] In some embodiments, the composition comprises four circular RNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Klf4, Sox2, and c-Myc, or a fragment or variant thereof. In some embodiments, the composition does not comprise a circular RNA encoding a reprogramming factor selected from the group consisting of Nanog and / or Lin28 (e.g., Lin28A or Lin28B), or a fragment or variant thereof. In some embodiments, the composition comprises four circular RNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Klf4, Sox2, and c-Myc, or a fragment or variant thereof. In some embodiments, the composition comprises five circular RNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, and / or Lin28 (e.g., Lin28A or Lin28B), or a fragment or variant thereof. In some embodiments, the composition does not comprise a circular RNA encoding c-Myc, or a fragment or variant thereof. In some embodiments, the composition comprises five circular RNAs, each encoding a reprogramming factor or a fragment or variant thereof selected from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, and / or Lin28 (e.g., Lin28A or Lin28B). In some embodiments, the composition comprises six circular RNAs, each encoding a reprogramming factor or a fragment or variant thereof selected from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc. In some embodiments, the composition comprises six circular RNAs, each encoding a reprogramming factor or a fragment or variant thereof selected from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc.

[0158]

[0181] In some embodiments, the composition comprises one or more circular RNAs encoding one or more reprogramming factors, and further comprises at least one additional auxiliary factor that may assist in reprogramming cells. In some embodiments, the composition further comprises an RNA polynucleotide (e.g., a linear RNA polynucleotide or a circular RNA) encoding the auxiliary factor. In some embodiments, the auxiliary factor is selected from miRNA (e.g., miRNA302 family (e.g., miR302d, miR302a, miR302c and miR302b), miR367, miR766, miR200c, miR369, miR372, Let7, miR19a / b), long non-coding RNA (e.g., LINcRNA-ROR), and exogenous circRNA (e.g., circBIRC6, circCORO1C, or circMAN1A2, circBIRC6, circCORO1C and circMAN1A2), or viral proteins (e.g., those listed in Table 2). In some embodiments, the composition consists of one or more circular RNAs encoding one or more reprogramming factors and does not include any additional RNA polynucleotides (e.g., linear RNA polynucleotides or circular RNAs) encoding auxiliary factors that may aid in reprogramming a cell.

[0159] Methods for reprogramming cells

[0182] In some embodiments, the present disclosure provides a method for reprogramming somatic cells. In some embodiments, the present disclosure provides a method for reprogramming somatic cells to generate iPSCs. In particular embodiments, the present disclosure provides a method for reprogramming somatic cells in suspension culture to generate iPSCs. In some embodiments, the method for generating iPSCs includes contacting somatic cells (e.g., contacting cells in suspension culture) with at least one of the circular RNAs described herein or compositions thereof and maintaining the cells under conditions to obtain reprogrammed cells (e.g., iPSCs). As used herein, the circular RNA introduced into a cell by the methods described herein is exogenous to the cell. In other words, the circular RNA introduced into a cell does not naturally exist in the cell into which it is introduced.

[0160]

[0183] In some embodiments, the somatic cell is a prokaryotic cell. In some embodiments, the somatic cell is a eukaryotic cell. In some embodiments, the somatic cell is an animal cell. In some embodiments, the somatic cell is a mammalian cell (e.g., a mouse, bovine, monkey, porcine, equine, ovine, or human cell). In some embodiments, the somatic cell is a human cell. In some embodiments, the somatic cell is a yeast, fungal, or plant cell.

[0161]

[0184] In some embodiments, the somatic cells are fibroblasts, peripheral blood-derived cells, endothelial progenitor cells, umbilical cord blood-derived cells, hepatocytes, keratinocytes, melanocytes, adipose tissue-derived cells, or urine-derived cells (e.g., renal epithelial progenitor cells). In some embodiments, the cells are epithelial cells, endothelial cells, neural cells, adipocytes, cardiac cells, skeletal muscle cells, immune cells, liver cells, splenocytes, lung cells, circulating blood cells, gastrointestinal cells, renal cells, chondrocytes, ocular cells, nervous system cells, central nervous system cells, bone cells, bone marrow cells, progenitor cells, or pancreatic cells. In some embodiments, the cells are isolated from any somatic tissue, including, but not limited to, brain, liver, lung, intestine, stomach, intestine, fat, muscle, uterus, skin, spleen, endocrine organs, bone, etc.

[0162]

[0185] In some embodiments, the somatic cells are adherent cells. In some embodiments, the cells are non-adherent cells. In some embodiments, the somatic cells are reprogrammed in suspension cell culture. In some embodiments, the somatic cells are blood cells (e.g., T cells, B cells, NK cells, NKT cells, peripheral blood mononuclear cells, or umbilical cord blood mononuclear cells). In some embodiments, the blood cells are reprogrammed in suspension cell culture. In some embodiments, the somatic cells are T cells or NK cells. In some embodiments, the T cells or NK cells are reprogrammed in suspension cell culture. In some embodiments, the somatic cells are CD34+ cells. In some embodiments, the CD34+ cells are reprogrammed in suspension cell culture.

[0163]

[0186] In some embodiments, the somatic cells are contacted with the circular RNA or composition thereof once. In some embodiments, the somatic cells are contacted with a plurality of different circular RNAs or one or more compositions thereof once. In some embodiments, the somatic cells are contacted with at least two different circular RNAs or one or more compositions thereof (e.g., 2, 3, 4, 5, or 6 circular RNAs or one or more compositions thereof) once. In some embodiments, the contacting is performed in suspension culture. In some embodiments, the cells are contacted with the circular RNA two or more times (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 times). In some embodiments, the cells are contacted with the plurality of circular RNAs two or more times (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 times). In some embodiments, the somatic cells are contacted with the circular RNA or composition thereof 2-6 times. In some embodiments, the somatic cells are contacted with the circular RNA or composition thereof twice. In some embodiments, the somatic cells are contacted with the circular RNA or composition thereof three times. In some embodiments, the somatic cells are contacted with the circular RNA or composition thereof four times. In some embodiments, the somatic cells are contacted with the circular RNA or composition thereof less than four times. In some embodiments, the contact is performed at effective intervals. The effective intervals can be, for example, once a day, once every other day, once every three days, once a week, once every two weeks, or once a month. In some embodiments, the circular RNA is contacted with the cells for the duration of the reprogramming process, and thus the contact is continuous throughout the entire reprogramming process. In some embodiments, the somatic cells are contacted with multiple circular RNAs (e.g., in suspension culture) one or more times, where the number of contacts is different for at least two circular RNAs. For example, in some embodiments, the somatic cells are contacted with multiple circular RNAs (e.g., in suspension culture), where the cells are contacted with at least one of the circular RNAs two or more times, and the cells are contacted with at least one other circular RNA only once. In some embodiments, somatic cells are contacted with multiple circular RNAs (e.g., in suspension culture), where the cells are contacted with at least one of the circular RNAs three or more times, and the cells are contacted with at least one other circular RNA only once or only twice.

[0164]

[0187] In some embodiments, the contacting comprises transfecting the circular RNA into the cell. In various embodiments, the methods described herein comprise directly contacting the cell with the circRNA or a composition thereof. In other words, the circular RNA synthesized or produced in vitro is directly contacted with (and thereby introduced into) the cell without the aid of a viral vector or DNA plasmid.

[0165]

[0188] In some embodiments, a method of reprogramming a cell (e.g., a method of generating iPSCs) includes contacting a somatic cell with a circular RNA or composition thereof, wherein the RNA is present at a concentration of at least 3 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 15 pg / cell, about 4 pg / cell to about 15 pg / cell, about 5 pg / cell to about 15 pg / cell, about 6 pg / cell to about 15 pg / cell, about 7 pg / cell to about 15 pg / cell, about 8 pg / cell to about 15 pg / cell, about 9 pg / cell to about 15 pg / cell, about 10 pg / cell to about 15 pg / cell, about 11 pg / cell to about 15 pg / cell, about 12 pg / cell to about 15 pg / cell, about 13 pg / cell to about 15 pg / cell, or about 14 pg / cell to about 15 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 14 pg / cell, about 4 pg / cell to about 14 pg / cell, about 5 pg / cell to about 4 pg / cell, about 6 pg / cell to about 14 pg / cell, about 7 pg / cell to about 14 pg / cell, about 8 pg / cell to about 14 pg / cell, about 9 pg / cell to about 14 pg / cell, about 10 pg / cell to about 14 pg / cell, about 11 pg / cell to about 14 pg / cell, about 12 pg / cell to about 14 pg / cell, or about 13 pg / cell to about 14 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 13 pg / cell, about 4 pg / cell to about 13 pg / cell, about 5 pg / cell to about 13 pg / cell, about 6 pg / cell to about 13 pg / cell, about 7 pg / cell to about 13 pg / cell, about 8 pg / cell to about 13 pg / cell, about 9 pg / cell to about 13 pg / cell, about 10 pg / cell to about 13 pg / cell, about 11 pg / cell to about 13 pg / cell, or about 12 pg / cell to about 13 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 12 pg / cell, about 4 pg / cell to about 12 pg / cell, about 5 pg / cell to about 12 pg / cell, about 6 pg / cell to about 12 pg / cell, about 7 pg / cell to about 12 pg / cell, about 8 pg / cell to about 12 pg / cell, about 9 pg / cell to about 12 pg / cell, about 10 pg / cell to about 12 pg / cell, or about 11 pg / cell to about 12 pg / cell.In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 11 pg / cell, about 4 pg / cell to about 11 pg / cell, about 5 pg / cell to about 11 pg / cell, about 6 pg / cell to about 11 pg / cell, about 7 pg / cell to about 11 pg / cell, about 8 pg / cell to about 11 pg / cell, about 9 pg / cell to about 11 pg / cell, or about 10 pg / cell to about 11 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 10 pg / cell, about 4 pg / cell to about 10 pg / cell, about 5 pg / cell to about 10 pg / cell, about 6 pg / cell to about 10 pg / cell, about 7 pg / cell to about 10 pg / cell, about 8 pg / cell to about 10 pg / cell, or about 9 pg / cell to about 10 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 9 pg / cell, about 4 pg / cell to about 9 pg / cell, about 5 pg / cell to about 9 pg / cell, about 6 pg / cell to about 9 pg / cell, about 7 pg / cell to about 9 pg / cell, or about 8 pg / cell to about 9 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 8 pg / cell, about 4 pg / cell to about 8 pg / cell, about 5 pg / cell to about 8 pg / cell, about 6 pg / cell to about 8 pg / cell, or about 7 pg / cell to about 8 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 7 pg / cell, about 4 pg / cell to about 7 pg / cell, about 5 pg / cell to about 7 pg / cell, or about 6 pg / cell to about 7 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 6 pg / cell, about 4 pg / cell to about 6 pg / cell, or about 5 pg / cell to about 6 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 5 pg / cell, or about 4 pg / cell to about 5 pg / cell. In some embodiments, the RNA is present at a concentration of about 3 pg / cell to about 4 pg / cell. In some embodiments, the RNA is present at a concentration of about 1 pg / cell, 2 pg / cell, 3 pg / cell, 4 pg / cell, 5 pg / cell, 6 pg / cell, 7 pg / cell, 8 pg / cell, 9 pg / cell, 10 pg / cell, 11 pg / cell, 12 pg / cell, 13 pg / cell, 14 pg / cell, or about 15 pg / cell.

[0166]

[0189] In some embodiments, the circular RNA is transfected into cells using lipid-mediated transfection. Lipid-mediated transfection stimulates the active uptake of nucleic acids by endocytosis. An exemplary lipid-mediated transfection reagent is Lipofectamine® (e.g., Lipofectamine® RNAiMAX® from ThermoFisher®). In some embodiments, the method of transfecting cells includes the steps of (i) diluting RNA and transfection reagent in separate tubes, (ii) combining RNA with transfection reagent to form a complex, (iii) adding the complex to cells, and (iv) assaying cells for protein expression. Detection of protein expression in cells can be achieved by several techniques, including Western blot analysis, immunocytochemistry, and fluorescence-mediated detection (e.g., FACS), among others.

[0167]

[0190] In some embodiments, the contacting comprises electroporating the circular RNA or composition thereof into the cell. Electroporation delivers nucleic acid by transiently opening holes in the cell membrane while the cell is in a solution in which the nucleic acid is present at high concentration. In some embodiments, electroporation uses the Neon® electroporation system.

[0168]

[0191] In some embodiments, the contacting comprises incubating the cells with the circRNA-LNP complex.

[0169]

[0192] In some embodiments, the contacting comprises one or more techniques, such as ballistic transfection (i.e., gene gun or biolistic transfection), magnetofection, peptide-mediated transfection (either non-covalent peptide / RNA nanoparticle-based transfection, such as Sigma-Aldrich's N-TER™ transfection system, or by covalently attaching peptides to RNA), and / or microinjection. Combinations of these techniques, used sequentially or simultaneously, can also be used.

[0170]

[0193] In some embodiments, a method of reprogramming a cell (e.g., a method of generating an iPSC) comprises contacting a somatic cell with at least one circular RNA encoding a reprogramming factor (e.g., a transcription factor) and maintaining the cell under conditions to obtain a reprogrammed cell (e.g., an iPSC). The reprogramming factor can be, for example, any of the reprogramming factors shown in Table 1. In some embodiments, the cell is contacted with a plurality of circular RNAs, where each circular RNA encodes a reprogramming factor selected from the reprogramming factors shown in Table 1.

[0171]

[0194] In some embodiments, the present disclosure provides a method of reprogramming a cell, wherein the cell is contacted with a combination of circular RNA according to any one of combinations 1 to 106 as shown in Table 3A below.

[0172] [Table 9]

[0173] [Table 10]

[0174] [Table 11]

[0175] [Table 12]

[0176]

[0195] In some embodiments, the disclosure provides a method of reprogramming cells in suspension comprising contacting the cells with a combination of circular RNAs according to any one of combinations 1-106 as shown in Table 3A above. In some embodiments, the circular RNAs of such combination (i.e., one of combinations 1-106) are contacted with the cells in suspension multiple times. In some embodiments, at least one of the circular RNAs of such combination (i.e., one of combinations 1-106) are contacted with the cells in suspension multiple times, and at least one of the circular RNAs of such combination is contacted with the cells in suspension once. In some embodiments, one or more of the circular RNAs of such combination are contacted with the cells in suspension one, two, three, or four times.

[0177]

[0196] In some embodiments, the disclosure provides a method of reprogramming blood cells (e.g., T cells, B cells, NK cells, NKT cells, peripheral blood mononuclear cells, umbilical cord blood mononuclear cells, CD34+ cells), comprising contacting the cells with a combination of circular RNAs according to any one of combinations 1-106 as shown in Table 3A above. In some embodiments, the blood cells are T cells. In some embodiments, the circular RNAs of such combinations (i.e., one of combinations 1-106) are contacted multiple times with T cells in suspension. In some embodiments, at least one of the circular RNAs of such combinations (i.e., one of combinations 1-106) are contacted multiple times with T cells in suspension, and at least one other of the circular RNAs of such combinations are contacted once with T cells in suspension. In some embodiments, one or more of the circular RNAs of such combinations are contacted once, twice, three times, or four times with T cells in suspension.

[0178]

[0197] In some embodiments, the blood cells are NK cells. In some embodiments, such combinations (i.e., one of combinations 1-106 of circular RNAs) are contacted with NK cells in suspension multiple times. In some embodiments, at least one of such combinations (i.e., one of combinations 1-106 of circular RNAs) is contacted with NK cells in suspension multiple times, and at least one of such combinations of circular RNAs is contacted with NK cells in suspension once. In some embodiments, one or more of such combinations of circular RNAs are contacted with NK cells in suspension one, two, three, or four times.

[0179]

[0198] In some embodiments, the disclosure provides a method of reprogramming CD34+ cells in suspension comprising contacting CD34+ cells with a combination of circular RNAs according to any one of combinations 1-106 as shown in Table 3A above. In some embodiments, the circular RNAs of such combination (i.e., one of combinations 1-106) are contacted with CD34+ cells in suspension multiple times. In some embodiments, at least one of the circular RNAs of such combination (i.e., one of combinations 1-106) are contacted with CD34+ cells in suspension multiple times and at least one other of the circular RNAs of such combination are contacted with CD34+ cells in suspension once. In some embodiments, one or more of the circular RNAs of such combination are contacted with CD34+ cells in suspension one, two, three, or four times.

[0180]

[0199] In some embodiments, the reprogramming factor is Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, or L-Myc. In some embodiments, the reprogramming factor is Oct3 / 4. In some embodiments, the reprogramming factor is Klf4. In some embodiments, the reprogramming factor is Sox2. In some embodiments, the reprogramming factor is Nanog. In some embodiments, the reprogramming factor is Lin28 (e.g., Lin28A or Lin28B). In some embodiments, the reprogramming factor is c-Myc. In some embodiments, the reprogramming factor is L-Myc.

[0181]

[0200] In some embodiments, a method of reprogramming a cell (e.g., a method of generating iPSCs) comprises contacting a somatic cell with two or more circular RNAs, each encoding a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, and L-Myc, and maintaining the cell under conditions to obtain a reprogrammed cell (e.g., iPSCs). In some embodiments, the cell is contacted with at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more circular RNAs, each encoding a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, or L-Myc.

[0182]

[0201] In some embodiments, the method of reprogramming a cell (e.g., a method of generating an iPSC) comprises contacting a somatic cell with six circular RNAs encoding the reprogramming factors Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), and c-Myc. In some embodiments, the method of reprogramming a cell (e.g., a method of generating an iPSC) comprises contacting a somatic cell with six circular RNAs encoding the reprogramming factors Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), and L-Myc.

[0183]

[0202] In some embodiments, the method of reprogramming a cell (e.g., a method of generating iPSCs) comprises contacting a somatic cell with five circular RNAs encoding the reprogramming factors Oct3 / 4, Klf4, Sox2, Nanog, and Lin28 (e.g., Lin28A or Lin28B). In some embodiments, the method does not comprise contacting a somatic cell with a circular RNA encoding c-Myc or L-Myc.

[0184]

[0203] In some embodiments, the method of reprogramming a cell (e.g., a method of generating iPSCs) comprises contacting a somatic cell with four circular RNAs encoding the reprogramming factors Oct3 / 4, Klf4, Sox2, and c-Myc. In some embodiments, the method of reprogramming a cell (e.g., a method of generating iPSCs) comprises contacting a somatic cell with four circular RNAs encoding the reprogramming factors Oct3 / 4, Klf4, Sox2, and L-Myc. In some embodiments, the method does not comprise contacting a somatic cell with a circular RNA encoding Nanog and / or Lin28 (e.g., Lin28A or Lin28B).

[0185]

[0204] In some embodiments, the method of reprogramming a cell (e.g., a method of generating iPSCs) comprises contacting a somatic cell with three circular RNAs encoding the reprogramming factors Oct3 / 4, Klf4, and Sox2. In some embodiments, the method does not comprise contacting a somatic cell with circular RNAs encoding Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, and / or L-myc.

[0186]

[0205] In some embodiments, a method of reprogramming a somatic cell (e.g., generating iPSCs) comprises contacting the somatic cell with one or more circular RNAs encoding one or more reprogramming factors, and further comprises contacting the cell with at least one additional RNA polynucleotide (e.g., a linear RNA polynucleotide or a circular RNA) encoding an auxiliary factor that can aid in reprogramming the cell. In some embodiments, the auxiliary factor is selected from miRNA (e.g., miRNA302(a-d), miR367, miR766, miR200c, miR369, miR372, Let7, miR19a / b), long non-coding RNA (e.g., LINcRNA-ROR), and exogenous circRNA (e.g., circBIRC6, circCORO1C, or circMAN1A2, circBIRC6, circCORO1C, and circMAN1A2), or viral proteins (e.g., those listed in Table 2). In some embodiments, a method of reprogramming somatic cells (e.g., generating iPSCs) comprises contacting the somatic cells with one or more circular RNAs encoding one or more reprogramming factors, and further comprises contacting the cells with at least one additional exogenous factor selected from Vitamin C, Valproic Acid, CHIR99021, Parnate, SB431542, PD0325901, BIX-01294, Lithium Maxadilan, 8-Br-cAMP, A-83-01, Tiazovivin, Y-27632, EPZ004777, and DAPT.

[0187]

[0206] In some embodiments, the method of reprogramming a somatic cell (e.g., generating iPSCs) comprises contacting the somatic cell with one or more circular RNAs encoding one or more reprogramming factors, and does not include contacting the cell with any additional RNA polynucleotides (e.g., linear RNA polynucleotides or circular RNAs) encoding auxiliary factors that may aid in reprogramming the cell. In some embodiments, the method of reprogramming a somatic cell (e.g., generating iPSCs) comprises contacting the somatic cell with one or more circular RNAs encoding one or more reprogramming factors, and does not include contacting the cell with auxiliary factors that aid in reprogramming the cell.

[0188]

[0207] Some illustrative RNA combinations that may be used in the methods of reprogramming cells are shown in Table 4 below. In Table 4, each row represents a different combination that may be contacted with a cell, where "X" indicates that RNA is contacted with the cell. For example, in combination #1, the cell is contacted with a circular RNA encoding a reprogramming factor. In combination #15, the cell is contacted with a circular RNA encoding a reprogramming factor, a circular RNA that does not encode any protein or miRNA, a circular or linear RNA encoding a miRNA, and a circular or linear RNA encoding a viral protein.

[0189] [Table 13]

[0190]

[0208] The contacting may be performed by any of the methods described above, such as by transfection, electroporation, and / or using a circRNA-LNP complex. In some embodiments, the contacting comprises incubating the cells with one or more circular RNAs, such as circular RNAs encoding reprogramming factors.

[0191]

[0209] In some embodiments, the method of making iPSCs may include maintaining the cells under conditions under which reprogrammed iPSCs are obtained. Such conditions are known to those skilled in the art and may vary depending on the cell type. As an example, the somatic cells may first be placed in a flask with an appropriate medium so that it is about 75% to about 90% confluent on the day of contact with the circRNA (day 0). The cells may then be contacted with the circRNA (e.g., by transfection). The transfected cells may be placed in a culture dish and incubated overnight. The medium may be changed as needed for the next 10 to 14 days. In some embodiments, the medium may be supplemented with one or more additional agents to enhance the reprogramming of the cells. The cells may be monitored for the appearance of iPSC colonies, which are picked and transferred to another dish for expansion.

[0192]

[0210] To confirm the pluripotency of iPSCs, isolated clones can be tested for the expression of one or more stem cell markers. Stem cell markers can be selected from, for example, Oct4, Lin28 (e.g., Lin28A or Lin28B), SOX2, SSEA4, SSEA3, TRA-1-81, TRA-1-60, CD9, Nanog, Fbxl5, Ecatl, Esgl, Eras, Gdf3, Fgf4, Cripto, Daxl, Zpf296, Slc2a3, Rexl, Utfl, and Nat1. Methods for detecting the expression of such markers can include, for example, RT-PCR and immunological methods for detecting the presence of the encoded polypeptide.

[0193]

[0211] In some embodiments, the pluripotency of the cells is confirmed by measuring the ability of the cells to differentiate into cells of each of the three germ layers. In some embodiments, teratoma formation in immunocompromised rodents can be used to determine the pluripotency nature of isolated clones.

[0194]

[0212] In some embodiments, circRNA reprogramming requires less frequent and / or fewer transfections to achieve iPSC reprogramming (compared to linear RNA-based approaches). For example, circRNA reprogramming may require about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% fewer transfections to achieve reprogramming when compared to linear RNA-based approaches.

[0195]

[0213] In some embodiments, circRNA reprogramming enhances reprogramming efficiency compared to linear RNA-based approaches. "Reprogramming efficiency" refers to a quantitative or qualitative measure of iPSC generation from a starting cell population. Readouts of reprogramming efficiency include quantification of the number of iPSC colonies present at a particular time point during a reprogramming protocol (as an assessment of colony formation rate) or at the completion of a reprogramming protocol (as an assessment of the total number of iPSC colonies generated during a particular protocol). iPSC colonies can be identified quantitatively (such as by staining for pluripotency markers and counting the number of stained cells) or qualitatively by assessment of morphological characteristics (e.g., tightly packed cells, such that each cell in the colony has a more or less uniform shape and diameter, the colony contains clearly defined borders, and the cells within the iPSC colony contain high nuclear to cytoplasmic ratios and prominent nucleoli). Reprogramming efficiency can also include assessment of the relative maturity of iPSC colonies among various reprogramming protocols. The maturity of iPSC colonies can be determined by the morphological characteristics noted above.

[0196]

[0214] Increased reprogramming efficiency refers to an increase in one or more readouts of reprogramming efficiency when comparing two or more reprogramming protocols. For example, and as detailed in this example, reprogramming with circRNA-encoded reprogramming factors increases reprogramming efficiency compared to reprogramming with linear RNA-encoded reprogramming factors.

[0197]

[0215] In some embodiments, an increase in reprogramming efficiency comprises an increase in the total number of iPSC colonies present at the end of a first reprogramming protocol compared to the total number of iPSC colonies present at the end of a second and / or third reprogramming protocol. In some embodiments, an increase in reprogramming efficiency comprises an increase in the total number of iPSC colonies present at a particular time point during a first reprogramming protocol compared to the total number of iPSC colonies present at the same time point during a second and / or third reprogramming protocol (i.e., an increase in the rate of iPSC colony formation).

[0198] Methods for cell transdifferentiation

[0216] Provided herein is a method for transdifferentiating cells using circular RNA. In some embodiments, the method for directly converting cells from a first cell type to a second cell type comprises contacting the cells with circular RNA or a composition thereof as described herein, and maintaining the cells under conditions in which the cells are converted to the second cell type. In some embodiments, the cells do not enter an intermediate pluripotent state. In some embodiments, the cells are directly converted from a first cell type to a second cell type, and do not become progenitor cells.

[0199]

[0217] In some embodiments, the circular RNA encodes one or more transdifferentiation factors capable of transdifferentiating a cell from a first cell type to a second cell type. In some embodiments, a reprogramming factor (e.g., a reprogramming factor in Table 1) can function as a transdifferentiation factor in a given context or when used in combination with other transdifferentiation factors. For example, Sox2 functions as a reprogramming factor when used in reprogramming a somatic cell to an iPSC, but functions as a transdifferentiation factor when used in transdifferentiating a first somatic cell (e.g., a fibroblast) to a second somatic cell (e.g., a neural stem cell or a cardiomyocyte). In some embodiments, the circular RNA encodes MyoD, C / EBPα, C / EBPβ, Pdx1, Ngn3, Mafa, Pdx1, Hnf4α, Foxa1, Foxa2, Foxa3, Ascl1 (also known as Mash1), Brn2, Myt11, miR-124, Brn2, Myt11, Ascl1, Nurr1, Lmx1a, Ascl1, Brn2, Myt11, Lmx1a, FoxA2, ​​Oct4, Sox2, Klf4, and c-Myc, Tbx5, Mef2c, Gata-4, and / or Mesp1. In some embodiments, the circular RNA encodes one or more reprogramming factors listed in Table 1.

[0200]

[0218] In some embodiments, the first cell type is an iPSC. In some embodiments, the first cell type is a differentiated fibroblast.

[0201]

[0219] In some embodiments, the second cell type is a muscle cell, a neuron, a cardiomyocyte, a hepatocyte, a kidney cell, a chondrocyte, a bone cell, an islet cell, a keratinocyte, a T cell, or a NK cell. In some embodiments, the second cell type is a muscle cell, a neuron, a cardiomyocyte, a hepatocyte, a pancreatic islet cell, a keratinocyte, a T cell, or a NK cell.

[0202]

[0220] In some embodiments, a method for directly converting a cell from a first cell type to a second cell type comprises contacting a cell with a plurality of circular RNAs, wherein each circular RNA encodes a transdifferentiation factor according to one of the combinations listed in Table 5.

[0203]

[0221] In some embodiments, a method for directly converting a cell from a first cell type to a second cell type comprises contacting the cell with a plurality of circular RNAs, where each circular RNA encodes a transdifferentiation factor listed in Table 5. In some embodiments, the cell is contacted with at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more circular RNAs.

[0204]

[0222] In some embodiments, a method for directly converting a cell from a first cell type to a second cell type comprises contacting the cell with two circular RNAs and maintaining the cell under conditions in which the cell is converted to the second cell type. In some embodiments, the first and second circular RNAs each encode a transdifferentiation factor listed in Table 5, wherein the first and second circular RNAs do not encode the same transdifferentiation factor.

[0205]

[0223] In some embodiments, a method for directly converting a cell from a first cell type to a second cell type comprises contacting the cell with three circular RNAs and maintaining the cell under conditions in which the cell is converted to the second cell type. In some embodiments, the first, second, and third circular RNAs each encode a transdifferentiation factor listed in Table 5, wherein the first, second, and third circular RNAs do not encode the same transdifferentiation factor.

[0206]

[0224] In some embodiments, a method for directly converting a cell from a first cell type to a second cell type comprises contacting the cell with four circular RNAs and maintaining the cell under conditions in which the cell is converted to the second cell type. In some embodiments, the first, second, third, and fourth circular RNAs each encode a transdifferentiation factor listed in Table 5, wherein the first, second, third, and fourth circular RNAs do not encode the same transdifferentiation factor.

[0207]

[0225] In some embodiments, a method for directly converting a cell from a first cell type to a second cell type comprises contacting the cell with five circular RNAs and maintaining the cell under conditions in which the cell is converted to the second cell type. In some embodiments, the first, second, third, fourth, and fifth circular RNAs each encode a transdifferentiation factor listed in Table 5, wherein the first, second, third, fourth, and fifth circular RNAs do not encode the same transdifferentiation factor.

[0208]

[0226] In some embodiments, a method for directly converting a cell from a first cell type to a second cell type comprises contacting the cell with six circular RNAs and maintaining the cell under conditions in which the cell is converted to the second cell type. In some embodiments, the first, second, third, fourth, fifth, and sixth circular RNAs each encode a transdifferentiation factor listed in Table 5, wherein the first, second, third, fourth, fifth, and sixth circular RNAs do not encode the same transdifferentiation factor.

[0209]

[0227] In some embodiments, a method for directly converting a cell from a first cell type to a second cell type comprises contacting the cell with seven circular RNAs and maintaining the cell under conditions in which the cell is converted to the second cell type. In some embodiments, the first, second, third, fourth, fifth, and sixth circular RNAs each encode a transdifferentiation factor listed in Table 5, wherein the first, second, third, fourth, fifth, and sixth circular RNAs do not encode the same transdifferentiation factor.

[0210]

[0228] In some embodiments, a method for directly converting a cell from a first cell type to a second cell type comprises contacting the cell with a plurality of circular RNAs and maintaining the cell under conditions in which the cell is converted to the second cell type. In some embodiments, each of the circular RNAs each encodes a transdifferentiation factor listed in Table 5, wherein none of the circular RNAs encodes the same transdifferentiation factor.

[0211]

[0229] In some embodiments, the cells are contacted with a circular RNA encoding one or more reprogramming factors listed in Table 5. In some embodiments, a method of directly converting a cell from a first cell type as listed in Table 5 to a second cell type as listed in Table 5 comprises contacting the cell with a circular RNA encoding one or more reprogramming factors listed in Table 5 and maintaining the cell under conditions in which the cell is converted to the second cell type. The first cell type can be, for example, any of the cell types listed in Table 5. The second cell type can be, for example, any of the cell types listed in Table 5.

[0212]

[0230] In some embodiments, the disclosure provides compositions comprising one or more circular RNAs, where each circular RNA encodes one or more of the transdifferentiation factors listed in Table 5. In some embodiments, the disclosure provides compositions comprising a plurality of circular RNAs, where each circular RNA encodes at least one of the transdifferentiation factors listed in Table 5.

[0213]

[0231] In some embodiments, a method of transdifferentiation of a cell comprises contacting a cell with one or more circular RNAs, wherein each of the circular RNAs encodes a transdifferentiation factor listed in Table 5. In some embodiments, a method of transdifferentiation of a cell comprises contacting a cell with one or more circular RNAs, wherein each of the circular RNAs encodes a transdifferentiation factor listed in Table 5, wherein the cell is any one of the "first cell types" listed in Table 5.

[0214]

[0232] In some embodiments, the method of transdifferentiation of cells comprises contacting a first cell type listed in column A of any combination number shown in Table 5 with a corresponding one or more transdifferentiation factors listed in column B of that same transdifferentiation combination to produce a second cell type listed in column C of that same combination number, where at least one transdifferentiation factor listed in column B is encoded by a circular RNA. In some embodiments, all of the one or more transdifferentiation factors listed in column B for a given transdifferentiation combination are encoded by one or more circularized RNAs. In some embodiments, the first cell type is transdifferentiated into a second cell type using a transdifferentiation factor listed in column B for any one of combination numbers 1-151. In some embodiments, the first cell type is any one of the cell types listed in column A for any one of combination numbers 1-151. In some embodiments, the second cell type is any one of the second cell types listed in column C for any one of combination numbers 1-151.

[0215] [Table 14]

[0216] [Table 15]

[0217] [Table 16]

[0218] [Table 17]

[0219] [Table 18]

[0220] [Table 19]

[0221] [Table 20]

[0222]

[0233] Contacting can be performed by any of the methods described above (e.g., by transfection, electroporation, and / or use of circRNA-LNP complexes).

[0223]

[0234] In some embodiments, the cells are contacted with the circular RNA once. In some embodiments, the cells are contacted with the circular RNA more than once, for example, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times. In some embodiments, the contact is performed at an effective interval. The effective interval can be, for example, once a day, once every other day, once every 3 days, once a week, once every 2 weeks, or once a month.

[0224]

[0235] As explained above, the method of directly converting a cell from a first cell type to a second cell type can include maintaining the cell under conditions that convert the cell to the second cell type. Such conditions are known to those skilled in the art and can vary depending on the cell type. As an example, the cells can be contacted with one or more circular RNAs and then cultured in standard medium, optionally supplemented with various reprogramming factors. The cells will be monitored to observe morphology and the presence of markers characteristic of the second cell type.

[0225]

[0236] Also provided herein are transdifferentiated cells produced using the methods described herein.

[0226]

[0237] Also provided herein are compositions comprising transdifferentiated cells, wherein the transdifferentiated cells comprise one or more circular RNAs encoding a transdifferentiation factor. In some embodiments, the transdifferentiated factor is any one of the transdifferentiation factors or combinations of transdifferentiation factors listed in Table 5. In some embodiments, the transdifferentiated cells are any one of the second cell types listed in Table 5. In some embodiments, the transdifferentiated cells are derived from a first cell type that is any one of the first cell types listed in Table 5.

[0227] Differentiation of iPSCs using circular RNA

[0238] Also provided are iPSCs generated using the methods described herein. In some embodiments, the iPSCs express one or more of Oct4, SOX2, Lin28, SSEA4, SSEA3, TRA-1-81, TRA-1-60, CD9, Nanog, Fbxl5, Ecatl, Esgl, Eras, Gdf3, Fgf4, Cripto, Daxl, Zpf296, Slc2a3, Rexl, Utfl, and Nat1.

[0228]

[0239] Also provided herein are differentiated cells derived from iPSCs produced using the methods described herein. Methods for differentiation of iPSCs are known to those skilled in the art. In some embodiments, the differentiated cells are muscle cells, nervous system cells, central nervous system cells, eye cells, chondrocytes, bone cells, tendon cells, cardiomyocytes, liver cells, kidney cells, pancreatic islet cells, keratinocytes, T cells, or NK cells. In some embodiments, the differentiated cells are cell types belonging to the lineages of, for example but not limited to, muscle, nerve, eye, cartilage, bone, connective tissue, heart, liver, kidney, pancreas, skin, or hematopoietic lineages.

[0229]

[0240] In some embodiments, iPSCs described herein (or iPSCs generated using methods not described herein) may be differentiated by contacting the iPSCs with one or more circular RNAs encoding a differentiation factor. For example, in some embodiments, the iPSCs are contacted with a circular RNA encoding, or a DNA molecule encoding, a differentiation factor capable of differentiating the iPSCs into a cell type of interest, such as a T cell. In some embodiments, the differentiation factor is selected from RORA, HLF, MYB, KLF4, ERG, SOX4, LUC, HOXA9, HOXA10, and HOXA5. In some embodiments, the iPSCs are contacted with at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or at least 11 circular RNAs, where each circular RNA encodes a differentiation factor selected from RORA, HLF, MYB, KLF4, ERG, SOX4, LUC, HOXA9, HOXA10, and HOXA5. In some embodiments, the iPSCs are contacted with at least 1, at least 2, at least 3, at least 4, or at least 5 circular RNAs, where each circular RNA encodes a differentiation factor selected from HOXA9, ERG, RORA, SOX4, or MYB. In some embodiments, the iPSCs are contacted with a plurality of circular RNAs, where each circular RNA encodes at least one of HOXA9, ERG, RORA, SOX4, or MYB. In some embodiments, the iPSCs are contacted with at least one circular RNA, where the circRNA encodes one or more of the differentiation factors listed in Table 6. In some embodiments, the iPSCs are additionally contacted with EZH1 shRNA. Expression of EZH1 shRNA can facilitate the switch from lineage-restricted hematopoietic progenitor cells to progenitor cells with multi-lymphoid potential.

[0230]

[0241] In some embodiments, iPSCs differentiate into CD34+CD38- cells. In some embodiments, iPSCs differentiate into CD34+CD38- cells upon contacting the iPSCs with one or more circular RNAs encoding one or more of the following differentiation factors: RORA, HLF, MYB, KLF4, ERG, SOX4, LUC, HOXA9, HOXA10, or HOXA5.

[0231]

[0242] In some embodiments, CD34+CD45+ bone marrow progenitor cells are contacted with a circular RNA encoding one or more of RORA, HLF, MYB, KLF4, ERG, SOX4, LUC, HOXA9, HOXA10, or HOXA5, or a DNA molecule encoding the same. In some embodiments, CD34+CD45+ bone marrow progenitor cells are contacted with a circular RNA encoding one or more of HOXA9, ERG, RORA, SOX4, or MYB, or a DNA molecule encoding the same. In some embodiments, contacting iPSCs with one or more circular RNAs as described above transdifferentiates CD34+CD45+ cells into CD34+CD38- cells. In some embodiments, the cells resulting from contacting are self-renewing HSPCs (hematopoietic stem and progenitor cells) with erythroid and lymphoid potential.

[0232]

[0243] In some embodiments, iPSCs generated using the methods described herein are younger when compared to iPSCs generated using conventional methods, such as the use of viral vectors encoding reprogramming factors or transfection of linear RNA encoding reprogramming factors. As described herein, "younger" refers to the cells being reprogrammed more quickly (i.e., within about 5, about 6, about 7, or about 8 days after transfection) compared to conventional methods (i.e., about 9 days or more).

[0233]

[0244] In some embodiments, the iPSCs express one or more biomarkers at different levels when compared to iPSCs produced using conventional methods. For example, in some embodiments, the iPSCs express lower levels of markers associated with cell stress and / or cell death (apoptosis) when compared to iPSCs produced using conventional methods. For example, in some embodiments, the iPSCs express lower levels of one or more heat shock proteins or caspases when compared to iPSCs produced using conventional methods.

[0234]

[0245] In some embodiments, the genome of the iPSCs has different epigenetic modifications when compared to iPSCs generated using conventional methods, for example, in some embodiments, the iPSCs may contain altered levels of DNA methylation and / or histone modifications.

[0235]

[0246] In some embodiments, the T cells are contacted with one or more circular RNAs (or DNA molecules encoding same) encoding factors that can improve the efficacy of the T cells. In this context, improving efficacy refers to promoting the survival of the T cells and / or their anti-tumor activity when used in an immuno-oncology setting. For example, the T cells may be contacted with one or more circular RNAs encoding IL-12, IL-18, IL-15, or IL-7.

[0236]

[0247] In some embodiments, the T cells are contacted with one or more circular RNAs (or DNA molecules encoding same) that improve the ability of the T cells to home to tumor tissue. For example, the T cells may be contacted with one or more circular RNAs encoding CXCR2, CCR2B, or heparanase.

[0237]

[0248] In some embodiments, T cells are contacted with one or more circular RNAs (or DNA molecules encoding same) that help improve survival and / or promote switching to a central memory phenotype. For example, T cells may be contacted with one or more circular RNAs encoding Suv39h1.

[0238] Combinatorial methods for reprogramming and editing the genome of cells

[0249] Combining the generation method of iPSC with its genome editing method enhances the diagnostic and therapeutic power of iPSC. As used herein, the terms "genome editing" and "editing genome" refer to the modification of specific loci of a cell's nucleic acid (e.g., DNA or RNA). Genome editing can correct the genetic mutations that cause disease from diseased patients, and can also be used to induce specific mutations in disease-free wild-type cells (such as iPSCs). Thus, the present disclosure provides a combined method for reprogramming and editing the genome of a cell. In some embodiments, the circular RNA described herein can be used in the reprogramming and editing method of a cell's genome.

[0239]

[0250] Genome editing can include, for example, inducing double-stranded DNA breaks in the gene modification region. In some embodiments, a DNA locus is replaced with an exogenous sequence by complementing a targeting vector. Any one of the following enzymes may be used to edit the DNA of a cell: zinc finger nucleases, homing endonucleases, TALENs (transcription activator-like effector nucleases), NgAgos (argonaute endonucleases), SGNs (structure-guided endonucleases), RGNs (RNA-guided nucleases), or modified or truncated variants thereof. In some embodiments, the RNA-guided nucleases are described in WO 2019 / 236566 (e.g., APG05083.1, APG07433.1, APG07513.1, APG08290.1, APG05459.1, APG04583.1, and APG1688.1). RNA-guided nucleases), WO 2021 / 030344 (e.g., APG05733.1, APG06207.1, APG01647.1, APG08032.1, APG05712.1, APG01658.1, APG06498.1, APG09106.1, APG09882.1, APG02675.1, APG01405.1, APG06250.1, APG06877.1, APG09053.1, APG04293.1, APG01308.1, APG06646.1, APG09748, and APG07433.1 RNA-guided nucleases), and the RNA-guided nucleases disclosed in any one of WO 2020 / 139783 (APG00969, APG03128, APG09748, APG00771, APG02789, APG09106, APG02312, APG07386, APG09980, APG05840, APG05241, APG07280, APG09866, APG00868 RNA-guided nucleases), each of which is herein incorporated by reference in its entirety.In some embodiments, the RNA-guided nuclease is a Cas9 nuclease, a Cas12(a) nuclease (Cpf1), a Cas12b nuclease, a Cas12c nuclease, a TrpB-like nuclease, a Cas13a nuclease (C2c2), a Cas13b nuclease, a Cas14 nuclease, or a modified or truncated variant thereof.

[0240]

[0251] In some embodiments, Cas9 nuclease is used to edit the genome of a cell. Cas9 is a large multifunctional protein with two putative nuclease domains, HNH and RuvC-like. The HNH and RuvC-like domains cleave the DNA strand opposite the complementary 20 nucleotide sequence of the crRNA and its complementary strand, respectively. There are several variants of the CRISPR-Cas9 system, any one of which may be used in the methods disclosed herein: (1) The original CRISPR-Cas9 system functions by inducing a DNA double-strand break initiated by wild-type Cas9 nuclease guided by a single RNA. (2) The nickase variant of Cas9 (D10A mutant), generated by mutation of either the Cas9 HNH domain or the RuvC-like domain, is guided by a paired guide RNA. (3) An engineered nuclease variant of Cas9 with enhanced specificity (eSpCas9). (4) Catalytically inactive dead Cas9 (dCas9) variants are generated by mutating both domains (HNH and RUvC-like). dCas9 can be combined with transcriptional repressors or activators to modify the transcription of endogenous genes (CRISPRa or CRISPRi) or fused to fluorescent proteins to image genomic loci. (5) CRISPR-Cas9 is fused to cytidine deaminase to generate variants that induce direct conversion of cytidine to uridine, thus avoiding DNA double-strand breaks. In some embodiments, the Cas9 nuclease is isolated or derived from S. pyogenes or S. aureus.

[0241]

[0252] Cas9, and other RNA-guided nucleases, require an RNA guide sequence ("guide RNA" or "gRNA") to target a specific locus. In some embodiments, the gRNA is a single guide ("sgRNA"). The sgRNA may include a spacer sequence and a scaffold sequence. The spacer sequence is complementary to and targets the enzyme to the target cleavage sequence. The scaffold region binds the RNA-guided nuclease enzyme.

[0242]

[0253] Exemplary enzymes that can be used to edit cellular RNA include, but are not limited to, ADAR (adenosine deaminase acting on RNA) family enzymes. For example, the enzyme can be human ADAR1, ADAR2, or ADAR3, or modified or truncated variants thereof. In some embodiments, the enzyme can be ADAR from squid (e.g., Loligo pealeii), such as sqADAR2, or modified or truncated variants thereof. In some embodiments, the enzyme can be ADAR from C. elegans (e.g., ceADAR1 or ceADAR2) or D. melanogaster (e.g., dADAR), or modified or truncated variants thereof.

[0243]

[0254] In some embodiments, a method for reprogramming and editing the genome of a cell comprises (i) contacting the cell with a circular RNA comprising a protein coding sequence, where the protein coding sequence encodes at least one reprogramming factor, and (ii) contacting the cell with an enzyme capable of editing the DNA or RNA of the cell.

[0244]

[0255] In some embodiments, a method for reprogramming and editing the genome of a cell comprises contacting a cell with (i) a circular RNA comprising a protein coding sequence, where the protein coding sequence encodes at least one reprogramming factor, and (ii) a nucleic acid encoding an enzyme capable of editing the DNA or RNA of the cell.

[0245]

[0256] In some embodiments, the cells are contacted with the circular RNA before contacting the enzyme or the nucleic acid encoding same. In some embodiments, the cells are contacted with the circular RNA after contacting the enzyme or the nucleic acid encoding same. In some embodiments, the cells are contacted with the circular RNA at about the same time as they are contacted with the enzyme or the nucleic acid encoding same.

[0246]

[0257] In some embodiments, the methods of reprogramming and editing the genome of a cell further comprise contacting the cell with a nucleic acid encoding a guide RNA, or a guide RNA.

[0247]

[0258] A composition for reprogramming and editing a cell's genome may include, for example, a circular RNA (or a DNA molecule encoding the same) and an enzyme capable of editing DNA or RNA (or a DNA or RNA molecule encoding the same). In some embodiments, the circular RNA includes a protein coding sequence. In some embodiments, the circular RNA does not encode a protein. In some embodiments, the circular RNA is circBIRC6 (SEQ ID NO: 29), circCORO1C (SEQ ID NO: 30), or circMAN1A2 (SEQ ID NO: 31).

[0248] Combinatorial methods for transdifferentiation and editing of the genome of cells

[0259] The circular RNAs described herein may also be used in methods for transdifferentiation and editing the genome of a cell. Thus, provided herein are compositions and methods for transdifferentiation and editing the genome of a cell.

[0249]

[0260] In some embodiments, the method of transdifferentiation and editing the genome of a cell comprises contacting a cell with (i) a circular RNA comprising a protein coding sequence, the protein coding sequence encoding at least one transdifferentiation factor, and (ii) an enzyme capable of editing the DNA or RNA of the cell. In some embodiments, the transdifferentiation factor is selected from any of those listed in Table 5.

[0250]

[0261] In some embodiments, a method for transdifferentiation and editing the genome of a cell comprises contacting a cell with (i) a circular RNA comprising a protein coding sequence, the protein coding sequence encoding at least one transdifferentiation factor, and (ii) a nucleic acid encoding an enzyme capable of editing the DNA or RNA of the cell.

[0251]

[0262] The enzyme used for editing DNA or RNA in the method of transdifferentiating and editing the genome of a cell can be any of the enzymes listed above.

[0252]

[0263] In some embodiments, the cells are contacted with the circular RNA before contacting the enzyme or the nucleic acid encoding same. In some embodiments, the cells are contacted with the circular RNA after contacting the enzyme or the nucleic acid encoding same. In some embodiments, the cells are contacted with the circular RNA at about the same time as they are contacted with the enzyme or the nucleic acid encoding same.

[0253]

[0264] In some embodiments, the methods of transdifferentiation and editing the genome of a cell further comprise contacting the cell with a nucleic acid encoding a guide RNA, or a guide RNA.

[0254]

[0265] A composition for transdifferentiation and editing of a cell's genome may include, for example, a circular RNA (or a DNA molecule encoding the same) and an enzyme capable of editing DNA or RNA (or a DNA or RNA molecule encoding the same). In some embodiments, the circular RNA comprises a protein coding sequence. In some embodiments, the circular RNA does not encode a protein. In some embodiments, the circular RNA is circBIRC6 (SEQ ID NO: 29), circCORO1C (SEQ ID NO: 30), or circMAN1A2 (SEQ ID NO: 31). In some embodiments, the circular RNA encodes a reprogramming factor disclosed herein. In some embodiments, the circular RNA encodes one or more of Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, and L-Myc. In some embodiments, the circular RNA encodes one or more of the transdifferentiation factors listed in Table 5.

[0255] Additional Methods

[0266] As one of skill in the art will appreciate, the circular RNAs and related compositions described herein may be useful in one or more of the following methods:

[0256]

[0267] In some embodiments, provided herein are methods of reprogramming cells that result in reduced cell death compared to methods using linear RNA, comprising contacting the cells with a circular RNA, complex, vector, or composition as described herein, and maintaining the cells under conditions in which the protein is expressed. In some embodiments, reprogramming-induced cell death is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 500% or more compared to reprogramming methods using linear RNA. In some embodiments, the cells are contacted with a combination of circular RNAs, where the combination of circular RNAs includes (i) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28 (e.g., Lin28A or Lin28B), and circ In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD.

[0257]

[0268] Also provided herein is a method of decreasing the time from reprogramming to picking, comprising contacting cells with a circular RNA, complex, vector, or composition described herein and maintaining the cells under conditions in which the protein is expressed, wherein the time from reprogramming to picking is decreased compared to reprogramming methods using linear RNA. As used herein, the term "picking" refers to manual selection of iPSC colonies by mechanical dissociation. In some embodiments, this time is decreased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 500% or more compared to reprogramming methods using linear RNA. In some embodiments, the cells are contacted with a combination of circular RNAs, wherein the combination of circular RNAs includes (i) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28 (e.g., Lin28A or Lin28B), and circ In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD.

[0258]

[0269] Also provided herein is a method of reducing the number of transfections induced to achieve cell reprogramming, comprising contacting a cell with a circular RNA, complex, vector, or composition described herein, and maintaining the cell under conditions in which the protein is expressed. In some embodiments, the number of transfections is reduced compared to methods using linear RNA. In some embodiments, the number of transfections to induce cell reprogramming is 1, 2, 3, 4, 5, 6, or 7 times. In some embodiments, the number of transfections is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 500% or more compared to methods using linear RNA. In some embodiments, the cells are contacted with a combination of circular RNAs, wherein the combination of circular RNAs is selected from the group consisting of (i) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28 (e.g., Lin28A or Lin28B), and circ (ii) circOct3 / 4, circKlf4, circSox2, circNanog, and circLin28 (e.g., Lin28A or Lin28B); (iii) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28, and circL-Myc; (iv) circOct3 / 4, circKlf4, circSox2, circNanog, and circLin28 (e.g., Lin28A or Lin28B); (v) circOct3 / 4, circKlf4, circSox2, and circC-Myc; (vi) circOct3 / 4, circKlf4, circSox2, and circL-Myc; or (vii) circOct3 / 4, circKlf4, and circSox2. In some embodiments, the cell is contacted with circMyoD.

[0259]

[0270] Also provided herein is a method of increasing the duration of protein expression in a cell, comprising contacting the cell with a circular RNA, complex, vector, or composition described herein, and maintaining the cell under conditions in which the protein is expressed. In some embodiments, the duration of protein expression is increased compared to a method comprising transfecting the cell with a linear RNA encoding the same protein. In some embodiments, the duration of protein expression is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 500% or more compared to a method comprising transfecting the cell with a linear RNA encoding the same protein. In some embodiments, the duration of protein expression is increased by at least 1 hour, at least 4 hours, at least 8 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, or more compared to a method comprising transfecting the cell with a linear RNA encoding the same protein.In some embodiments, the cells are contacted with a combination of circular RNAs, wherein the combination of circular RNAs is selected from the group consisting of (i) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28 (e.g., Lin28A or Lin28B), and circ In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD.

[0260]

[0271] Also provided herein is a method of improving cell reprogramming efficiency, comprising contacting a cell with a circular RNA, complex, vector, or composition described herein and maintaining the cell under conditions in which the protein is expressed, wherein the efficiency of cell reprogramming is increased compared to cell reprogramming methods in which linear RNA is used. In some embodiments, the cell reprogramming efficiency is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 500% or more compared to methods in which linear RNA is used. Enhanced cell reprogramming efficiency may be observed based on qualitative and / or qualitative assessments, including, but not limited to, reduced cell death, reduced immune response induced stress as measured by IFN-γ secretion, reduced stress response gene induction. In some embodiments, the cells are contacted with a combination of circular RNAs, wherein the combination of circular RNAs is selected from the group consisting of (i) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28 (e.g., Lin28A or Lin28B), and circ In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD.

[0261]

[0272] Also provided herein is a method for increasing the number of reprogrammed cell colonies formed after reprogramming, comprising contacting cells with a circular RNA, complex, vector, or composition, and maintaining the cells under conditions in which the protein is expressed, wherein the number of reprogrammed cell colonies formed after reprogramming is increased compared to a cell reprogramming method in which linear RNA is used. In some embodiments, the number of reprogrammed cell colonies is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 500% or more compared to a method in which linear RNA is used. In some embodiments, the increase in the number of colonies may be observed at about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 days after transfection with one or more circRNAs encoding transcription factors. In some embodiments, the cells are contacted with a combination of circular RNAs, wherein the combination of circular RNAs is selected from the group consisting of (i) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28 (e.g., Lin28A or Lin28B), and circ (ii) circOct3 / 4, circKlf4, circSox2, circNanog, and circLin28 (e.g., Lin28A or Lin28B); (iii) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28 (e.g., Lin28A or Lin28B), and circL-Myc; (iv) circOct3 / 4, circKlf4, circSox2, circNanog, and circLin28 (e.g., Lin28A or Lin28B); (v) circOct3 / 4, circKlf4, circSox2, and circC-Myc; (vi) circOct3 / 4, circKlf4, circSox2, and circL-Myc; or (vii) circOct3 / 4, circKlf4, and circSox2.In some embodiments, the cells are contacted with circMyoD.

[0262]

[0273] Also provided herein are methods of reprogramming cells in suspension, comprising contacting the cells in suspension with a circular RNA, complex, vector, or composition described herein, and maintaining the cells under conditions in which the protein is expressed. In some embodiments, the cells express CD34 (i.e., the cells are CD34+). In some embodiments, the cells are contacted with a combination of circular RNAs, wherein the combination of circular RNAs includes (i) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28 (e.g., Lin28A or Lin28B), and circ In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD. In some embodiments, the cell is contacted with circMyoD.

[0263]

[0274] Also provided herein is a method of improving the morphological maturity of reprogrammed colonies, comprising contacting cells in suspension with a circular RNA, complex, vector, or composition described herein and maintaining the cells under conditions in which the protein is expressed, wherein the morphological maturity is improved compared to cell reprogramming methods in which linear RNA is used. Improved morphological maturity can include, for example, more tightly packed colonies, colonies with more cells having uniform shape and diameter, colonies with well-defined borders, and cells within the iPSC colony that contain higher nucleus-to-cytoplasm ratios and / or prominent nucleoli. In some embodiments, the morphological maturity of reprogrammed colonies is improved by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 500% or more compared to methods in which linear RNA is used. In some embodiments, the cells are contacted with a combination of circular RNAs, wherein the combination of circular RNAs is selected from the group consisting of (i) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28 (e.g., Lin28A or Lin28B), and circ (ii) circOct3 / 4, circKlf4, circSox2, circNanog, and circLin28 (e.g., Lin28A or Lin28B); (iii) circOct3 / 4, circKlf4, circSox2, circNanog, circLin28 (e.g., Lin28A or Lin28B), and circL-Myc; (iv) circOct3 / 4, circKlf4, circSox2, circNanog, and circLin28 (e.g., Lin28A or Lin28B); (v) circOct3 / 4, circKlf4, circSox2, and circC-Myc; (vi) circOct3 / 4, circKlf4, circSox2, and circL-Myc; or (vii) circOct3 / 4, circKlf4, and circSox2.In some embodiments, the cells are contacted with circMyoD.

[0264]

[0275] Also provided herein is a suspension culture comprising one or more CD34-expressing cells, wherein the CD34-expressing cells comprise one or more circRNAs encoding a reprogramming factor. In some embodiments, the reprogramming factor is selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, and L-Myc.

[0265]

[0276] Also provided herein is a method of inducing mesenchymal-epithelial transition (MET) from a somatic cell to an iPSC, comprising contacting the somatic cell with one or more circular RNAs encoding reprogramming factors.

[0266]

[0277] Also provided herein is a method of inducing mesenchymal-epithelial transition (MET) from a somatic cell to an iPSC, comprising contacting the somatic cell with one or more circular RNAs encoding reprogramming factors.

[0267] Compositions and cells

[0278] Also provided herein is a composition comprising a circular RNA. In some embodiments, the composition comprises (i) a circular RNA and (ii) a carrier. In some embodiments, the composition comprises (i) a vector encoding a circular RNA and (ii) a carrier. Suitable carriers include, for example, sterile water, a sterile buffer solution (e.g., a solution buffered with phosphate, citrate, or acetate, etc.), a sterile medium, polyalkylene glycols, hydrogenated naphthalene (e.g., a biocompatible lactide polymer), lactide / glycolide copolymer, or polyoxyethylene / polyoxypropylene copolymer. In some embodiments, the carrier may include a substance for covalently attaching a polymer, such as lactose, mannitol, polyethylene glycol, a complex with a metal ion, or incorporation of a material into or on a particular preparation of a polymeric compound, such as polylactic acid, polyglycolic acid, on a hydrogel or liposome, a microemulsion, a micelle, a unilamellar or multilamellar vesicle, a red blood cell fragment, or a spheroplast. In some embodiments, the pH of the carrier is in the range of 5.0 to 8.0, such as in the range of about 6.0 to about 7.0. In some embodiments, the carrier includes a salt component (e.g., sodium chloride, potassium chloride) or other components that make the solution, for example, isotonic. Additionally, the carrier may include additional components, such as fetal bovine serum, growth factors, human serum albumin (HSA), polysorbate 80, sugars, or amino acids. Suitable vectors include plasmids (e.g., DNA plasmids) and viral vectors.

[0268]

[0279] Also provided herein is a cell comprising a circular RNA or composition as described herein. In some embodiments, the cell is a prokaryotic cell. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a mammalian cell (e.g., a mouse, bovine, monkey, porcine, equine, ovine, or human cell). In some embodiments, the cell is a human cell.

[0269] kit

[0280] Kits for cell reprogramming and kits for iPSC generation are also provided. In some embodiments, the kit comprises at least one circular RNA as described herein. In some embodiments, the kit comprises a container that contains the circular RNA. In some embodiments, the kit comprises a plurality of containers, where each container comprises a circular RNA. In some embodiments, the kit comprises a container that comprises a plurality of circular RNA molecules, where each circular RNA molecule encodes a protein. In some embodiments, the kit also comprises a set of instructions for using at least one circular RNA to reprogram cells.

[0270]

[0281] In some embodiments, the kit comprises one or more circular RNAs, where each circular RNA encodes at least one protein. In some embodiments, the kit may further comprise a linear or circular RNA encoding a miRNA. In some embodiments, the kit may comprise a single container housing each of (i) one or more circular RNAs, where each circular RNA encodes a protein, (ii) optionally a circular RNA that does not encode any protein or miRNA (e.g., circBIRC6, circCORO1c, circMAN1A2), and (iii) optionally a linear or circular RNA encoding a miRNA. In some embodiments, the kit may comprise multiple containers, where each container comprises one of (i) at least one circular RNA encoding a protein, (ii) optionally a circular RNA that does not encode any protein or miRNA, or a DNA molecule encoding the same, and (iii) optionally a linear or circular RNA encoding a miRNA. In some embodiments, the kit also comprises a set of instructions for using at least one circular RNA to reprogram a cell.

[0271]

[0282] In some embodiments, a kit for reprogramming somatic cells and / or generating iPSCs is provided. In some embodiments, the kit comprises at least one circular RNA encoding a reprogramming factor (e.g., a transcription factor). In some embodiments, the kit comprises a container that houses the circular RNA. In some embodiments, the kit comprises a plurality of containers, where each container comprises a circular RNA. In some embodiments, the kit comprises a container that comprises a plurality of circular RNA molecules, where each circular RNA molecule encodes a transcription factor. In some embodiments, the kit also comprises a set of instructions for use of the at least one circular RNA for reprogramming somatic cells and / or generating iPSCs.

[0272]

[0283] In some embodiments, the kit comprises one or more circular RNAs, where each circular RNA encodes at least one reprogramming factor. The reprogramming factor may be, for example, any one of the reprogramming factors listed in Table 1. In some embodiments, the kit may further comprise a circular RNA that does not encode any protein or miRNA, or a DNA molecule encoding the same. In some embodiments, the kit may further comprise a linear or circular RNA that encodes an miRNA, or a DNA molecule encoding the same. In some embodiments, the kit may comprise a single container housing each of (i) one or more circular RNAs, each of which encodes a reprogramming factor, (ii) optionally, a circular RNA that does not encode any protein or miRNA (e.g., circBIRC6, circCORO1c, circMAN1A2), and (iii) optionally, a linear or circular RNA that encodes an miRNA. In some embodiments, the kit may include multiple containers, where each container contains one of: (i) at least one circular RNA encoding a reprogramming factor, (ii) optionally a circular RNA that does not encode any protein or miRNA (e.g., circBIRC6, circCORO1c, circMAN1A2), (iii) optionally a linear or circular RNA encoding a miRNA. In some embodiments, the kit also includes a set of instructions for use of the at least one circular RNA for reprogramming cells and / or generating iPSCs.

[0273]

[0284] In some embodiments, a kit for transdifferentiation of cells is provided. In some embodiments, the kit comprises at least one circular RNA encoding a reprogramming factor (e.g., a transcription factor). In some embodiments, the kit comprises a container that contains the circular RNA. In some embodiments, the kit comprises a plurality of containers, where each container comprises a circular RNA. In some embodiments, the kit comprises a container that comprises a plurality of circular RNA molecules, where each circular RNA molecule comprises a sequence encoding a transdifferentiation factor. In some embodiments, the kit also comprises a set of instructions for use of at least one circular RNA for transdifferentiation of cells.

[0274]

[0285] In some embodiments, the kit comprises one or more circular RNAs, where each circular RNA comprises a sequence encoding at least one transdifferentiation factor. The transdifferentiation factor may be, for example, any one of the transdifferentiation factors listed in Table 5. In some embodiments, the kit may further comprise a circular RNA that does not encode any protein or miRNA. In some embodiments, the kit may further comprise a circular RNA that encodes a miRNA. In some embodiments, the kit may comprise a single container that contains each of (i) one or more circular RNAs, where each circular RNA encodes a transdifferentiation factor, (ii) optionally a circular RNA that does not encode any protein or miRNA, and (iii) optionally a circular RNA that encodes a miRNA. In some embodiments, the kit may comprise multiple containers, where each container comprises one of (i) at least one circular RNA encoding a transdifferentiation factor, (ii) optionally a circular RNA that does not encode any protein or miRNA, and (iii) optionally a circular RNA that encodes a miRNA. In some embodiments, the kit also comprises a set of instructions for use of at least one circular RNA for expression of a transdifferentiation factor in a cell.

[0275]

[0286] In some embodiments, the kit comprises a plurality of circular RNAs, where each circular RNA encodes a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), c-Myc, and L-Myc, or a combination thereof. Each of the circular RNAs may be provided in a separate container or may be provided in a single container.

[0276]

[0287] In some embodiments, the kit comprises a plurality of circular RNAs, wherein each of the circular RNAs encodes a reprogramming factor selected from Oct3 / 4, Sox2, and Klf4, or a combination thereof. Each of the circular RNAs may be provided in a separate container or may be provided in a single container.

[0277]

[0288] In some embodiments, the kit comprises a plurality of circular RNAs, wherein each of the circular RNAs encodes a reprogramming factor selected from Oct3 / 4, Sox2, c-Myc, and Klf4, or a combination thereof. Each of the circular RNAs may be provided in a separate container or may be provided in a single container.

[0278]

[0289] In some embodiments, the kit comprises a plurality of circular RNAs, wherein each of the circular RNAs encodes a reprogramming factor selected from Oct3 / 4, Sox2, L-Myc, and Klf4, or a combination thereof. Each of the circular RNAs may be provided in a separate container or may be provided in a single container.

[0279]

[0290] In some embodiments, the kit comprises a plurality of circular RNAs, where each circular RNA encodes a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, and Lin28 (e.g., Lin28A or Lin28B), or a combination thereof. Each of the circular RNAs may be provided in a separate container or may be provided in a single container.

[0280]

[0291] In some embodiments, the kit comprises a plurality of circular RNAs, where each circular RNA encodes a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), and c-Myc, or a combination thereof. Each of the circular RNAs may be provided in a separate container or may be provided in a single container.

[0281]

[0292] In some embodiments, the kit comprises a plurality of circular RNAs, where each circular RNA encodes a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28 (e.g., Lin28A or Lin28B), and L-Myc, or a combination thereof. Each of the circular RNAs may be provided in a separate container or may be provided in a single container.

[0282]

[0293] In some embodiments, the kit may include a linear RNA capable of being circularized, or a DNA sequence encoding the same. In some embodiments, the kit may further include one or more reagents for circularizing the linear RNA, such as an RNA or DNA ligase, or Mg2+ and guanosine 5' triphosphate (GTP).

[0283]

[0294] In some embodiments, the kit includes (i) a container containing a circular RNA encoding OCT4 and a buffer (e.g., 1-10 mM sodium citrate, pH 6.5); (ii) a container containing a circular RNA encoding SOX2 and a buffer (e.g., 1-10 mM sodium citrate, pH 6.5); (iii) a container containing a cirRNA encoding KLF4 and a buffer (e.g., 1-10 mM sodium citrate, pH 6.5); and (iv) packaging and instructions therefor. The kit may further include a container containing a circular RNA encoding c-MYC or L-MYC and a buffer (e.g., 1-10 mM sodium citrate, pH 6.5); a container containing a cirRNA encoding LIN28 (e.g., Lin28A or Lin28B) and a buffer (e.g., 1-10 mM sodium citrate, pH 6.5); a container containing a cirRNA encoding NANOG and a buffer (e.g., 1-10 mM sodium citrate, pH 6.5); or a combination thereof.

[0284]

[0295] In some embodiments, the kit comprises: (i): (a) one or more circular RNA reprogramming factors of any one or more combinations of circularized reprogramming factors listed in Table 3, each individually contained in a separate container, or two or more of such factors combined together in a single or multiple containers; and (ii) packaging and instructions therefor.

[0285]

[0296] In some embodiments, the kit comprises: (i): one or more circular RNA reprogramming factors of any one or more combinations of circularized reprogramming factors listed in Table 3, each contained individually in a separate container, or two or more of such factors combined together in a single or multiple containers; and each circularized reprogramming factor and / or circular RNA factor of Table 3, each suspended in a buffer; and (iii) packaging and instructions therefor.

[0286]

[0297] In any of the kits described above, the circular RNA may be provided in a composition further comprising a buffer. The buffer may comprise, for example, 1 to 10 mM sodium citrate. In some embodiments, the pH of the buffer ranges from about 2 to about 12, such as about 6.5.

[0287] [Table 21]

[0288] [Table 22]

[0289] [Table 23]

[0290] [Table 24]

[0291] [Table 25]

[0292] [Table 26]

[0293] [Table 27]

[0294] [Table 28]

[0295] [Table 29]

[0296] Further Numbered Embodiments

[0298] Further numbered embodiments of the present disclosure are as follows:

[0297]

[0299] Embodiment 1. A method of generating induced pluripotent stem cells (iPSCs), comprising contacting blood cells in suspension with a circular RNA encoding at least one reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc, or a fragment or variant thereof, and maintaining the cells under conditions such that iPSCs are obtained.

[0298]

[0300] Embodiment 2. The method of embodiment 1, wherein the blood cells are selected from T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, peripheral blood mononuclear cells (PBMCs), and cord blood mononuclear cells (CBMCs).

[0299]

[0301] Embodiment 3. The method of embodiment 1, wherein the blood cells are selected from T cells and NK cells.

[0300]

[0302] Embodiment 4. A method of generating induced pluripotent stem cells (iPSCs), comprising contacting CD34+ cells in suspension with a circular RNA encoding at least one reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc, or a fragment or variant thereof, and maintaining the cells under conditions such that iPSCs are obtained.

[0301]

[0303] Embodiment 5. The method of any one of embodiments 1 to 4, wherein at least one reprogramming factor is a human or humanized reprogramming factor.

[0302]

[0304] Embodiment 6. The method of any one of embodiments 1 to 5, wherein at least one reprogramming factor is Oct3 / 4, and Oct3 / 4 has the amino acid sequence of SEQ ID NO: 7, or a sequence at least 90% or at least 95% identical thereto.

[0303]

[0305] Embodiment 7. The method of embodiment 3, wherein the circular RNA comprises a nucleic acid sequence of SEQ ID NO: 8, or a sequence at least 90% or at least 95% identical thereto.

[0304]

[0306] Embodiment 8. The method of any one of embodiments 1 to 5, wherein at least one reprogramming factor is Klf4, and Klf4 has the amino acid sequence of SEQ ID NO: 9 or 10, or a sequence at least 90% or at least 95% identical thereto.

[0305]

[0307] Embodiment 9. The method of embodiment 8, wherein the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 11, or a sequence at least 90% or at least 95% identical thereto.

[0306]

[0308] Embodiment 10. The method of any one of embodiments 1 to 5, wherein at least one reprogramming factor is Sox2, and Sox2 has the amino acid sequence of SEQ ID NO: 12, or a sequence at least 90% or at least 95% identical thereto.

[0307]

[0309] Embodiment 11. The method of embodiment 10, wherein the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 13, or a sequence at least 90% or at least 95% identical thereto.

[0308]

[0310] Embodiment 12. The method of any one of embodiments 1 to 5, wherein at least one reprogramming factor is Nanog, and Nanog has the amino acid sequence of SEQ ID NO: 14 or 15, or a sequence at least 90% or at least 95% identical thereto.

[0309]

[0311] Embodiment 13. The method of embodiment 12, wherein the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 16, or a sequence at least 90% or at least 95% identical thereto.

[0310]

[0312] Embodiment 14. The method of any one of embodiments 1 to 5, wherein at least one reprogramming factor is Lin28A, and Lin28A has the amino acid sequence of SEQ ID NO: 17, or a sequence at least 90% or at least 95% identical thereto.

[0311]

[0313] Embodiment 15. The method of embodiment 14, wherein the circular RNA comprises a nucleic acid sequence of SEQ ID NO: 18, or a sequence at least 90% or at least 95% identical thereto.

[0312]

[0314] Embodiment 16. The method of any one of embodiments 1 to 5, wherein at least one reprogramming factor is c-Myc, and c-Myc has the amino acid sequence of SEQ ID NO: 19 or 20, or a sequence at least 90% or at least 95% identical thereto.

[0313]

[0315] Embodiment 17. The method of embodiment 16, wherein the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 21, or a sequence at least 90% or at least 95% identical thereto.

[0314]

[0316] Embodiment 18. The method of any one of embodiments 1 to 5, wherein at least one reprogramming factor is L-Myc, and L-Myc has the amino acid sequence of any one of SEQ ID NOs: 22 to 24, or a sequence at least 90% or at least 95% identical thereto.

[0315]

[0317] Embodiment 19. The method of embodiment 18, wherein the circular RNA comprises a nucleic acid sequence of SEQ ID NO: 25, or a sequence at least 90% or at least 95% identical thereto.

[0316]

[0318] Embodiment 20. The method of any one of embodiments 1 to 19, wherein the circular RNA is substantially non-immunogenic.

[0317]

[0319] Embodiment 21 The method of embodiment 20, wherein the circular RNA comprises one or more M-6-methyladenosine (m6A) residues.

[0318]

[0320] Embodiment 22. The method of any one of embodiments 1 to 21, wherein the circular RNA comprises from about 200 nucleotides to about 5,000 nucleotides.

[0319]

[0321] Embodiment 23 The method of any one of embodiments 1 to 22, wherein the circular RNA comprises an internal ribosome entry site (IRES) operably linked to the protein coding sequence.

[0320]

[0322] Embodiment 24. The method of any one of embodiments 1 to 23, wherein the circular RNA encodes two or more reprogramming factors selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc.

[0321]

[0323] Embodiment 25. The method of any one of embodiments 1-5, comprising contacting a cell with a first circular RNA encoding Oct4 or a fragment or variant thereof, a second circular RNA encoding Sox2 or a fragment or variant thereof, a third circular RNA encoding Klf4 or a fragment or variant thereof, a fourth circular RNA encoding C-Myc or a fragment or variant thereof, a fifth circular RNA encoding Lin28 or a fragment or variant thereof, and a sixth circular RNA encoding Nanog or a fragment or variant thereof.

[0322]

[0324] Embodiment 26. The method of any one of embodiments 1 to 5, comprising contacting the cell with one or more circular RNAs encoding one or more of the group of reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc, or fragments or variants thereof.

[0323]

[0325] Embodiment 27. A method of generating induced pluripotent stem cells (iPSCs), comprising contacting CD34+ cells in suspension with six circular RNAs, a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, a third circular RNA encoding Klf4, a fourth circular RNA encoding C-Myc, a fifth circular RNA encoding Lin28, and a sixth circular RNA encoding Nanog, and maintaining the cells under conditions such that iPSCs are obtained.

[0324]

[0326] Embodiment 28. A method of generating induced pluripotent stem cells (iPSCs), comprising contacting CD34+ cells in suspension with three circular RNAs, a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, and a third circular RNA encoding Klf4, and maintaining the cells under conditions such that iPSCs are obtained.

[0325]

[0327] Embodiment 29. The method of embodiment 28, which does not include contacting the CD34+ cells with circular RNA encoding any of Nanog, Lin28, and c-Myc.

[0326]

[0328] Embodiment 30. A method of generating induced pluripotent stem cells (iPSCs), comprising contacting CD34+ cells in suspension with three circular RNAs, a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, and a third circular RNA encoding Klf4, and a fourth circular RNA encoding c-Myc, and maintaining the cells under conditions such that iPSCs are obtained.

[0327]

[0329] Embodiment 31 The method of embodiment 30, which does not include contacting CD34+ cells with circular RNA encoding either Nanog or Lin28.

[0328]

[0330] Embodiment 32. A method of generating induced pluripotent stem cells (iPSCs), comprising contacting CD34+ cells in suspension with three circular RNAs, a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, and a third circular RNA encoding Klf4, a fourth circular RNA encoding Nanog, and a fifth circular RNA encoding Lin 28, and maintaining the cells under conditions such that iPSCs are obtained.

[0329]

[0331] Embodiment 33. The method of embodiment 32, which does not include contacting CD34+ cells with circular RNA encoding c-Myc.

[0330]

[0332] Embodiment 34. The method of any one of embodiments 1 to 33, wherein the cell is not contacted with any factor selected from E3, K3, B18R.

[0331]

[0333] Embodiment 35. The method of any one of embodiments 1 to 33, wherein the cell is not contacted with any microRNA (miR).

[0332]

[0334] Embodiment 36. The method of any one of embodiments 1 to 33, wherein the cell is not contacted with one or more factors selected from E3, K3, B18R, one or more microRNAs (miRs), or a combination thereof.

[0333]

[0335] The method of embodiment 37 or 36, wherein the miR comprises miR302a, miR302b, miR302c, miR302d, and miR367.

[0334]

[0336] Embodiment 38. The method of any one of embodiments 1 to 37, wherein the cell is directly contacted with at least one circular RNA.

[0335]

[0337] Embodiment 39. The method of any one of embodiments 1 to 38, wherein the cell is contacted once with each of the at least one circular RNA.

[0336]

[0338] Embodiment 40. The method of any one of embodiments 1 to 38, comprising contacting the cell with each of at least one circular RNA two, three, four or more times.

[0337]

[0339] Embodiment 41 The method of any one of embodiments 1 to 38, comprising contacting the cell with each of the at least one circular RNA less than four times.

[0338]

[0340] Embodiment 42. The method of any one of embodiments 1 to 38, comprising contacting the cell with each of at least one circular RNA 2 to 4 times.

[0339]

[0341] Embodiment 43. The method of any one of embodiments 1 to 42, wherein the concentration of each of the at least one circular RNA is at least 3 pg RNA / cell.

[0340]

[0342] Embodiment 44. The method according to any one of embodiments 1 to 42, wherein the concentration of each of the at least one circular RNA is from about 5 pg RNA / cell to about 15 pg RNA / cell.

[0341]

[0343] Embodiment 45. The method of any one of embodiments 1 to 44, wherein the contacting of the cells is performed by electroporation.

[0342]

[0344] Embodiment 46. The method of any one of embodiments 1-26 or 38-45, further comprising contacting the cell with an RNA polynucleotide encoding one or more viral proteins selected from E3, K3, or B18R.

[0343]

[0345] Embodiment 47. The method of embodiment 46, wherein (a) B18R has a sequence of SEQ ID NO: 26, or a sequence at least 90% or at least 95% identical thereto; (b) E3 has a sequence of SEQ ID NO: 27, or a sequence at least 90% or at least 95% identical thereto; and / or (c) K3 has a sequence of SEQ ID NO: 28, or a sequence at least 90% or at least 95% identical thereto.

[0344]

[0346] Embodiment 48. The method of any one of embodiments 1-26 or 38-47, further comprising contacting the cell with one or more microRNAs (miRs).

[0345]

[0347] Embodiment 49. The method of embodiment 48, wherein the miR is selected from miR302a, miR302b, miR302c, miR302d, and miR367.

[0346]

[0348] Embodiment 50. The method of any one of embodiments 1 to 49, resulting in one or more of: (i) an increase in the number of reprogrammed iPSCs present at the end of culture compared to a method of generating iPSCs with one or more linear RNAs; and / or (ii) a decrease in cell death at one or more time points during reprogramming compared to a method of generating iPSCs with one or more linear RNAs.

[0347]

[0349] Embodiment 51. The method of any one of embodiments 1 to 49, which results in each of: (i) an increase in the number of reprogrammed iPSCs present at the end of culture compared to a method of generating iPSCs with one or more linear RNAs; and (ii) a decrease in cell death at one or more time points during reprogramming compared to a method of generating iPSCs with one or more linear RNAs.

[0348]

[0350] Embodiment 52. An iPSC produced using the method according to any one of embodiments 1 to 51.

[0349]

[0351] Embodiment 53. A differentiated cell derived from the iPSCs of embodiment 52.

[0350]

[0352] Embodiment 54. The differentiated cell of embodiment 53, which is a muscle cell, a nervous system cell, a central nervous system cell, an eye cell, a chondrocyte, a bone cell, a tendon cell, a kidney cell, a cardiomyocyte, a liver cell, a pancreatic islet cell, a keratinocyte, a T cell, or a NK cell.

[0351]

[0353] Embodiment 55. A method for reprogramming and editing the genome of a cell, comprising: (i) contacting the cell with a recombinant circular RNA comprising a protein coding sequence, wherein the protein coding sequence encodes at least one reprogramming factor; and (ii) contacting the cell with an enzyme capable of editing the DNA or RNA of the cell, or a nucleic acid encoding the same.

[0352]

[0354] Embodiment 56. A method for reprogramming and editing the genome of a cell, comprising simultaneously contacting the cell with (i) a recombinant circular RNA comprising a protein coding sequence, the protein coding sequence encoding at least one reprogramming factor, and (ii) an enzyme capable of editing the DNA or RNA of the cell, or a nucleic acid encoding the same.

[0353]

[0355] Embodiment 57. The method of embodiment 55 or 56, wherein at least one reprogramming factor is a human or humanized reprogramming factor.

[0354]

[0356] Embodiment 58. The method of any one of embodiments 55 to 57, wherein at least one reprogramming factor is Oct3 / 4, and Oct3 / 4 has the amino acid sequence of SEQ ID NO: 7, or a sequence at least 90% or at least 95% identical thereto.

[0355]

[0357] Embodiment 59. The method of embodiment 59, wherein the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 8, or a sequence at least 90% or at least 95% identical thereto.

[0356]

[0358] Embodiment 60. The method of any one of embodiments 55 to 57, wherein at least one reprogramming factor is Klf4, and Klf4 has the amino acid sequence of SEQ ID NO: 9 or 10, or a sequence at least 90% or at least 95% identical thereto.

[0357]

[0359] Embodiment 61. The method of embodiment 60, wherein the recombinant circular RNA comprises the nucleic acid sequence of SEQ ID NO: 11, or a sequence at least 90% or at least 95% identical thereto.

[0358]

[0360] Embodiment 62. The method of any one of embodiments 55 to 57, wherein at least one reprogramming factor is Sox2, and Sox2 has the amino acid sequence of SEQ ID NO: 12, or a sequence at least 90% or at least 95% identical thereto.

[0359]

[0361] Embodiment 63. The method of embodiment 62, wherein the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 13, or a sequence at least 90% or at least 95% identical thereto.

[0360]

[0362] Embodiment 64. The method of any one of embodiments 55 to 57, wherein at least one reprogramming factor is Nanog, and Nanog has the amino acid sequence of SEQ ID NO: 14 or 15, or a sequence at least 90% or at least 95% identical thereto.

[0361]

[0363] Embodiment 65. The method of embodiment 64, wherein the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 16, or a sequence at least 90% or at least 95% identical thereto.

[0362]

[0364] Embodiment 66. The method of any one of embodiments 55 to 57, wherein at least one reprogramming factor is Lin28A, wherein Lin28A has the amino acid sequence of SEQ ID NO: 17, or a sequence at least 90% or at least 95% identical thereto.

[0363]

[0365] Embodiment 67. The method of embodiment 66, wherein the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 18, or a sequence at least 90% or at least 95% identical thereto.

[0364]

[0366] Embodiment 68. The method of any one of embodiments 55 to 57, wherein at least one reprogramming factor is c-Myc, and c-Myc has the amino acid sequence of SEQ ID NO: 19 or 20, or a sequence at least 90% or at least 95% identical thereto.

[0365]

[0367] Embodiment 69. The method of embodiment 68, wherein the recombinant circular RNA comprises the nucleic acid sequence of SEQ ID NO: 21, or a sequence at least 90% or at least 95% identical thereto.

[0366]

[0368] Embodiment 70. The method of any one of embodiments 55 to 57, wherein at least one reprogramming factor is L-Myc, and L-Myc has the amino acid sequence of any one of SEQ ID NOs: 22 to 24, or a sequence at least 90% or at least 95% identical thereto.

[0367]

[0369] Embodiment 71. The method of embodiment 70, wherein the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 25, or a sequence at least 90% or at least 95% identical thereto.

[0368]

[0370] Embodiment 72. The method of any one of embodiments 55 to 57, wherein the circular RNA is substantially non-immunogenic.

[0369]

[0371] Embodiment 73. The method of embodiment 72, wherein the circular RNA comprises one or more M-6-methyladenosine (m6A) residues.

[0370]

[0372] Embodiment 74. The method of any one of embodiments 55 to 73, wherein the circular RNA comprises from about 200 nucleotides to about 5,000 nucleotides.

[0371]

[0373] Embodiment 75. The method of any one of embodiments 55 to 74, wherein the circular RNA comprises an internal ribosome entry site (IRES) operably linked to the protein coding sequence.

[0372]

[0374] Embodiment 76. The method of any one of embodiments 55 to 75, wherein the circular RNA encodes two or more reprogramming factors selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc.

[0373]

[0375] Embodiment 77. The method of embodiment 55 or 56, comprising contacting a cell with a first circular RNA encoding Oct4 or a fragment or variant thereof, a second circular RNA encoding Sox2 or a fragment or variant thereof, a third circular RNA encoding Klf4 or a fragment or variant thereof, a fourth circular RNA encoding C-Myc or a fragment or variant thereof, a fifth circular RNA encoding Lin28 or a fragment or variant thereof, and a sixth circular RNA encoding Nanog or a fragment or variant thereof.

[0374]

[0376] Embodiment 78. The method of embodiment 55 or 56, comprising contacting the cell with one or more circular RNAs encoding Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, and L-Myc, or fragments or variants thereof.

[0375]

[0377] Embodiment 79. The method of any one of embodiments 55 to 78, wherein the cell is not contacted with any auxiliary factor selected from E3, K3, B18R, or any microRNA (miR).

[0376]

[0378] Embodiment 80. The method of any one of embodiments 55 to 79, wherein the cell is directly contacted with at least one circular RNA.

[0377]

[0379] Embodiment 81. The method of any one of embodiments 55 to 80, wherein the cell is contacted once with each of the at least one circular RNA.

[0378]

[0380] Embodiment 82. The method of any one of embodiments 55 to 80, comprising contacting a cell with at least one, two, three, four or more of each of the circular RNAs.

[0379]

[0381] Embodiment 83 The method of any one of embodiments 55 to 80, comprising contacting the cell with each of the at least one circular RNA less than four times.

[0380]

[0382] Embodiment 84. The method of any one of embodiments 55 to 80, comprising contacting the cell with each of at least one circular RNA 2 to 4 times.

[0381]

[0383] Embodiment 85. The method of any one of embodiments 55 to 84, wherein the concentration of at least one circular RNA is at least 3 pg RNA / cell.

[0382]

[0384] Embodiment 86. The method according to any one of embodiments 55 to 85, wherein the concentration of at least one circular RNA is from about 5 pg RNA / cell to about 15 pg RNA / cell.

[0383]

[0385] Embodiment 87. The method of any one of embodiments 55 to 86, wherein the contacting of the cells is performed by electroporation.

[0384]

[0386] Embodiment 88. The method of embodiment 87, wherein the electroporation uses a Neon® electroporation system.

[0385]

[0387] Embodiment 89. The method of any one of embodiments 55-78 or 80-88, comprising contacting a cell with an RNA polynucleotide encoding one or more viral proteins selected from E3, K3, or B18R.

[0386]

[0388] Embodiment 90. The method of embodiment 89, wherein (a) B18R has a sequence of SEQ ID NO: 26, or a sequence at least 90% or at least 95% identical thereto; (b) E3 has a sequence of SEQ ID NO: 27, or a sequence at least 90% or at least 95% identical thereto; and / or (c) K3 has a sequence of SEQ ID NO: 28, or a sequence at least 90% or at least 95% identical thereto.

[0387]

[0389] Embodiment 91. The method of any one of embodiments 55-78 or 80-90, comprising contacting a cell with a microRNA (miR) selected from miR302a, miR302b, miR302c, miR302d, and miR367.

[0388]

[0390] Embodiment 92. The method of any one of embodiments 55 to 88, wherein the cell is not contacted with any viral protein selected from E3, K3, B18R, or with any microRNA (miR) selected from miR302a, miR302b, miR302c, miR302d, and miR367.

[0389]

[0391] Embodiment 93. The method of any one of embodiments 55 to 82, wherein the enzyme is a transcription activator-like effector nuclease (TALEN), an Argonaute endonuclease (NgAgo), a structure-guided endonuclease (SGN), an RNA-guided nuclease (RGN), an adenosine deaminase acting on RNA (ADAR), or a modified or truncated variant thereof.

[0390]

[0392] Embodiment 94. The method of embodiment 93, wherein the RGN is a Cas nuclease selected from Cas9 nuclease, Cas12(a) nuclease (Cpf1), Cas12b nuclease, Cas12c nuclease, TrpB-like nuclease, Cas13a nuclease (C2c2), Cas13b nuclease, Cas14 nuclease, or modified or truncated variants thereof.

[0391]

[0393] Embodiment 95. The method of embodiment 94, wherein the RGN is a Cas9 nuclease, and the Cas9 nuclease is isolated or derived from S. pyogenes or S. aureus.

[0392]

[0394]

[0033] In an embodiment 96, the RGN is selected from the group consisting of APG05083.1, APG07433.1, APG07513.1, APG08290.1, APG05459.1, APG04583.1, and APG1688.1, APG05733.1, APG06207.1, APG01647.1, APG08032.1, APG05712.1, APG01658.1, APG06498.1, APG09106.1, APG09882.1, APG02675.1, APG01405.1, APG06250.1, APG06 877.1, APG09053.1, APG04293.1, APG01308.1, APG06646.1, APG09748, APG07433.1, APG00969, APG03128, APG09748, APG00771, APG02789, APG09106, APG02312, APG07386, APG09980, APG05840, APG05241, APG07280, APG09866, and APG00868.

[0393]

[0395] Embodiment 97. The method of any one of embodiments 55 to 96, further comprising contacting the cell with a guide RNA, or a nucleic acid encoding same.

[0394]

[0396] Embodiment 98. The method of any one of embodiments 55 or 57 to 97, wherein the cell is contacted with the circular RNA before being contacted with the enzyme or a nucleic acid encoding same.

[0395]

[0397] Embodiment 99. The method of any one of embodiments 55 or 87 to 97, wherein the cell is contacted with the recombinant circular RNA after contacting the cell with the enzyme or a nucleic acid encoding same.

[0396]

[0398] Embodiment 100. The method of any one of embodiments 55 to 99, wherein the cell is contacted with an enzyme capable of editing the cell's DNA or RNA, or a nucleic acid encoding the same, and a guide RNA, or a nucleic acid encoding the same.

[0397]

[0399] Embodiment 101. The method of embodiment 100, wherein the enzyme is capable of editing the DNA of a cell, and the enzyme and the guide RNA are complexed as a ribonucleoprotein prior to contact with the cell.

[0398]

[0400] Embodiment 102. The method according to any one of embodiments 55 to 101, wherein the contacting of the cells is performed by electroporation.

[0399]

[0401] Embodiment 103. A cell produced by the method according to any one of embodiments 55 to 102.

[0400]

[0402] Embodiment 104. A method for reprogramming a cell, comprising contacting the cell with one or more circular RNAs encoding six reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0401]

[0403] Embodiment 105. The method of embodiment 104, comprising contacting the cell with six circular RNAs, each encoding a reprogramming factor from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0402]

[0404] Embodiment 106. The method according to embodiment 104 or 105, wherein either the circular RNA or the linear RNA is conjugated to a lipid nanoparticle.

[0403]

[0405] Embodiment 107. The method of any one of embodiments 104 to 106, wherein the cell is not contacted with one or more factors selected from E3, K3, B18R, or one or more microRNAs (miR).

[0404]

[0406] 107A. The method of any one of claims 1-51, 55-102, or 104-107, wherein the circular RNA is exogenous to the cell.

[0405]

[0407] Embodiment 108. A cell produced by the method of any one of embodiments 104 to 107A.

[0406]

[0408] Embodiment 109. A somatic cell comprising one or more exogenous circular RNAs encoding reprogramming factors, wherein the reprogramming factors are selected from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0407]

[0409] Embodiment 110. The somatic cell of embodiment 109, wherein the somatic cell comprises one or more exogenous circular RNAs, each of the one or more circular RNAs encoding a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0408]

[0410] Embodiment 111. The somatic cell of embodiment 109, wherein the somatic cell comprises six exogenous circular RNAs, each of which encodes one of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0409]

[0411] Embodiment 112. The somatic cell of embodiment 109, wherein the somatic cell comprises five exogenous circular RNAs, each of which encodes one of Oct3 / 4, Klf4, Sox2, Nanog, and Lin28.

[0410]

[0412] Embodiment 113. The somatic cell of embodiment 109, wherein the somatic cell comprises four exogenous circular RNAs, each of which encodes one of Oct3 / 4, Klf4, Sox2, and c-Myc.

[0411]

[0413] Embodiment 114. The somatic cell of embodiment 109, wherein the somatic cell comprises three exogenous circular RNAs, each of which encodes one of Oct3 / 4, Klf4, and Sox2.

[0412]

[0414] Embodiment 115. A suspension culture comprising one or more CD34+ cells, wherein the CD34+ cells comprise one or more exogenous circRNAs encoding reprogramming factors.

[0413]

[0415] Embodiment 116. The suspension culture of embodiment 115, wherein the CD34+ cells comprise six exogenous circRNAs, each encoding one reprogramming factor selected from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0414]

[0416] Embodiment 117. The suspension culture of embodiment 115 or 116, wherein the CD34+ cells do not contain exogenous nucleic acids encoding auxiliary factors selected from E3, K3, B18R, or microRNA (miR).

[0415]

[0417] Embodiment 118. A composition comprising one or more circular RNAs encoding reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0416]

[0418] Embodiment 119. A composition comprising two or more circular RNAs encoding reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0417]

[0419] Embodiment 120. A composition comprising six circular RNAs, each encoding one of the reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0418]

[0420] Embodiment 121. A composition comprising five circular RNAs, each encoding one of the reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, and Lin28.

[0419]

[0421] Embodiment 122. A composition comprising four circular RNAs, each encoding one of the reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, and c-Myc.

[0420]

[0422] Embodiment 123. A composition comprising three circular RNAs, each encoding one of the reprogramming factors consisting of Oct3 / 4, Klf4, and Sox2.

[0421]

[0423] Embodiment 124. A kit comprising a composition according to any one of embodiments 118 to 123.

[0422]

[0424] Embodiment 125. A cell comprising a composition according to any one of embodiments 118 to 123.

[0423]

[0425] Embodiment 126. The cell of embodiment 125, which is a eukaryotic cell.

[0424]

[0426] Embodiment 127. The cell of embodiment 126, which is a mammalian cell.

[0425]

[0427] Embodiment 128. The cell of embodiment 127, which is a human cell.

[0426]

[0428] Embodiment 129. A cell according to any one of embodiments 125 to 128, which is a CD34+ cell, a T cell, or a NK cell.

[0427]

[0429] Embodiment 130. CD34+ cells comprising one or more circular RNAs encoding one or more reprogramming factors selected from either Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc, or L-Myc.

[0428]

[0430] Embodiment 131. The CD34+ cell of embodiment 130, wherein the reprogramming factors consist of all six of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

[0429]

[0431] Embodiment 132. The CD34+ cell of embodiment 130, wherein the reprogramming factors consist of all six of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and L-Myc.

[0430]

[0432] Embodiment 133. The CD34+ cells of embodiment 130, wherein the reprogramming factors consist of Oct3 / 4, Klf4, Sox2, Nanog, and Lin28.

[0431]

[0433] Embodiment 134. The CD34+ cell of embodiment 130, wherein the reprogramming factors consist of Oct3 / 4, Klf4, Sox2, and c-Myc.

[0432]

[0434] Embodiment 135. The CD34+ cell of embodiment 130, wherein the reprogramming factors consist of Oct3 / 4, Klf4, and Sox2.

[0433]

[0435] Embodiment 136. A CD34+ cell according to any one of embodiments 130 to 135, exhibiting at least one stemness marker selected from SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, TRA-2-49 / 6E, alkaline phosphatase, Sox2, E-cadherin, UTF-1, Oct4, Rex1, Nanog, or a combination thereof.

[0434]

[0436] Embodiment 137. A CD34+ cell according to any one of embodiments 130 to 136, wherein the one or more circular RNAs are exogenous to the cell.

[0435]

[0437] Embodiment 138. A CD34+ cell according to any one of embodiments 130 to 137, further comprising one or more genetic modifications.

[0436]

[0438] Embodiment 139. The CD34+ cell of embodiment 138, wherein the one or more genetic modifications comprise a gene knockout.

[0437]

[0439] Embodiment 140. The CD34+ cell of embodiment 138 or 139, wherein the one or more genetic modifications comprise a gene knock-in.

[0438]

[0440] Embodiment 141. An induced pluripotent stem cell (iPSC) derived from a CD34+ cell according to any one of embodiments 130 to 140.

[0439]

[0441] Embodiment 142. The iPSC of embodiment 141, wherein the cells are hypoimmunogenic.

[0440]

[0442] Embodiment 143. A differentiated cell generated from an iPSC according to embodiment 141 or 142.

[0441]

[0443] Embodiment 144. A method for treating a disease or condition, comprising administering to a subject in need thereof an iPSC according to embodiment 141 or 142 or a differentiated cell according to embodiment 126.

[0442]

[0444] Embodiment 145. A method for transdifferentiating a somatic cell, comprising contacting the cell with one or more exogenous circular RNAs.

[0443]

[0445] Embodiment 146. A transdifferentiated cell produced by the method of embodiment 145.

[0444]

[0446] Embodiment 147. A method for differentiating a cell from an induced pluripotent stem cell (iPSC), comprising contacting the iPSC with one or more circular RNAs.

[0445]

[0447] Embodiment 148. A differentiated cell produced by the method of embodiment 147. EXAMPLES

[0446] Working Example

[0448] The following examples are included herein for illustrative purposes only and are not intended to be limiting.

[0447] Example 1: Circular RNA reprogramming of CD34+ cells in suspension

[0449] An experiment was performed to evaluate the feasibility of reprogramming CD34+ cells in suspension. A schematic diagram of the timeline and process of this reprogramming experiment is provided in Figure 4. Exemplary sequences of circularized RNA are provided in SEQ ID NOs: 8, 11, 13, 16, 18, and 21 and are detailed in Table 6 below.

[0448] [Table 30]

[0449]

[0450] Briefly, cord blood-derived CD34+ cells were expanded for 3 days (from day -3 to day 0) in SCGM medium (Cellgenix) containing five cytokines - SCF, FLT3L, TPO, IL-3, and IL-6 (100 ng / mL each). On day 0, 0.5 × 106 Cells were pelleted, washed, and resuspended in 100-120 μL of buffer for transfection by electroporation. Cells were electroporated with a Neon® electroporator set at 1600V, 10 ms pulse width, 3 pulses. RNA cocktails (C14 and C6) were delivered to CD34 cells at two concentrations: 5.2 pg / cell and 13 pg / cell. These concentrations were chosen based on previous experiments using a lower RNA / cell ratio (2.6 pg / cell) and resulting in unsuccessful CD34+ cell reprogramming (data not shown). The RNA cocktail used in this experiment contained the following components: (a) C14 cocktail - six circRNAs encoding OCT4, SOX2, KLF4, cMYC, NANOG and LIN28A (OSKMNL) separately + a linear RNA encoding E3 / K3 / B18R (EKB) + five miRs (miR302a, -b, -c, -d and miR367). (b) C6 cocktail = six circRNAs separately encoding OCT4, SOX2, KLF4, cMYC, NANOG, and LIN28A (OSKMNL).

[0450]

[0451] The stoichiometry of the six reprogramming factors OSKMNL is 3:1:1:1:1:1. The transfection frequency and amount of RNA delivered with each of the cocktails are shown in Table 7.

[0451] [Table 31]

[0452]

[0452] On day 0, CD34 cells (0.5 × 10 6 ) was used as a positive control. Negative controls included mock transfections (RNase- and DNase-free water) performed simultaneously with the other transfections (once a day for 6 days (group 14 in Table 7) or once every other day for 4 days (group 13 in Table 7)) and untransfected CD34 cells. All controls were 0.5×106 This was performed with CD34+ cells.

[0453] After each transfection, cells were resuspended in complete SCGM medium containing 10 μM of ROCK inhibitor Y27632 and seeded in 24-well non-adherent plates. The day after the final transfection, cell number and viability were determined for each condition, including controls (SeV, mock, and CD34+ cells alone). All cells were plated in iMatrix-511-coated 12-well tissue culture-treated plates in complete SCGM medium (containing cytokines) and 10 μM Y27632. Plated cells were grown in 5% O2 (low-oxygen incubator).

[0454] On days 4-6, half of the medium (1 ml) from each well was replaced with 1 ml of cytokine-free SCGM medium. The medium replacement on day 4 contained 10 μM Y27632. The medium replacement on the remaining days did not contain 10 μM Y27632. On day 7, half of the medium (1 ml) from each well was replaced with 1 ml of PSC medium (Nutristem hPSC-XF for cells grown on iM511 or Stemfit medium for cells grown on Vtn). From day 8 onwards, the entire medium in each well was replaced with 2 ml of PSC medium until iPSC colonies were ready for picking.

[0455] Initially, small clumps resembling iPSC-like colonies were observed by days 6-7 (for SeV) and 8 (for C14). By day 11, cell clusters were observed in three of the circRNA conditions (top three rows). These clusters continued to proliferate and grow in size, assuming iPSC morphology. See Figure 5.

[0456] On days 22-23 of reprogramming, cultures were fixed and stained with pluripotency markers Tra-1-81 and OCT4, and whole-well images were scanned using an IncuCyte. iPSC colonies showed positive staining for pluripotency markers Tra-1-81+ and Oct4+. Cultures transfected twice (performed on days 0 and 2) with either 5.2 pg (group 1) or 13 pg (group 5) of C14 cocktail (Figure 6A and 6B) showed a larger area of ​​Tra-1-81 / Oct4 double positive cells. Transfection of 5.2 pg (group 3) of C14 cocktail for 4 consecutive days (Figure 6C) also resulted in TRA-1-81 and OCT4 positive iPSC colonies.

[0457] Representative phase contrast images of circRNA-reprogrammed iPSC clones at passage 1 are shown in Figure 7. These iPSC clones derived from circRNA-reprogrammed CD34 cells were capable of being picked and expanded in culture.

[0458] These results demonstrate the suspension reprogramming of CD34+ cells using circRNAs encoding reprogramming factors. C14 cocktail successfully reprogrammed CD34 cells either 1) by transfection on days 0 and 2, or 2) by transfection on days 1, 2, 3, and 4. Reprogramming efficiency was similar to SeV reprogramming (group 11), further demonstrating the robustness of circRNA reprogramming. Mock electroporation (x2) followed by SeV reprogramming resulted in extensive cell death but still yielded iPSC colonies, suggesting that the electroporation procedure itself is not a contraindication in terms of initiating and progressing iPSC reprogramming.

[0459] Example 2: Simultaneous reprogramming and gene editing of fibroblasts

[0459] To demonstrate the generation of B2M- / - iPSCs by simultaneous reprogramming (by circRNA) and editing of the B2M gene, experiments were performed using hematopoietic fibroblasts (HDFs).

[0460]

[0460] Two protocols were compared: (1) a one-step protocol illustrating simultaneous reprogramming and editing of HDFs, and (2) a two-step protocol illustrating sequential editing and reprogramming of HDFs.

[0461] For the one-step protocol, HDFs were reprogrammed with circRNAs following a previously optimized circRNA reprogramming protocol - i.e., two transfections using RNAiMAX transfection reagent on days 0 and 2. The C14 reprogramming cocktail was used, which included six circRNAs encoding reprogramming factors OCT4, SOX2, KLF4, cMYC, NANOG, and LIN28A (OSKLMN) + linear mRNA encoding E3 / K3 / B18R + five microRNAs (miR302a, -b, -c, -d, and miR367). An mRNA polynucleotide encoding LEG14 RNA-guided nuclease (Life Edit Therapeutics, Morrisville, NC) and an sgRNA targeting the B2M gene (Life Edit Therapeutics, Morrisville, NC) were co-transfected with the circRNA reprogramming cocktail. The following three conditions were tested: (a) No nuclease / sgRNA cotransfection (b) Cotransfect nuclease / sgRNA on day 0 (RE1) (c) Co-transfect nuclease / sgRNA on days 0 and 2 (RE2)

[0462]

[0462] For each of RE1 and RE2, three different densities of HDFs (25K, 50K and 75K in each well) were simultaneously reprogrammed and edited.

[0463] For the 2-step protocol, HDFs were first transfected with RNP complexes containing RNA-guided nucleases and B2M-targeting sgRNAs using a Neon® electroporator. Three different settings were tested (see Table 9). Electroporated HDFs were then plated in culture to optimal confluency (approximately 6 days) and seeded into 6-well plates for circRNA reprogramming following the same procedure used for the 1-step protocol.

[0464] On day 21 of reprogramming, cultures were fixed and stained with pluripotency markers Tra-1-81 and OCT4, and whole-well images were scanned using an IncuCyte. iPSC colonies showed positive staining for Tra-1-81- and Oct4. Figure 8 shows the staining results for the 1-step protocol. Figure 10 shows the staining results for the 2-step protocol.

[0465] The editing efficiency of the one-step (simultaneous) and two-step (sequential) protocols was measured by the % reads that showed indels in the region around the sgRNA target site (exon 1 of the B2M gene). Editing efficiency was determined by PCR amplification of the region of interest and sequencing the resulting amplicons using Ilumina's Mi-Seq NGS system. The results of the one-step protocol are shown in Table 8. When cells were edited twice (RE2), 100% editing efficiency was observed as all reads showed various indels.

[0466] [Table 32]

[0467]

[0466] The B2M allele of two iPSC clones derived from the one-step simultaneous reprogramming and editing protocol was further analyzed. The results show that this editing protocol generated both heterozygous and homozygous clones (data not shown).

[0468] The results of the two-step protocol are shown in Table 9. 5 HDFs were electroporated with ribonucleoprotein (RNP) complexes containing RNA-guided nuclease and sgRNA targeting the B2M gene. Edited cells were expanded in culture and seeded at three different densities (25K, 50K, and 75K) in 6-well plates for reprogramming with C14 circRNA cocktail. Editing efficiency was determined (for three different Neon® parameters) in 16 different physically separate clones that were subcloned for lysis and PCR amplification of the region of interest. Amplicon reads were sequenced using Ilumina's Mi-Seq NGS system. As shown in Table 9, all three electroporation parameter conditions resulted in high editing efficiency of the B2M gene.

[0469] [Table 33]

[0470]

[0468] Figure 9 provides representative images of iPSC clones derived from a one-step simultaneous reprogramming and editing protocol. These clones exhibit typical iPSC morphology and can be expanded in culture. Clones derived from the RE1 protocol (one delivery of editing factors) are shown in the top row. Clones derived from the RE2 protocol (two deliveries of editing factors) are shown in the bottom row.

[0471] These data demonstrate that both one-step (simultaneous) and two-step (sequential) editing protocols were successful in generating edited (B2M- / - or B2M- / +) iPSCs. The one-step protocol represents true simultaneous reprogramming and editing. One transfection of editing factors (RNA-guided nuclease + sgRNA) resulted in an editing efficiency of 50-70%, and two transfections of editing factors resulted in an editing efficiency of approximately 100%. The two-step protocol also resulted in an extremely high editing efficiency of approximately 100%.

[0472] Example 3: circRNA reprogramming in suspension of CD34+ cells without auxiliary factors Experiments were performed to test different transfection regimens for C6 circRNA cocktail reprogramming in suspension of CD34+ cells. The cocktail contains only circRNAs encoding reprogramming factors OCT4, SOX2, KLF4, cMYC, LIN28A, and NANOG (OSKMLN). The goal of these experiments was to demonstrate the feasibility of reprogramming suspension cells and further demonstrate that E3 / K3 / B18R and microRNAs are not required when reprogramming with circRNA cocktail.

[0473]

[0471] Figure 11 provides a schematic of the timing and experimental design of these experiments. Table 10 provides experimental details for each of the conditions tested. In addition to the C14 and C6 cocktails, the C11 cocktail (containing 6 circRNAs + 5 microRNAs encoding OSKMLN reprogramming factors) was also tested.

[0474] [Table 34]

[0475] Cord blood-derived CD34+ cells were reprogrammed into iPSCs by electroporating the cells with one of the following cocktails: (a) C14 cocktail - circRNAs encoding OCT4, SOX2, KLF4, cMYC, NANOG and LIN28A reprogramming factors (OSKMNL) separately + linear RNA encoding E3 / K3 / B18R + five miRs (miR302a, -b, -c, -d and miR367); (b) C11 cocktail - six circRNAs encoding OCT4, SOX2, KLF4, cMYC, NANOG and LIN28A reprogramming factors (OSKMNL) separately + five miRs (miR302a, -b, -c, -d and miR367); or (c) C6 cocktail - circRNAs encoding OCT4, SOX2, KLF4, cMYC, NANOG, and LIN28A (OSKMNL) separately

[0476]

[0473] The stoichiometry of the six reprogramming factors OSKMNL was 3:1:1:1:1:1.

[0477] Briefly, cord blood-derived CD34+ cells were expanded for 3 days (day -3 to day 0) in SCGM medium (Cellgenix) containing five cytokines - SCF, FLT3L, TPO, IL3 and IL6 (100 ng / ml each). On day 0, 0.5×10 cells were expanded for each condition. 6 Cells were pelleted, washed, and resuspended in 100-120 μL of buffer for transfection by electroporation. To introduce the RNA cocktail, cells were electroporated with a Neon® electroporator set at 1600V, 10 ms pulse width, 3 pulses. Negative controls for this experiment included mock transfections (RNase, DNase free water) performed once a day for 4 days, as well as untransfected CD34+ cells. Both negative controls were incubated with 0.5×10 6After each transfection, cells were resuspended in complete SCGM medium containing 10 μM Y27632 and seeded into 24-well non-adherent plates.

[0478] The day after the final transfection, cell number and viability were determined for each condition, including controls (mock-transfected and non-transfected CD34+ cells). All cells were plated onto iMatrix-511-coated 12-well tissue culture treated plates in complete SCGM medium (containing cytokines) and 10 μM Y27632. Cells were grown in 5% O2 (low oxygen incubator).

[0479] On days 4-5, half of the medium (1 ml) from each well was replaced with 1 ml SCGM medium + 10 μM Y27632 medium without cytokines. On day 6, half of the medium (1 ml) from each well was replaced with 1 ml SCGM medium without cytokines and 10 μM Y27632 medium without cytokines. On day 7, half of the medium (1 ml) from each well was replaced with 1 ml PSC medium (Nutristem hPSC-XF for cells grown on iM511 or Stem fit medium for cells grown on Vtn). From day 8 onwards, all of the medium in each well was replaced with 2 ml PSC medium until iPSC colonies were ready to be picked.

[0480]

[0477] Figure 12A-C show the morphological progression of CD34+ cell reprogramming using C14, C6, and C11 circRNA cocktails. At day 4, small attached cell clusters were observed from most conditions. At day 7, early iPSC-like colonies appeared from all conditions. These clusters continued to proliferate and grow in size, assuming iPSC morphology.

[0481]

[0478] Figure 13A provides a representative image of a 6-well plate of iPSC colonies reprogrammed with C6 (8 pg) reprogramming cocktail, segmented and identified using the object count function in the analysis module of Incucyte. Figure 13B provides a comparison of reprogramming efficiency observed early (days 8-10) upon reprogramming with different circRNA cocktails.

[0482] All conditions tested (C14, C11, C6 and C14+edit) generated iPSC colonies from CD34+ cells by days 4-7. Both transfection schedules (two transfections every other day (Figure 12) and four consecutive days of transfection (data not shown)) resulted in reprogramming and generation of iPSCs. Among these conditions, 8 pg of C6 (two transfections every other day) generated the highest number of iPSC colonies compared to all other conditions (see Figure 13B). Even at low seeding densities (as low as 12.5K cells), colonies were observed on day 3. With 8 pg of C6 cocktail, reprogramming efficiency was about 3%.

[0483] Example 4: Optimization of RNA electroporation in CD34+ cells Experiments were performed to optimize electroporation protocols for CD34+ cells. Transfection of linear mRNA vs. circRNA RNA was tested and compared with Neon® electroporation (100 μL tip volume) and Lonza Amaxa nucleofector (20 μL volume).

[0484] A schematic diagram of the experimental method is shown in Figure 14. Briefly, CD34+ cells from umbilical cord blood were thawed and expanded in SCGM medium (Cellgenix) containing five cytokines - SCF, FLT3L, TPO, IL-3 and IL-6 (100ng / ml each) for 3 days (day -3 to day 0). On day 0, CD34+ cells were harvested, washed and resuspended in a suitable buffer for electroporation using the Neon® system or Nucleofactor from Lonza.

[0485] Linear unmodified mRNA (TriLink) or circRNA (unmodified) encoding nGFP (0.25 or 0.5ug) was electroporated using the Neon® or Lonza electroporation system. Transfections were performed twice, on days 0 and 2. For Neon®-based transfections, 1x10 6 Cells were washed, resuspended in Buffer T and electroporated with a Neon® 100 μl tip at 1600 V, 10 ms pulse width, 3 pulses. For Lonza-based transfections, 1 × 10 6 Cells were washed and resuspended in 20 μl of P3 nucleofector solution supplemented as per manufacturer's instructions (4.5:1 ratio). Cells were electroporated in 16-well cuvettes using program E0-100 for suspension cells as recommended by Lonza. Cells were immediately transferred to non-adherent plates in complete SCGM medium.

[0486]

[0483] 100,000 cells were harvested, fixed and analyzed for protein expression on days 1, 2, 3, 4 and 5 after electroporation. nGFP protein expression was also measured using the Incucyte real-time imaging platform in live cells in suspension, as well as by flow cytometry (to measure nGFP expression at the cellular level) after the initial transfection.

[0487]

[0484] Figure 15 shows the kinetics of nGFP protein expression as determined by IncuCyte imaging. nGFP protein levels were measured every 6 hours by Incucyte. RNA (linear or circular) transfected with the Neon® electroporator, but not with the Lonza Amaxa nucleofector, produced a significant peak of nGFP protein expression after the first transfection on day 0. After the second transfection on day 2, only circRNA transfected with the Neon® electroporator produced a high peak of nGFP protein expression. Linear mRNA transfected with the Neon® electroporator produced a very low peak after the second transfection. Using the Lonza Amaxa nucleofector, transfection of either linear mRNA or circRNA did not produce any significant nGFP protein expression.

[0488]

[0485] Figure 16 illustrates flow cytometry analysis of nGFP protein levels one day after initial transfection. Transfection of RNA with the Neon® electroporator resulted in higher nGFP protein levels compared to transfection of RNA with the Lonza Amaxa nucleofector.

[0489] These data demonstrate that, at least under these conditions, electroporation of cord blood-derived CD34+ cells using the Neon® system is more efficient in delivering both linear mRNA and circRNA compared to electroporation with Lonza's 4D nucleoporator. After two transfections using the Neon® system, circRNA resulted in much higher nGFP protein levels compared to linear mRNA (Figure 15).

[0490] Example 5: Effect of RNase R treatment on circRNA synthesis as determined by reporter protein expression

[0487] Experiments were performed to determine whether RNase R treatment (as part of the circRNA production process) had any effect on downstream protein expression and / or cell viability.

[0491] Two cell types were used - HDFs and CD34+ cells. A single transfection with circRNA encoding nGFP with or without RNase R treatment was performed. Linear mRNA encoding nGFP was used as a reference. Transfection methods and experimental parameters are outlined in Table 11. Readings of nGFP expression were performed by Incucyte (every 6 hours) and flow cytometry (every 24 hours, days 1-5).

[0492] [Table 35]

[0493]

[0489] Figure 17 provides the results of nGFP protein expression in fibroblasts (HDF) after RNA transfection with RNAiMAX (50ng / 24 wells) as analyzed by IncuCyte. Single transfections of linear mRNA encoding nGFP, circRNA encoding nGFP with RNaseR treatment, or circRNA encoding nGFP without RNaseR treatment were performed using RNAiMAX. After transfection, nGFP protein levels were measured every 6 hours by IncuCyte. Linear mRNA transfection resulted in a rapid increase in nGFP protein, peaking around 48 hours, followed by a rapid decrease in expression over the next 2 days. CircRNA with and without RNaseR treatment showed a similar protein expression pattern - a modest increase in nGFP protein levels compared to linear mRNA, which also peaked around 48 hours, followed by a gradual decrease over the next 2 days. Treating circRNA with RNase R as a purification step increased the purity of circRNA preps (from ∼60% to ∼90% circRNA, data not shown), where there was a minimal effect on protein expression in fibroblasts.

[0494] FIG. 18 provides the results of nGFP protein expression in CD34 cells after RNA transfection using Neon® (250ng / 6 wells) as analyzed by IncuCyte. Linear mRNA encoding nGFP, circRNA encoding nGFP with RNaseR treatment, or circRNA encoding nGFP without RNaseR treatment were transfected into CD34+ cells using a Neon® electroporator. After one transfection, nGFP protein levels were measured every 6 hours by IncuCyte. In contrast to the observations in fibroblasts, circRNA (both with and without RNaseR treatment) resulted in higher and longer-lasting protein expression compared to linear mRNA. The difference in protein levels between RNaseR+ and RNaseR- circRNAs was minimal.

[0495] Example 6: Reducing the number of reprogramming factors to reprogram CD34+ cells Experiments were performed to evaluate the reprogramming of CD34+ cells in the absence of c-Myc, Lin28A, and / or Nanog. We also evaluated whether a single transfection of C6 cocktail (OCT4, SOX2, KLF4, c-MYC, NANOG, and LIN28A) was sufficient to reprogram CD34+ cells. Reprogramming results with circRNA reprogramming factors were compared to linear mRNA cocktail.

[0496]

[0492] The conditions tested in these experiments are outlined in Table 12.

[0497] [Table 36]

[0498] The reprogramming cocktails tested were as follows: (i) C6 cocktail - circRNAs encoding OCT4, SOX2, KLF4, cMYC, NANOG and LIN28A (OSKMNL) separately. The stoichiometry of these six reprogramming factors, OSKMNL, is 3:1:1:1:1:1 (b) C5(cMyc-shedding)-circRNAs encoding OCT4, SOX2, KLF4, NANOG, and LIN28A (OSKNL) separately. The stoichiometry of these five reprogramming factors, OSKNL, is 3:1:1:1:1:1. (i) C4 (Nanog and Lin28A minus) - a circRNA that differentially encodes OCT4, SOX2, KLF4, and cMYC (OSKM). The stoichiometry of these four reprogramming factors, OSKM, is 3:1:1:1. (ii) C3 (cMyc, Nanog and Lin28A minus) - a circRNA that differentially encodes OCT4, SOX2 and KLF4 (OSK). The stoichiometry of these three reprogramming factors is 3:1:1. (c) Linear mRNA - A cocktail from the Stemgent reprogramming kit and linear mRNA purchased from Trilink were tested - each encoding six factors OCT4, SOX2, KLF4, cMYC, NANOG, and LIN28A (OSKMNL).

[0499]

[0494] Please note that the six factors used for reprogramming in the Stemgent (S), TriLink (L), and circRNA (C) cocktails are identical. However, the total molecular weights of the constructs encoding these factors are different. Therefore, this affected the total amount of RNA delivered to each cell per transfection (as shown in Table 12).

[0500]

[0495] A schematic summarizing this experimental protocol is shown in FIG.

[0501] Briefly, cord blood-derived CD34+ cells were expanded for 3 days (day -3 to day 0) in SCGM medium (Cellgenix) containing five cytokines - SCF, FLT3L, TPO, IL3 and IL6 (100 ng / mL each). On day 0, 0.5×10 cells were expanded for each condition. 6 Cells were pelleted, washed, and resuspended in 100–120 μL of buffer for transfection by electroporation using a Neon electroporator set at 1600 V, 10 ms pulse width, and 3 pulses.

[0502] As a negative control, mock transfections (with RNase, DNase free water) were performed at the same time as the other transfections (condition 10 in Table 12). Untransfected CD34+ cells were also included as a negative control (condition 11 in Table 12). Both controls had the same number of cells as all test conditions (0.5×10 6 The positive control used in this experiment was the SeV Cytotune 2.0-encoded reprogramming cocktail encoding Oct4, Sox2, Klf4, and c-Myc.

[0503] After each transfection, cells were resuspended in complete SCGM medium containing 10 μM Y27632 and seeded into 24-well non-adherent plates. On the day of the final transfection (day 3), cell number and viability were determined for each condition, including controls (mock and CD34 alone). All cells were plated into iMatrix-511-coated 12-well tissue culture-treated plates in complete SCGM medium (containing cytokines) and 10 μM Y27632. Cells were grown in 5% O2 (low oxygen incubator).

[0504] From days 4 to 6, half of the medium (1 mL) from each well was replaced with 1 mL SCGM medium without cytokines, and only until day 4, the medium was supplemented with 10 μM Y27632. On day 7, half of the medium (1 mL) from each well was replaced with 1 mL PSC medium (Nutristem hPSC-XF for cells grown on iM511 or Stemfit medium for cells grown on Vtn). From day 8 onwards, all medium in each of the 6 wells was replaced with 2 mL PSC medium until iPSC colonies were ready to be picked.

[0505] As shown in Figure 20A, the C6 cocktail was successful in generating colonies with typical iPSC morphology. The C4 cocktail, which still contained c-Myc but omitted Nanog and Lin28A, also generated numerous iPSC colonies (similar to C6). Importantly, reprogramming with C5 and C3 cocktails, both of which omitted c-Myc, demonstrated lower reprogramming efficiency compared to the C6 and C4 cocktails, but these conditions still generated iPSC colonies. Thus, there were fewer colonies in the C5 and C3 cultures compared to the C6 and C4 cultures. Further results are shown in Figure 20B, which illustrates the observation that the C5, C4, and C3 cocktails all reprogram CD34+ cells, but the absence of c-Myc results in smaller colonies and lower overall efficiency.

[0506] Figure 21 shows the morphological progression of CD34+ reprogramming using only one transfection of C6 circRNA cocktail. Two RNA doses were tested - 8pg per cell and 3.2pg per cell. In cultures transfected with 8pg RNA per cell, adherent cell clusters appeared at approximately day 8 and continued to increase in size into iPSC-like colonies. However, one transfection of 3.2pg RNA per cell did not result in successful reprogramming of CD34+ cells. This demonstrates that CD34+ cells can be reprogrammed by a single delivery of circRNAs encoding reprogramming factors, provided that sufficient concentrations of RNA are used.

[0507]

[0502] Figure 22 shows the morphological progression of CD34+ reprogramming using linear mRNA. CD34+ cells were reprogrammed using a reprogramming RNA cocktail (S6, OSKMLN) from ReproCell / Stemgent's StemRNA 3rd Generation Reprogramming Kit and a linear mRNA cocktail (L6, OSKMLN) containing individual linear mRNAs purchased from Trilink. Two transfections were performed on days 0 and 2. However, no iPSC colonies were formed in either S6 or L6 cultures. A comparison between the morphological progression observed with the C6 cocktail and that observed with the S6 and L6 cocktails is provided in Figure 23.

[0508]

[0503] Figure 24 demonstrates the reprogramming efficiency of CD34+ cells measured using IncuCyte. The reprogramming efficiency of circRNA cocktails C6, C5, C4 and C3, and linear mRNA cocktails from Stemgent (S6) and Trilink (L6) are compared in Figure 24A. Reprogramming of CD34+ cells using circRNA C6 cocktail with one or two transfections is shown in Figure 24B. Two different amounts of RNA per cell for each transfection were tested (3.2pg and 8pg). Note that only the high amount of RNA (8pg) reprogrammed iPSCs after one transfection with C6 cocktail. High (8pg) and low (3.2pg) amounts of RNA were able to reprogram CD34+ cells with two transfections.

[0509] Figures 25 and 26 show staining for pluripotency markers Tra-1-81 (green) and OCT4 (red) for 6-well plates transfected with various concentrations of C6 cocktail (Figure 25) and C3, C4, C5 cocktail (Figure 26). All well images were scanned at 4x using an IncuCyte. Different wells represent different seeding densities (left to right, top to bottom: 12.5k, 25k, 25k, 50k, and 50k). Tra-1-81- and Oct4 double positive areas are putative iPSC colonies.

[0510]

[0505] These experiments demonstrate the following conclusions:

[0511] 1. The use of circRNAs allows reprogramming with a minimal number of factors. Although the omission of c-Myc (C5 and C3 cocktails) did indeed reduce the morphological progression rate to iPSCs as well as the overall reprogramming efficiency compared to the progression rate and efficiency observed with the C6 cocktail (OSKMLN), these data demonstrate that CD34+ cells can be successfully reprogrammed even in the absence of c-Myc. Similarly, the omission of Nanog, Lin28 and c-Myc (C3 cocktail) reduced the reprogramming efficiency, but this reduction was not as severe as compared to the C5 cocktail. In other words, C5 and C3 were relatively similar in terms of their reprogramming efficiency. Even though the efficiency was reduced, colonies with typical iPSC morphology and expressing pluripotency markers could be found in both C5 and C3 cultures.

[0512] 2. Retaining c-Myc but omitting Nanog and Lin28 (C4 cocktail) showed similar reprogramming progression and efficiency as the C6 cocktail, suggesting that Nanog and Lin28 are not essential for reprogramming CD34+ cells to iPSCs when circRNAs are used to deliver reprogramming factors.

[0513] 3. c-Myc promotes efficient circRNA reprogramming in CD34+ cells. However, in the absence of c-Myc, circRNA reprogramming can still occur, albeit less efficiently (slower iPSC colony formation rate, fewer iPSC colonies) compared to c-Myc-containing cocktails (see Figures 20A and 20B).

[0514] 4. CD34+ cells can be reprogrammed with a single transfection of C6 cocktail. These experiments demonstrate that RNA concentration is important for successful reprogramming. At 8 pg RNA per cell, reprogramming was successful, but at 3.2 pg RNA per cell, no iPSC colonies were formed.

[0515] 5. Linear mRNA cocktails (S6 and L6) similar (in terms of molar amounts and stoichiometry) to the C6 circRNA cocktail failed to reprogram CD34+ cells following the same transfection / electroporation protocol (two transfections on days 0 and 2) used for the analogous circRNA reprogramming cocktails. These experiments demonstrate that circular RNA reprogramming is uniquely suitable for footprint-free suspension culture reprogramming and that these circular RNA constructs provide beneficial functional effects compared to analogous linear mRNA constructs.

[0516] Example 7: Characterization of circRNA-reprogrammed iPSCs in long-term culture Experiments were performed to characterize iPSCs generated by the methods described in the previous examples in long-term culture conditions with cell passage up to 20 passages. A summary of the experimental protocol is shown in Figure 27. Briefly, after two electroporations of circRNA reprogramming cocktail (day 0 and day 2), iPSC colonies typically appeared between days 10-14 and were ready for picking by day 18. Individual iPSC colonies were manually picked and cultured in StemFit Basic 03 medium up to passage 20 for characterization. At passaging, iPSCs were detached and dissociated into small clumps using Versen solution (Thermo Fisher). The ROCK inhibitor Y-27632 was added on the day of passaging and removed the next day. At each passaging, iPSCs were seeded at a specific density to allow a consistent passaging cycle of 4 days for all clones. Morphology, viability, population doubling time, and differentiation capacity into three different germ layers were determined. The reprogramming conditions used for each iPSC clone in these experiments are defined in Table 13.

[0517] [Table 37]

[0518] The overall reprogramming efficiency of the various protocols used is provided in Table 14. As shown, C6, C4, and C3 cocktails were able to successfully reprogram CD34+ cells, with C6 and C4 producing higher reprogramming efficiencies.

[0519] [Table 38]

[0520]

[0513] Cells at passage 0 were grown for 4-7 days and then passaged. Cells from subsequent passages were passaged every 4 days. Between days 52-63 after electroporation, the iPSC cell cultures at passage 10 were harvested, stained, and analyzed by flow cytometry for OCT4, SSEA4, and TRA 1-81 expression. The positive control used in this experiment was a commercially available iPSC derived episomal vector encoding Oct4, Sox2, Klf4, Myc, Nanog, Lin28, and SV40 (epiIPSC, A18945, Thermo Fisher). 293 T cells were used as a negative staining control. As shown in Table 15, reprogramming with the C14, C6, C4 and C3 cocktail led to cultures with a high percentage of iPSCs expressing OCT4, SSEA4 and TRA 1-81 (pluripotency markers) when characterized at passage 10.

[0521] [Table 39]

[0522] As shown in Figure 28A, iPSC clones derived from mixed donor CD34+ cells with reprogramming cocktails C14, C6, and C4 gave rise to colonies with typical iPSC morphology that were maintained up to passage 20. Similarly, Figure 28B shows that iPSC clones derived from single donor CD34+ cells with reprogramming cocktails C6, C4, and C3 gave rise to colonies with typical iPSC morphology that were maintained up to passage 20.

[0523] Furthermore, as shown in Figure 29A and Figure 29B, iPSC clones exhibited high viability in long-term culture (i.e., over 20 cell passages) when analyzed by nucleocounter NC_200. "Alt" means "alternate day" when used to designate samples, i.e., clones were generated by two rounds of circRNA electroporation on days 0 and 2 as described above. iPSC clones derived from mixed donor (Figure 29A) cord blood CD34+ cells maintained 75-98% viability at every cell passage from passage 4 to passage 20, and most clones kept over 90% viability. Except for two clones with approximately 85% viability at passage 18, all clones derived from single donor (Figure 29B) cord blood CD34+ cells consistently had over 90% viability at every cell passage from passage 4 to passage 18.

[0524] In addition, as shown in Fig. 30A and Fig. 30B, circRNA-induced iPSCs exhibited consistent population doubling times over long-term culture, calculated based on viable cell numbers per passage day. iPSC clones derived from mixed-donor (Fig. 30A) and single-donor (Fig. 30B) cord blood CD34+ cells doubled in population on average in 18-24 hours from passage 4 to passage 20, which is consistent with typical iPSC doubling times. The passage number at which population doubling times began to register varied among clones (from p5, p6, and p8), resulting in parallel lines for the three groups in Fig. 31A. The cumulative population doublings of circRNA-induced iPSCs from mixed-donor CD34+ cells were consistently 60-80-fold at passage 20, as shown in Figure 31A, while the cumulative population doublings of circRNA-induced iPSCs from single-donor CD34+ cells were consistently 70-80-fold at passage 20, as shown in Figure 31B.

[0525] Moreover, FIG. 32 shows that after reprogramming with C14, C6, C4 or C3 cocktail, the resulting iPSC cells were able to give rise to all three primary germ layer cell layers. Endoderm expressed SOX17 and FOXA2. Mesoderm expressed Brachyury (T) and did not express FOXA2. Ectoderm expressed PAX6. RNA sequencing (RNA seq) analysis was also performed on the resulting iPSC cultures. Three separate RNA seq runs were performed on the resulting iPSC cultures. The first sequencing run included samples from 11 VR1+VR2 clones and 9 clones from mixed donor CD34+ cells reprogrammed with C14, C6, and C4 cocktail. The second and third sequencing runs included samples from 10 clones, run in duplicate, from a single donor CD34+ cells reprogrammed with C6, C4, and C3 cocktails, respectively, and cord blood cells were used as controls. CELL net analysis was used to classify samples into cell types based on their expression of regulatory signatures.

[0526] All circRNA-induced iPSC clones had a gene signature corresponding to that of embryonic stem cells (ESCs) defined based on the gene regulatory network (GRN) of ESCs, which consisted of 206 genes by CellNet analysis. Among these 206 genes related to ESC GRN, the expression of LIN28A, LIN28B, NANOG, POU5F1, and SOX2 was high in all circRNA-induced iPSC samples. Principal component analysis (PCA) and Pearson correlation confirmed that there was no batch effect and showed no clustering between C6, C4, and C3 (data not shown).

[0527]

[0519] In summary, this data indicates that circRNA-reprogrammed iPSCs from different donors, reprogrammed using C14, C6, C4 and C3 cocktails as described in this disclosure, are stable in terms of their morphology, remain viable, continue to undergo cell division at similar rates, and maintain a consistent cellular identity closely resembling ESCs even after multiple cell passages and under long-term cell culture conditions.

[0528] Example 8: Genetic and epigenetic stability of circRNA-reprogrammed iPSCs Experiments were performed to evaluate the genetic and epigenetic stability of circRNA-reprogrammed iPSCs after multiple cell passages and long-term culture. A total of 32 circRNA-reprogrammed iPSC clones were subjected to G-banding karyotyping at passage 10, and 29 of the 32 clones had normal karyotypes. The karyotypes of these 29 clones were then determined again at passage 20. As summarized in Table 16, more than 85% of the clones had normal karyotypes at passages 10 and 20, which is higher than the generally expected rate of 80%.

[0529] [Table 40]

[0530]

[0521] Whole genome sequencing was also performed on the same clones to detect oncogenic variants. As summarized in Table 17, none of the clones showed oncogenic TP53 variants. Furthermore, bisulfite genome sequencing was performed on the same clones to detect DNA methylation, and as shown in Table 17, all clones showed DNA methylation in the IGF2 / H19 imprinting control region, which was consistent with the parental DNA methylation.

[0531] [Table 41]

[0532]

[0522] Collectively, these data demonstrate that circRNA-induced iPSCs are both genetically and epigenetically stable after long-term in vitro culture.

[0533] Example 9: Benefits of iPSC reprogramming with circRNA Based on the experimental data presented herein, the characteristics of iPSC reprogramming with circRNA were compared with other reprogramming methods, such as Sendai virus, episomal vector, and mRNA reprogramming. Table 18 summarizes the advantages of iPSC reprogramming with circRNA. Reprogramming with circRNA is suitable for blood cells, has no risk of genomic integration, does not require removal of exogenously introduced reprogramming factors in iPSCs (RNA has a short half-life, so once delivered, it is quickly removed within a few days), does not require the inclusion of p53 as part of the combination of reprogramming factors, does not require the use of additional factors to mediate immune evasion, does not require the use of microRNA, and allows reprogramming without the use of myc. Among other reprogramming methods, the use of Sendai virus and episomal vectors required removal of reprogramming factors. The use of Sendai virus, episomal vector, and mRNA required the use of myc for efficient reprogramming. Furthermore, the use of episomal vectors carried the risk of genomic integration, while the use of mRNA was not suitable for reprogramming blood cells and required the use of additional factors to mediate immune evasion and enhance reprogramming efficiency. In summary, we have shown that iPSC reprogramming with episomal vectors and mRNA is complicated and prohibitively expensive, while reprogramming with Sendai virus is limited to use in eye and central nervous system indications. However, iPSC reprogramming with circRNA not only overcomes these limitations but also allows for direct reprogramming from blood cells in suspension, and thus appears to be a superior method.

[0534] [Table 42]

[0535]

[0524] The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. The present invention is defined by the following claims, including equivalents of the claims.

Claims

1. 1. A method of generating induced pluripotent stem cells (iPSCs), comprising contacting blood cells in suspension with a circular RNA encoding at least one reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc, or a fragment or variant thereof, and maintaining the cells under conditions such that the iPSCs are obtained.

2. 2. The method of claim 1, wherein the blood cells are selected from T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, peripheral blood mononuclear cells (PBMCs), and cord blood mononuclear cells (CBMCs).

3. The method of claim 1 , wherein the blood cells are selected from T cells and NK cells.

4. 1. A method of generating induced pluripotent stem cells (iPSCs), comprising contacting CD34+ cells in suspension with a circular RNA encoding at least one reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc, or a fragment or variant thereof, and maintaining the cells under conditions such that the iPSCs are obtained.

5. The method of any one of claims 1 to 4, wherein said at least one reprogramming factor is a human or humanized reprogramming factor.

6. 6. The method of any one of claims 1 to 5, wherein said at least one reprogramming factor is Oct3 / 4, said Oct3 / 4 having an amino acid sequence of SEQ ID NO: 7, or a sequence at least 90% or at least 95% identical thereto.

7. 4. The method of claim 3, wherein the circular RNA comprises a nucleic acid sequence of SEQ ID NO: 8, or a sequence at least 90% or at least 95% identical thereto.

8. 6. The method of any one of claims 1 to 5, wherein the at least one reprogramming factor is Klf4, and the Klf4 has the amino acid sequence of SEQ ID NO: 9 or 10, or a sequence at least 90% or at least 95% identical thereto.

9. 9. The method of claim 8, wherein the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 11, or a sequence at least 90% or at least 95% identical thereto.

10. 6. The method of any one of claims 1 to 5, wherein said at least one reprogramming factor is Sox2, and Sox2 has the amino acid sequence of SEQ ID NO: 12, or a sequence at least 90% or at least 95% identical thereto.

11. 11. The method of claim 10, wherein the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 13, or a sequence at least 90% or at least 95% identical thereto.

12. The method of any one of claims 1 to 5, wherein said at least one reprogramming factor is Nanog, said Nanog having the amino acid sequence of SEQ ID NO: 14 or 15, or a sequence at least 90% or at least 95% identical thereto.

13. 13. The method of claim 12, wherein the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 16, or a sequence at least 90% or at least 95% identical thereto.

14. 6. The method of any one of claims 1 to 5, wherein said at least one reprogramming factor is Lin28A, said Lin28A having the amino acid sequence of SEQ ID NO: 17, or a sequence at least 90% or at least 95% identical thereto.

15. 15. The method of claim 14, wherein the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 18, or a sequence at least 90% or at least 95% identical thereto.

16. 6. The method of any one of claims 1 to 5, wherein the at least one reprogramming factor is c-Myc, and the c-Myc has the amino acid sequence of SEQ ID NO: 19 or 20, or a sequence at least 90% or at least 95% identical thereto.

17. 17. The method of claim 16, wherein the circular RNA comprises the nucleic acid sequence of SEQ ID NO: 21, or a sequence at least 90% or at least 95% identical thereto.

18. The method of any one of claims 1 to 5, wherein the at least one reprogramming factor is L-Myc, and the L-Myc has an amino acid sequence of any one of SEQ ID NOs: 22 to 24, or a sequence at least 90% or at least 95% identical thereto.

19. 19. The method of claim 18, wherein the circular RNA comprises a nucleic acid sequence of SEQ ID NO: 25, or a sequence at least 90% or at least 95% identical thereto.

20. The method of any one of claims 1 to 19, wherein the circular RNA is substantially non-immunogenic.

21. The circular RNA is a nucleic acid sequence that contains one or more M-6-methyladenosines (m 6 The method of claim 20, comprising: A) residue.

22. 22. The method of any one of claims 1 to 21, wherein the circular RNA comprises from about 200 nucleotides to about 5,000 nucleotides.

23. 23. The method of any one of claims 1 to 22, wherein the circular RNA comprises an internal ribosome entry site (IRES) operably linked to a protein coding sequence.

24. 24. The method of any one of claims 1 to 23, wherein the circular RNA encodes two or more reprogramming factors selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc.

25. 6. The method of any one of claims 1 to 5, wherein the method comprises contacting the cell with a first circular RNA encoding Oct4 or a fragment or variant thereof, a second circular RNA encoding Sox2 or a fragment or variant thereof, a third circular RNA encoding Klf4 or a fragment or variant thereof, a fourth circular RNA encoding C-Myc or a fragment or variant thereof, a fifth circular RNA encoding Lin28 or a fragment or variant thereof, and a sixth circular RNA encoding Nanog or a fragment or variant thereof.

26. 6. The method of any one of claims 1 to 5, comprising contacting the cell with one or more circular RNAs encoding one or more of the group of reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc, or fragments or variants thereof.

27. 1. A method of producing induced pluripotent stem cells (iPSCs), comprising contacting blood cells or CD34+ cells in suspension with six circular RNAs, the six circular RNAs being a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, a third circular RNA encoding Klf4, a fourth circular RNA encoding C-Myc, a fifth circular RNA encoding Lin28, and a sixth circular RNA encoding Nanog, and maintaining the cells under conditions such that the iPSCs are obtained.

28. 1. A method of producing induced pluripotent stem cells (iPSCs), comprising contacting blood cells or CD34+ cells in suspension with three circular RNAs, a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, and a third circular RNA encoding Klf4, and maintaining the cells under conditions such that the iPSCs are obtained.

29. 29. The method of claim 28, which does not include contacting the blood cells or CD34+ cells with circular RNA encoding any of Nanog, Lin28, and c-Myc.

30. 1. A method of producing induced pluripotent stem cells (iPSCs), comprising contacting blood cells or CD34+ cells in suspension with three circular RNAs, a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, and a third circular RNA encoding Klf4, and a fourth circular RNA encoding C-Myc, and maintaining the cells under conditions such that the iPSCs are obtained.

31. 31. The method of claim 30, which does not include contacting the blood cells or CD34+ cells with circular RNA encoding either Nanog or Lin28.

32. 1. A method of producing induced pluripotent stem cells (iPSCs), comprising contacting blood cells or CD34+ cells in suspension with three circular RNAs, a first circular RNA encoding Oct4, a second circular RNA encoding Sox2, and a third circular RNA encoding Klf4, a fourth circular RNA encoding Nanog, and a fifth circular RNA encoding Lin 28, and maintaining the cells under conditions such that the iPSCs are obtained.

33. 33. The method of claim 32, which does not include contacting the CD34+ cells with a circular RNA encoding c-Myc.

34. The method of any one of claims 1 to 33, wherein the cells are not contacted with any factor selected from E3, K3, B18R.

35. The method of any one of claims 1 to 33, wherein the cell is not contacted with any microRNA (miR).

36. 34. The method of any one of claims 1 to 33, wherein the cell is not contacted with one or more factors selected from E3, K3, B18R, one or more microRNAs (miRs), or combinations thereof.

37. 37. The method of claim 35 or 36, wherein the miRs include miR302a, miR302b, miR302c, miR302d, and miR367.

38. The method of any one of claims 1 to 37, wherein the cell is directly contacted with the at least one circular RNA.

39. 39. The method of any one of claims 1 to 38, wherein the cell is contacted once with each of the at least one circular RNA.

40. 39. The method of any one of claims 1 to 38, comprising contacting said cell with each of said at least one circular RNA 2, 3, 4 or more times.

41. 39. The method of any one of claims 1 to 38, comprising contacting said cell with each of said at least one circular RNA less than four times.

42. 39. The method of any one of claims 1 to 38, comprising contacting said cell with each of said at least one circular RNA 2 to 4 times.

43. The method of any one of claims 1 to 42, wherein the concentration of each of said at least one circular RNA is at least 3 pg RNA / cell.

44. 43. The method of any one of claims 1 to 42, wherein the concentration of each of said at least one circular RNA is from about 5 pg RNA / cell to about 15 pg RNA / cell.

45. The method of any one of claims 1 to 44, wherein said contacting of said cells is performed by electroporation.

46. 46. ​​The method of any one of claims 1-26 or 38-45, further comprising contacting the cell with an RNA polynucleotide encoding one or more viral proteins selected from E3, K3, or B18R.

47. (a) the B18R has a sequence of SEQ ID NO: 26, or a sequence at least 90% or at least 95% identical thereto; (b) said E3 has a sequence of SEQ ID NO: 27, or a sequence at least 90% or at least 95% identical thereto; and / or (c) said K3 has a sequence of SEQ ID NO: 28, or a sequence at least 90% or at least 95% identical thereto; 47. The method of claim 46.

48. 50. The method of any one of claims 1-26 or 38-47, further comprising contacting the cell with one or more microRNAs (miRs).

49. 49. The method of claim 48, wherein the miR is selected from miR302a, miR302b, miR302c, miR302d, and miR367.

50. (i) an increase in the number of reprogrammed iPSCs present at the end of the culture compared to a method of generating iPSCs with one or more linear RNAs; and / or (ii) reduced cell death at one or more time points during reprogramming compared to methods generating iPSCs with one or more linear RNAs; The method of any one of claims 1 to 49, wherein the method results in one or more of:

51. (i) an increase in the number of reprogrammed iPSCs present at the end of culture compared to methods of generating iPSCs with one or more linear RNAs; and (ii) reduced cell death at one or more time points during reprogramming compared to methods generating iPSCs with one or more linear RNAs; The method of any one of claims 1 to 49, wherein each of

52. 52. iPSCs produced using the method of any one of claims 1 to 51.

53. A differentiated cell derived from the iPSC of claim 52.

54. 54. The differentiated cell of claim 53, wherein the differentiated cell is a muscle cell, a nervous system cell, a central nervous system cell, an eye cell, a chondrocyte, a bone cell, a tendon cell, a kidney cell, a cardiomyocyte, a liver cell, a pancreatic islet cell, a keratinocyte, a T cell, or a NK cell.

55. 1. A method for reprogramming and editing the genome of a cell, comprising: (i) contacting the cell with a recombinant circular RNA comprising a protein coding sequence, wherein the protein coding sequence encodes at least one reprogramming factor; and (ii) contacting the cell with an enzyme capable of editing the DNA or RNA of the cell, or a nucleic acid encoding the enzyme. The method includes:

56. 1. A method for reprogramming and editing the genome of a cell, comprising: (i) a recombinant circular RNA comprising a protein coding sequence, wherein the protein coding sequence encodes at least one reprogramming factor; and (ii) an enzyme capable of editing the DNA or RNA of the cell, or a nucleic acid encoding the enzyme simultaneously contacting the cells with

57. 57. The method of claim 55 or 56, wherein the at least one reprogramming factor is a human or humanized reprogramming factor.

58. 58. The method of any one of claims 55 to 57, wherein said at least one reprogramming factor is Oct3 / 4, and said Oct3 / 4 has the amino acid sequence of SEQ ID NO: 7, or a sequence at least 90% or at least 95% identical thereto.

59. 60. The method of claim 59, wherein the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 8, or a sequence at least 90% or at least 95% identical thereto.

60. 58. The method of any one of claims 55 to 57, wherein said at least one reprogramming factor is Klf4, and said Klf4 has the amino acid sequence of SEQ ID NO: 9 or 10, or a sequence at least 90% or at least 95% identical thereto.

61. 61. The method of claim 60, wherein the recombinant circular RNA comprises the nucleic acid sequence of SEQ ID NO: 11, or a sequence at least 90% or at least 95% identical thereto.

62. 58. The method of any one of claims 55 to 57, wherein said at least one reprogramming factor is Sox2, and Sox2 has the amino acid sequence of SEQ ID NO: 12, or a sequence at least 90% or at least 95% identical thereto.

63. 63. The method of claim 62, wherein the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 13, or a sequence at least 90% or at least 95% identical thereto.

64. 58. The method of any one of claims 55 to 57, wherein said at least one reprogramming factor is Nanog, and said Nanog has the amino acid sequence of SEQ ID NO: 14 or 15, or a sequence at least 90% or at least 95% identical thereto.

65. 65. The method of claim 64, wherein the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 16, or a sequence at least 90% or at least 95% identical thereto.

66. 58. The method of any one of claims 55 to 57, wherein said at least one reprogramming factor is Lin28A, said Lin28A having the amino acid sequence of SEQ ID NO: 17, or a sequence at least 90% or at least 95% identical thereto.

67. 67. The method of claim 66, wherein the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 18, or a sequence at least 90% or at least 95% identical thereto.

68. 58. The method of any one of claims 55 to 57, wherein said at least one reprogramming factor is c-Myc, and said c-Myc has the amino acid sequence of SEQ ID NO: 19 or 20, or a sequence at least 90% or at least 95% identical thereto.

69. 69. The method of claim 68, wherein the recombinant circular RNA comprises the nucleic acid sequence of SEQ ID NO: 21, or a sequence at least 90% or at least 95% identical thereto.

70. 58. The method of any one of claims 55 to 57, wherein the at least one reprogramming factor is L-Myc, and the L-Myc has the amino acid sequence of any one of SEQ ID NOs: 22 to 24, or a sequence at least 90% or at least 95% identical thereto.

71. 71. The method of claim 70, wherein the recombinant circular RNA comprises a nucleic acid sequence of SEQ ID NO: 25, or a sequence at least 90% or at least 95% identical thereto.

72. 58. The method of any one of claims 55 to 57, wherein the circular RNA is substantially non-immunogenic.

73. The circular RNA is a nucleic acid sequence that contains one or more M-6-methyladenosines (m 6 73. The method of claim 72, comprising: A) residue.

74. 74. The method of any one of claims 55 to 73, wherein the circular RNA comprises from about 200 nucleotides to about 5,000 nucleotides.

75. 75. The method of any one of claims 55 to 74, wherein the circular RNA comprises an internal ribosome entry site (IRES) operably linked to the protein coding sequence.

76. 76. The method of any one of claims 55 to 75, wherein the circular RNA encodes two or more reprogramming factors selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc.

77. 57. The method of claim 55 or 56, comprising contacting the cell with a first circular RNA encoding Oct4 or a fragment or variant thereof, a second circular RNA encoding Sox2 or a fragment or variant thereof, a third circular RNA encoding Klf4 or a fragment or variant thereof, a fourth circular RNA encoding C-Myc or a fragment or variant thereof, a fifth circular RNA encoding Lin28 or a fragment or variant thereof, and a sixth circular RNA encoding Nanog or a fragment or variant thereof.

78. 57. The method of claim 55 or 56, comprising contacting the cell with one or more circular RNAs encoding Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, and L-Myc, or fragments or variants thereof.

79. 79. The method of any one of claims 55 to 78, wherein the cell is not contacted with any auxiliary factor selected from E3, K3, B18R, or any microRNA (miR).

80. 80. The method of any one of claims 55 to 79, wherein the cell is directly contacted with the at least one circular RNA.

81. 81. The method of any one of claims 55 to 80, wherein the cell is contacted once with each of the at least one circular RNA.

82. 81. The method of any one of claims 55-80, comprising contacting said cell with said at least one, two, three, four or more of each of said circular RNAs.

83. 81. The method of any one of claims 55 to 80, comprising contacting said cell with each of said at least one circular RNA less than four times.

84. 81. The method of any one of claims 55 to 80, comprising contacting said cell with each of said at least one circular RNA 2 to 4 times.

85. 85. The method of any one of claims 55 to 84, wherein the concentration of said at least one circular RNA is at least 3 pg RNA / cell.

86. 86. The method of any one of claims 55 to 85, wherein the concentration of the at least one circular RNA is from about 5 pg RNA / cell to about 15 pg RNA / cell.

87. 87. The method of any one of claims 55 to 86, wherein said contacting of said cells is performed by electroporation.

88. 88. The method of claim 87, wherein said electroporation uses a Neon® electroporation system.

89. 90. The method of any one of claims 55-78 or 80-88, comprising contacting the cell with an RNA polynucleotide encoding one or more viral proteins selected from E3, K3, or B18R.

90. (a) the B18R has a sequence of SEQ ID NO: 26, or a sequence at least 90% or at least 95% identical thereto; (b) said E3 has a sequence of SEQ ID NO: 27, or a sequence at least 90% or at least 95% identical thereto; and / or (c) said K3 has a sequence of SEQ ID NO: 28, or a sequence at least 90% or at least 95% identical thereto; 90. The method of claim 89.

91. 91. The method of any one of claims 55-78 or 80-90, comprising contacting the cell with a microRNA (miR) selected from miR302a, miR302b, miR302c, miR302d, and miR367.

92. 89. The method of any one of claims 55 to 88, wherein the cell is not contacted with any viral protein selected from E3, K3, B18R, or with any microRNA (miR) selected from miR302a, miR302b, miR302c, miR302d, and miR367.

93. 83. The method of any one of claims 55 to 82, wherein the enzyme is a transcription activator-like effector nuclease (TALEN), an Argonaute endonuclease (NgAgo), a structure-guided endonuclease (SGN), an RNA-guided nuclease (RGN), an adenosine deaminase acting on RNA (ADAR), or a modified or truncated variant thereof.

94. 94. The method of claim 93, wherein the RGN is a Cas nuclease selected from Cas9 nuclease, Cas12(a) nuclease (Cpf1), Cas12b nuclease, Cas12c nuclease, TrpB-like nuclease, Cas13a nuclease (C2c2), Cas13b nuclease, Cas14 nuclease, or modified or truncated variants thereof.

95. 95. The method of claim 94, wherein the RGN is a Cas9 nuclease, and the Cas9 nuclease is isolated or derived from S. pyogenes or S. aureus.

96. The RGN is selected from the group consisting of APG05083.1, APG07433.1, APG07513.1, APG08290.1, APG05459.1, APG04583.1, and APG1688.1, APG05733.1, APG06207.1, APG01647.1, APG08032.1, APG05712.1, APG01658.1, APG06498.1, APG09106.1, APG09882.1, APG02675.1, APG01405.1, APG06250.1, APG0687 7.1, APG09053.1, APG04293.1, APG01308.1, APG06646.1, APG09748, APG07433.1, APG00969, APG03128, APG09748, APG00771, APG02789, APG09106, APG02312, APG07386, APG09980, APG05840, APG05241, APG07280, APG09866, and APG00868.

97. 97. The method of any one of claims 55 to 96, further comprising contacting the cell with a guide RNA, or a nucleic acid encoding same.

98. 98. The method of any one of claims 55 or 57-97, wherein the cell is contacted with the circular RNA prior to contacting the enzyme or the nucleic acid encoding same.

99. 98. The method of any one of claims 55 or 87 to 97, wherein the cell is contacted with the recombinant circular RNA after being contacted with the enzyme or the nucleic acid encoding same.

100. 100. The method of any one of claims 55 to 99, wherein the cell is contacted with an enzyme capable of editing the DNA or RNA of the cell, or a nucleic acid encoding the same, and a guide RNA, or a nucleic acid encoding the same.

101. 101. The method of claim 100, wherein the enzyme is capable of editing the DNA of the cell, and the enzyme and the guide RNA are complexed as a ribonucleoprotein prior to contact with the cell.

102. The method of any one of claims 55 to 101, wherein said contacting of said cells is performed by electroporation.

103. A cell produced by the method of any one of claims 55 to 102.

104. A method for reprogramming a cell, comprising contacting the cell with one or more circular RNAs encoding six reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

105. 105. The method of claim 104, comprising contacting the cell with six circular RNAs, each encoding a reprogramming factor from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

106. 106. The method of claim 104 or 105, wherein either the circular RNA or the linear RNA is conjugated to a lipid nanoparticle.

107. 107. The method of any one of claims 104 to 106, wherein the cell is not contacted with one or more factors selected from E3, K3, B18R, or one or more microRNAs (miRs).

108. 108. The method of any one of claims 1-51, 55-102, or 104-107, wherein the circular RNA is exogenous to the cell.

109. A cell produced by the method of any one of claims 104 to 108.

110. A somatic cell comprising one or more exogenous circular RNAs encoding a reprogramming factor, said reprogramming factor being selected from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

111. The somatic cell of claim 110, wherein the somatic cell comprises one or more exogenous circular RNAs, each of the one or more circular RNAs encoding a reprogramming factor selected from Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

112. 111. The somatic cell of claim 110, wherein the somatic cell comprises six exogenous circular RNAs, each of which encodes one of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

113. The somatic cell of claim 110, wherein the somatic cell comprises five exogenous circular RNAs, each of which encodes one of Oct3 / 4, Klf4, Sox2, Nanog, and Lin28.

114. The somatic cell of claim 110, wherein the somatic cell comprises four exogenous circular RNAs, each of which encodes one of Oct3 / 4, Klf4, Sox2, and c-Myc.

115. The somatic cell of claim 110, wherein the somatic cell comprises three exogenous circular RNAs, each of which encodes one of Oct3 / 4, Klf4, and Sox2.

116. 1. A suspension culture comprising one or more CD34+ cells, wherein the CD34+ cells comprise one or more exogenous circRNAs encoding reprogramming factors.

117. 117. The suspension culture of claim 116, wherein the CD34+ cells contain six exogenous circRNAs, each encoding a reprogramming factor selected from the group consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

118. 118. The suspension culture of claim 116 or 117, wherein the CD34+ cells do not contain exogenous nucleic acid encoding an auxiliary factor selected from E3, K3, B18R, or microRNA (miR).

119. A composition comprising one or more circular RNAs encoding the reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

120. A composition comprising two or more circular RNAs encoding the reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

121. A composition comprising six circular RNAs, each encoding one of said reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

122. A composition comprising five circular RNAs, each encoding one of said reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, Nanog, and Lin28.

123. A composition comprising four circular RNAs, each encoding one of said reprogramming factors consisting of Oct3 / 4, Klf4, Sox2, and c-Myc.

124. A composition comprising three circular RNAs, each encoding one of said reprogramming factors consisting of Oct3 / 4, Klf4, and Sox2.

125. A kit comprising the composition of any one of claims 119 to 124.

126. A cell comprising the composition of any one of claims 119 to 124.

127. The cell of claim 126, which is a eukaryotic cell.

128. The cell of claim 127, which is a mammalian cell.

129. The cell of claim 128, which is a human cell.

130. The cell of any one of claims 126 to 128, which is a CD34+ cell, a T cell, or a NK cell.

131. CD34+ cells comprising one or more circular RNAs encoding one or more reprogramming factors selected from either Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc, or L-Myc.

132. The CD34+ cell of claim 131, wherein the reprogramming factors consist of all six of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and c-Myc.

133. The CD34+ cell of claim 131, wherein the reprogramming factors consist of all six of Oct3 / 4, Klf4, Sox2, Nanog, Lin28, and L-Myc.

134. The CD34+ cell of claim 131, wherein the reprogramming factors consist of Oct3 / 4, Klf4, Sox2, Nanog, and Lin28.

135. The CD34+ cell of claim 131, wherein the reprogramming factors consist of Oct3 / 4, Klf4, Sox2, and c-Myc.

136. The CD34+ cell of claim 131, wherein the reprogramming factors consist of Oct3 / 4, Klf4, and Sox2.

137. 137. The CD34+ cell of any one of claims 131-136, exhibiting at least one stemness marker selected from SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, TRA-2-49 / 6E, alkaline phosphatase, Sox2, E-cadherin, UTF-1, Oct4, Rex1, Nanog, or a combination thereof.

138. The CD34+ cell of any one of claims 131 to 137, wherein the one or more circular RNAs are exogenous to the cell.

139. The CD34+ cell of any one of claims 131 to 138, further comprising one or more genetic modifications.

140. The CD34+ cell of claim 139, wherein the one or more genetic modifications comprise a gene knockout.

141. The CD34+ cell of claim 139 or 140, wherein the one or more genetic modifications comprise gene knock-in.

142. An induced pluripotent stem cell (iPSC) derived from a CD34+ cell according to any one of claims 131 to 141.

143. The iPSC of claim 142, wherein the cells are hypoimmunogenic.

144. 144. A differentiated cell generated from the iPSC of claim 142 or 143.

145. A method for treating a disease or condition comprising administering to a subject in need thereof an iPSC of claim 142 or 143 or a differentiated cell of claim 126.

146. 1. A method for transdifferentiating a somatic cell, the method comprising contacting said cell with one or more exogenous circular RNAs.

147. A transdifferentiated cell produced by the method of claim 146.

148. A method for differentiating a cell from an induced pluripotent stem cell (iPSC), comprising contacting the iPSC with one or more circular RNAs.

149. A differentiated cell produced by the method of claim 148.

Citation Information

Patent Citations

  • Circular RNA for translation in eukaryotic cells

    JP2021526792A

  • Reprogramming Blood Cells to Pluripotent and Multipotent Stem Cells

    US20150139961A1